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 Mesenchymal stem cells (MSC) are used in therapy, often by injection into 
the blood.  Adhesion and migration from flowing blood may be critical steps for 
their recruitment in the microvasculature.  We aimed to understand how MSC from 
different sources might 'home' to injured tissue. MSC from Wharton’s jelly 
(WJMSC), bone marrow (BMMSC) or trabecular bone (TBMSC) were suspended in 
culture medium or added to whole blood, and perfused through capillaries coated 
with matrix proteins (collagen or fibronectin) or P- or E-selectin.  Initial comparisons 
showed that  none of the isolated MSC adhered to selectins even at low shear rate, 
while endothelial progenitor cells showed weak interactions.  All of the different 
cells were able to adhere to collagen or fibronectin at wall shear rates up to about 
70s
-1
, with adhesion in the order WJMSC>BMMSC>TBMSC.  Although BMMSC 
spread more efficiently than WJMSC, the WJMSC migrated faster through 8µm pore 
filters.  In whole blood, MSC failed to bind to fibronectin, while the fibronectin itself 
became covered in a single layer of spread platelets. When perfused over collagen, 
only WJMSC were found to attach, forming aggregates with platelets on the surface.  
However, all isolated MSC adhered to a surface coated with platelets.  Platelets 
binding to MSC  in flowing blood may have formed a shield affecting their 
attachment.  WJMSC appeared to activate those platelets,  and could aggregate with 
platelets activated on collagen.  Adhesion of MSC to matrix proteins and to platelets 
involved both β1- and β3-integrins.  Platelets used glycoproteins GpIb and GpIIbIIIa 
to adhere and aggregate on collagen, and GpIIbIIIa to adhere and spread on 
fibronectin, but these receptors did not support the interaction between MSC and 
platelets.   These results show intrinsic differences in adhesion and migration of 
 
 
different MSC, including interaction with platelets, that are predicted to influence 
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This thesis considers the  ability of circulating progenitor cells – endothelial 
progenitor cells (EPC) and especially mesenchymal stem cells (MSC) – to attach to 
vessel wall components from flow in isolation or in blood, and to migrate afterwards.  
It is based on the possibility that infused EPC or MSC might be used for therapy in 
vascular disease. 
1.1 Introduction – EPC, MSC and the need to study their recruitment 
 Endothelial progenitor cells (EPC) are circulating nucleated cells, distinct 
from leukocytes,  which are derived from the bone marrow and exist within the adult 
circulation.   Asahara et al, were the first who called a population of circulating cells 
that exhibit vascular regenerative characteristics  EPC in 1997 (Asahara et al., 1997)  
EPC may be defined as circulating cells that carry cell surface markers that are the 
same as those expressed by vascular endothelial cells (EC), e.g. CD34, VE-Cadherin 
and vascular endothelial growth  factor receptor2 (VEGFR2), but are distinct from 
mature EC (Yoder et al., 2007).  Hematopoietic and endothelial progenitor cells are 
thought to have a common precursor because they share many cell surface markers 
(Ingram et al., 2004). A number of markers have been used for EPC, but there are no 
unique markers.  Functionally, the most important feature of EPC is their capacity to 
differentiate into mature endothelial cells (Padfield et al., 2010, Harred et al., 1972).  
EPC thus have attracted great interest because of their potential uses  in angiogenic 
therapies,  or as having roles in repair or as biomarkers for cardiovascular disease 
(Ingram et al., 2004).  
          Mesenchymal stem cells (MSC) represent a group of progenitor cells existing 
in tissue stroma with pluripotent potential to give rise to different cells types, 
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especially adipocytes, chondrocytes and osteoblasts (Meirelles et al., 2006).  They 
carry markers similar to those on tissue fibroblasts and are difficult to distinguish 
from them. Functionally they are defined as plastic adherent property and able to 
differentiate into chondrocytes, adipocytes and osteocytes  (Lu et al., 2006). The 
differentiation potential of fibroblasts varies based on their source, for example 
fibroblast which are prepared from skin (hSDFs) have better differentiation potential 
than terminally differentiated fibroblasts. MSCs are discriminated from fibroblast 
(WI38) by two specific properties which are the capacity to form colonies and the 
differentiation potential. Other conventional  properties for MSCs such adhesion and 
the expression CD44, CD90, CD105 are considered unspecific for stem cells (Alt et 
al., 2011). 
               MSC have features which make them potential therapies for a number of 
diseases (Wei et al., 2013); For example, the ability of MSCs to differentiate into 
organ specific cells, makes them useful for  regenerative therapy and there have been 
many clinical trials e.g., to treat spinal cord injury and myocardial infarction (Wei et 
al., 2013).  MSC are also able to suppress immune responses (Teo et al., 2015, Karp 
and Teol, 2009).  MSC may be used in allogenic transplantation because there is 
little risk of immune rejection due to the lack  of immunogenicity.  Moreover, the 
isolation of MSCs is well established and quite simple, and there are few  ethical 
objections to their use, which makes them attractive as therapies for the future 
(Meirelles et al., 2006, Lennon and Caplan, 2006).  
              MSCs may be mobilized from the host or infused systemically (exogenous 
MSC).  There is no agreement on whether they naturally circulate and the homing 
process for injected or naturally circulating cells is uncertain. The fact that there are 
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no universal criteria for MSCs phenotype, makes MSC homing studies challenging. 
MSC in blood are very rare at least, and the fact that there are many different 
protocols for MSC culture means that there are no standard studies of their adhesive 
abilities or migration from peripheral blood into damaged tissue for regeneration  
           In general,  well-characterised paradigms are lacking for 'homing' of EPC or 
MSC, compared to the well studied adhesion cascades for leukocytes and platelets. 
While parallels are often drawn (Teo et al., 2015) there is not enough data to clearly 
define the steps by which progenitors adhere locally (within the vessel) or 
transmigrate across the endothelium.  Thus the abilities of different progenitors cells 
to bind to intact endothelium or to exposed matrix in damaged vessels is of interest.  
In this thesis, we set out to investigate MSC and EPC recruitment and migration, but 
concentrated on MSC after initial comparisons of adhesion from flow.  
              In the Introduction, the structure of the vascular system and the 
characteristics of blood flow are described first, before considering adhesive 
behaviour and recruitment of circulating cells, and of stem cells in particular. 
1.2 Blood vessels: structure, function and endothelial regulation.  
1.2.1 The vascular system 
 The vascular system is divided into arteries, capillaries and veins. Arteries 
carry oxygenated blood from the heart to the tissue. Their wall consists of three 
layers which support the high arterial blood pressure: tunica intima, tunica media and 
tunica adventitia (Anne and Allison, 2014). Tunica intima is the innermost layer 
made of endothelium having an underlying basement membrane which contains 
elastic fibres. The tunica media is made of primary smooth muscle and it has the 
highest thickness among the three layers. In addition to its support function, it assists 
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in regulating vessel blood flow and pressure. The outermost layer consists of 
connective tissue which contains different concentrations of elastic and collagen 
fibres. The density of this layer is high at its junction with tunica media, but at the 
peripheral region its morphology changes to lose connective fibres. The diameter of 
larger arteries is  >10mm and the smaller ones range from 0.1 to 10mm, the smallest 
being arterioles  (Tortora, 2011).  In relation to cell adhesion, damaged arteries are 
sites for platelet attachment to prevent blood loss, but leukcytes rarely adhere (Luu et 
al., 2010). 
 The capillaries link arterioles to post-capillary venules. The walls of 
capillaries are composed of endothelial cells overlaying a basement membrane. 
Vascular pericytes provide support to them but do not form a continuous sheet. 
Capillaries are the sites for exchange of nutrients, metabolites and gases between the 
interstitial space and blood.  They are permeable to small molecules such as water, 
oxygen and carbon dioxide, hormones and electrolytes, but not proteins. They range 
in diameter typically between about 5-10µm (Tortora, 2011).  
Deoxygenated blood is taken towards the heart through the venous system. When 
blood moves from capillaries, sub-branches of veins called venules receive it 
(diameter between 7 to 50 µm) and these enter gradually larger veins.  Venous walls 
are multi layered. There are three layers with higher connective tissue content and 
less smooth muscle than arteries. In general, walls of veins are thin in comparison 
with arteries and they only have to support a low blood pressure (Tortora, 2011). In 
relation to cell adhesion, post-capillary venules are the main site for leukocyte 
adhesion in inflammation (Adams and Nash, 1996).  
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1.2.2 Endothelial cells - function and roles in cell recruitment 
 The whole vascular system, including the heart and capillaries, is lined by a 
single layer of cells, endothelial cells, which are responsible for regulating the 
exchange of substances between the adjacent tissues and blood (Cines et al., 1998). 
A network of extracellular substances including heparin sulphate proteoglycan, 
laminins, thrombospondin, fibronectin, elastin and collagen constitute a basement 
membrane underneath the endothelial(Brown et al., 2006). Endothelial cells bind 
with the help of integrin adhesion molecules (see section 1.3.2) to the extracellular 
matrix proteins present in the basement membrane.  In most tissues, the endothelium 
forms a physical boundary separating the bloodstream from the surrounding 
environment.  In endocrine organs and the liver, fenestrated or discontinuous 
endothelial layers allow more free exchange of substances (Consigny and Vitali, 
1998, Shirota and Matsuda, 2003) 
 Endothelial cells perform a number of different functions including 
regulation of vascular permeability (Hutter et al., 2004) control of adhesion of 
leukocytes and platelets, modulation of vascular wall remodelling by controlling the 
movement of smooth muscle cells, secretion of bioactive molecules which regulate 
vascular tone and hence flow of blood, serving as a biochemical and physical barrier 
and provision of a non-thrombogenic surface (Consigny and Vitali, 1998, Shirota 
and Matsuda, 2003). In the context of this thesis, their roles in control of blood flow 
and of cell adhesion are the most relevant 
1.2.3 Regulation of blood flow 
 Endothelial cells secrete substances which influence vascular hemodynamics. 
Vasodilators like prostacyclin (PGI2) and nitric oxide (NO), and vasoconstrictors 
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like platelet-activating factor (PAF) and endothelin (ET) are released by the 
endothelial cells in order to regulate local blood flow and also blood pressure (Pique 
et al., 1989).  Endothelial cells secrete nitric oxide constitutively; however, a number 
of extracellular physical and chemical stimuli such as shear stress can also up 
regulate the production of nitric oxide. Besides nitric oxide,  PAF, ET and PGI2 are 
also mainly produced in response to environmental changes such as oxygen tension , 
blood flow, endothelial stretch, circulating cytokines and growth factors (Haworth, 
2006, Parenti et al., 1998).  
1.2.4 Regulation of interactions of platelets, leukocytes and stem cells with the 
vessel wall   
 In response to infection or tissue injury, and during the process of immune 
surveillance, platelets and white blood cells may interact with one another or with 
particular portions of endothelium or with exposed components of endothelium. 
These interactions are essentially involved in physiological processes of hemostasis 
and inflammation. However, unchecked attachment of platelets and white blood cells 
with the endothelial wall leads to thrombotic and inflammatory diseases.  Under the 
influence of shear forces, both white blood cells and platelets interact with the 
surface of blood vessels via a multi-step mechanism which involves (a) development 
of initial attachment which is mostly reversible; (b) activation of attached cells; (c) 
formation of stronger bond which is resistant to shear-forces and (4) spreading and 
aggregation (for platelets) or migration through endothelium (for leukocytes). 
(Springer, 1995). Endothelial cells control these adhesive interactions by actively 
regulating their expression of adhesion molecules and presentation of activatory or 
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inhibitory agents (including NO and PGI2 mentioned above).  The molecular 
mechanisms of the different steps are described in section 1.3.3. 
1.3 Circulation of blood and blood cells 
1.3.1 Concepts of blood flow 
1.3.1.1.  Introduction to blood and blood flow in the circulation 
 The blood is a suspension of cells (red blood cells, white blood cells, 
platelets) in plasma, which is a solution containing many inorganic ions and a high 
concentration of  proteins (~70g/l) (Hoffbrand, 1991).The red blood cells occupy 40-
45% of the volume of the blood (i.e., haematocrit = 40-45%) and outnumber 
platelets by about 10:1 and white blood cells by about 1000:1.  The blood may also 
contain very small numbers of circulating endothelial cells and endothelial 
progenitors, haematopoetic stem cells and mesenchymal stem cells (Roufosse et al., 
2004).  The main purpose of the cardiovascular circulation is to transport these 
contents around the body.          
 Red blood cells (RBC) are non-nucleated discs, biconcave in shape, with 
diameter ~8 μm and thickness ~2 μm. They are composed of an oxygen transporter 
protein called haemogloblin which is shielded by a flexible membrane.  RBC deliver 
oxygen to the tissues and carry carbon dioxide from the tissues to the lung for gas 
exchange. Under physiological conditions, there is no receptor-ligand interaction 
between RBC and the endothelium, but such interaction may occur in pathological 
states such as sickle cell disease (Shiu and McIntire, 2003). 
 White blood cells (WBC or leukocytes) are classified based on their 
granularity into granulocytes and agranulocytes (or mononuclear cells).  
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Granulocytes include basophils, eosinophils, and neutrophils. Mononuclear cells 
include monocytes and lymphocytes (Hoffbrand, 1991). WBC are spherical in the 
blood and composed of a plasma membrane, cytoskeleton, nucleus and a cortical 
layer rich in actin (Popel and Johnson, 2005). Their size and physical properties 
vary; for example, the most numerous are neutrophils (about 5x10
6
/ml blood) with 
diameter   8 μm.  White blood cells are major components of the immune system, 
and protect against infection and assist in tissue repair (Hoffbrand, 1991) When 
circulating WBC are confronted by inflammation or foreign antigens , a multi-step 
adhesion cascade is used to recruit them to the site of injury (see Section 1.3.3.1).  
 This cascade starts with leukocytes capture and rolling, followed by 
activation, firm adhesion and finally transmigration across the endothelium to the 
inflamed tissue.  
 Platelets are not considered true cells, as they are discoid, non-nucleated 
particles  ith diameter of    2 μm released by megakaryocytes in the bone marro .  
They play roles in preventing blood loss (haemostasis) by adhering to damaged 
vessels and promoting  blood coagulation (Hoffbrand, 1991). They express receptors 
and adhesion molecules which facilitate platelet-matrix and platelet-platelet 
interactions (see Section 1.3.3.3).    
 Blood flow is the consistent blood movement through the cardiovascular 
system driven by the pumping action of the heart. Blood flow maintains adequate 
supply of O2, nutrients and hormones; at the same time it helps the body to remove 
CO2 and metabolic wastes.   These processes are essential to maintain the cell-level 
metabolism, pH control, osmotic pressure and the body temperature (Tortora, 2011). 
Blood flow also delivers cells of the immune system. 
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 Under most conditions, the blood flow can be described  as 'laminar' when it 
travel in layers down the blood vessels.  Under steady conditions, the flow profile for 
long and straight vessels becomes parabolic, with highest velocity in the centre of the 
vessel.  In major arteries, at branches, sharp bends or where there is disease, complex 
patterns of flow occur and at very high flow rate turbulence may interrupt the 
laminar (Stein and HN., 1976 ).  
 The average blood flow velocity and the vessel diameter are inversely related 
(see Figure 1-1) (Silverthorn, 2007, Tortora, 2011). Average velocities are highest in 
the aorta and lowest in capillaries because the total cross-section area of the former is 
lower than the combined latter.  The flow passing over endothelial cells that line 
vessels generates a friction force against the blood flow which is known as shear 
stress (Traub and Berk, 1998). Shear stress is a critical hemodynamic force because 
it modulates the function of endothelial cells and also influences the ability of 
circulating cells to adhere to the vessel wall (Chien et al., 1998, Topper and 
Gimbrone, 1999).  
  The flow parameters which influence delivery of cells are explained in 
























Figure ‎1-1: The relation between velocity of flow and different cross-sectional 
area In Aorta.  




1.3.1.2 Haemodynamics and flow in model  vessels 
 
 The study of the physical factors that control blood flow is called 
Hemodynamics.  The first key factor is the pressure drop (    , equal to the 
difference between arterial pressure (PA) and venous pressure (PV), which is the 
driving force of blood flow (Q) through the circulation.  In general,  blood flow is 





This is analogous to Ohm’s la ,  here current is calculated by dividing voltage 






 Applying the equation to the whole cardiovascular system gives the relation 
between cardiac output (CO), total peripheral resistance (TPR) and the difference 
between mean arterial pressure and central venous pressure: 
CO = 
     
   
 
 In order to understand circulatory flow, the different factors which affect 
pressure, flow and resistance must be studied.  For example, usually, changes in 
vascular resistance or changes in pressure generated by the heart lead to changes in 
blood flow systemically or locally.  In this thesis, we will study blood flow and cell 
behaviour in individual model 'vessels'.  Therefore, the relation between resistance, 
pressure, and flow in simple tubes is described here. 
 The relation between volumetric  flow rate and pressure drop in a cylindrical 
vessel is described by the Poiseuille equation (see Figure 1-2A), where flow is 
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proportional to the fourth power of the radius, and inversely proprotional to the 
vessel length and viscosity of the fluid (blood).  The equation can be rewritten to 
sho  that the resistance (ΔP/Q) has t o components, one geometrical (dependent on 
vessel radius and length) and one rheological (dependent on blood viscosity).  The 
most important factor for physiological control of flow is vessel radius because 
resistance changes inversely to its fourth power, and arterial radius can be actively 
changed in vivo.  The viscosity of the blood also varies depending on its contents, as 
discussed in Section 1.3.1c. 
 The Poiseuille equation applies for steady flow of a fluid with constant 
viscosity (i.e., a Newtonian fluid)  in a rigid, straight tube, where there is laminar 
flow, which can be pictured as the flow of a fluid in layers parallel to each other 
without any disturbance between the layers.  The flow in a small region is illustrated 
in Figure 1-2B.  The velocity of each fluid layer is different.  The shear rate is 
equivalent to the velocity gradient or difference in velocity divided by the distance 
between layers.  The relative motion is resisted by a force generated by the friction 
between the layers, called the shear stress (force per unit area).  The friction depends 
on the fluid viscosity, which is defined as the ratio of shear stress to shear rate 
(Figure 1-2B). 
 In the case of the cylindrical tube, values for velocity, shear rate and shear 
stress are shown in Figure 1-3A.   The fluid velocity at particular position depends 
on the radial distance from the centre,  is zero at the vessel wall and reaches a 
maximum at the vessel axis.  The shear rate (rate of change of velocity) starts from 
zero at the axis and is maximum at the wall.  Shear stress follows the same pattern as 
it is equal to the shear rate multiplied by the viscosity.  When studying behaviour of 
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cells which may adhere to the vessel wall, the wall shear rate and wall shear stress 
are particularly important (see section 1.3.4.2). 
 In the flow assays carried out in this thesis, capillaries with rectangular cross-
section (microslides) are used, because they have better optical qualities (see Chapter 
2).  The equations for flow in rectangular microslides are shown in Figure 1-3B.  
Practically, the flow rate required to give the desired wall shear rate or stress can be 
calculated from the dimensions of the microslide and the viscosity of the flowing 
fluid (Cooke et al., 1993).  
The equations used for experiments here are: 
wall shear rate, w = 6.Q    
   w.h2 
wall shear stress, tw =   6..Q 
 
      w.h2 
where (in SI units), tw= wall shear stress (Pa), w= wall shear rate (s
-1
),  η = fluid 
viscosity  (Pa.s; e.g. 0.7x10
-3
 Pa.s for aqueous buffers at 37°C), Q = flow rate (m
3
/s),  
w = internal width of the microslide (3x10
-3




1.3.1.3   Blood viscosity and effects of RBC 
 
 Blood viscosity basically means the thickness of the blood, dependent on its 
contents.  Thin blood with low viscosity gives less resistance to blood flow. The 
viscosity of plasma depends on its protein concentration and is about 1.8 times that 
of water at 37°C.  However, due to the presence of red blood cells, viscosity of blood 
is about four times higher than water.  Physiologically, the viscosity varies with any 
alteration of haematocrit.  For example, if haematocrit increases from 40% to 60%, it 
15 
 
doubles the blood viscosity.  Plasma viscosity will increase, for example, in the acute 
phase response following injury or inflammation, because of a rise in fibrinogen 
concentration.  In addition, for a drop in body temperature of 1°C, the viscosity 































Pouiseuille's equation   
Volumetric flow rate,  Q =  dP R4      
            L     8  
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Planes slipping over each other: 
  Shear Rate,   = velocity gradient =  dV/dx (s-1) 
Frictional drag experienced: 
 Shear Stress, t  = force per unit area (Newtons. m-2 = Pascals, Pa) 
Viscosity  =  Shear Stress/Shear Rate (Pa.s) 
 e.g., water ~1mPa.s at room temp., 0.7mPa.s at 37°C 
B. Shear rate, shear stress and viscosity in uniform laminar flow 
Figure ‎1-2: Characteristics of laminar flow.  
 A.  Pattern of flow and equations for relations between  pressure drop, flow, resistance, 
vessel geometry and fluid viscosity for a cylindrical vessel.   B. Definition of shear rate, 
stress and viscosity.  (Adapted from Lecture Notes of Gerard Nash, University of 







Flow  rate, Q2a
P1 P2




A       Velocity at any radius, Vr    = 2Q . (1-r2/R2) 
 (parabolic flow profile)  R2  
  
        Wall shear rate,  w       = 4.Q    
      R
3 
 
        Wall shear stress, tw  = 4..Q  
 











B       Velocity at any distance x off centre 
    Vx = 6Q    .  (h
2/4- x2)  
      wh3  
 
 Wall shear rate,  w  =   6.Q    
               w.h2 
 
           Wall shear stress, tw  =    6..Q  
             w.h2 
        Velocity of particle by wall ~  w.a
  
Figure ‎1-3: .  Patterns of flow and equations for relations between flow rate, 
vessel geometry, shear rate and shear stress for A. cylindrical vessel, or B. vessel 
with rectangular cross-section. (Adapted from Lecture Notes of Gerard Nash, 
University of Birmingham; with permission).  
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Another  factor that affects blood viscosity and the resistance to flow is the shear 
rate.  At low shear rate (or stress)  the viscosity increases significantly due to the 
increase in cell to cell adhesion, called rouleaux formation or RBC aggregation 
(Nash, 1991). As shear increases, the rouleaux divide and scatter  Thus in the 
circulation, RBC undergo aggregation and then disaggregation under the effect of 
varying shear in different vessels (Nash, 1991, Nash et al., 1992). 
The decrease in blood viscosity with increasing shear rate is called shear thinning.  
In addition to changes in RBC aggregation, RBC deformation plays a role because 
the cells elongate and line up with each other with increasing shear (Nash, 1991). 
The RBC can alter their shape while staying unbroken with the help of the spectrin 
network underlying their membrane that maintains the cells intact and enables them 
to deform and also to pass through small vessels do n to 3μm in diameter (Nash and 
Dormandy, 1989).  
 The decline in blood viscosity a companying increasing  shear rate or stress 
means that the blood is non-Newtonian, and that the flow pattern in vessels may not 
be the same as that described above for Poiseuille flow (Goldsmith and Spain, 1984). 
The variation in blood flow behaviour in different vessels is described next. 
1.3.1.4  Red cell aggregation 
Rouleaux are tube-like aggregates of red blood cells which are stacked with the sides 
of highest area adjacent to each other.  It has been established that fibrinogen 
together with some other macromolecules present in blood induce the RBC 
aggregation (Fahraeus, 1929). Rampling and Sirs for instance demonstrated that 
reduction in plasma levels of fibrinogen caused reduction in tendency of the RBC to 
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form rouleaux (Rampling and Sirs, 1972). Normally, the concentration of 
fibrinogen in plasma is 0.2-0.3g/100ml (Chien et al., 1971). The correlation between 
elevated concentration of fibrinogen in plasma and augmented RBC aggregation is 
well recognized (Rampling and Sirs, 1972). In disease conditions such as chronic 
inflammation and hypertension and in diabetes, RBC aggregation is increased owing 
to elevated plasma levels of fibrinogen (Babu and Singh, 2004).  
During blood flow, the level of RBC aggregation in a blood vessel is 
governed by the balanced between forces i.e. fluid shear stress acting on cells to 
disintegrate the RBC aggregates and the force of temporary aggregation between 
RBCs which is influenced by the plasma fibrinogen levels (Barshtein et al., 2000). 
Rouleaux will typically form in an area of a blood vessel where shear rate is lower 
than ~50s‾¹ (Goldsmith, 1986). This suggests that rouleaux can be formed close to 
the centre of blood vessels even when shear rates at the wall are higher than the level 
which allows rouleaux formation (Korotaeva et al., 2007).  
Contribute to shear dependence of blood viscosity.  However, aggregation 
also causes an increase in migration of red blood cells towards the centre of vessels 
in tube (Goldsmith et al., 1999).  This inward motion can cause an increasing cell-
depleted layer near the wall as flow decreases.  In addition, this inward motion of red 
cells may displace other smaller objects towards the wall, a process called 
margination (see section 1.3.4.1) 
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1.3.2 Blood flow in different types of vessels 
1.3.2.1  Blood flow in large vessels 
 The behaviour of the blood inside large blood vessels (> 300 µm )is 
described as that of a Newtonian viscous incompressible fluid (Whitmore,  1967). 
Thus the Poiseuille equation and flow equations described above are usually applied.  
The velocity across the tube reaches its maximum on the axis and reaches its 
minimum at the wall, whereas the shear rate and stress are maximal at the wall and  
minimal on the tubes axis.   The simple laminar flow may be disturbed at sharp 
bends and junctions of vessels (Goldsmith, 1986).  
1.3.2.2  Blood flow in intermediate sized vessels 
 The rheological features of the blood are very important in smaller blood 
vessels.   It is not accurate to describe the blood as a homogenous fluid, as the red 
cells tend to move inward and travel faster down the centre of the vessel with a 
slower moving plasma sheath (Whitmore,  1967). Lift forces cause the RBC to move 
from the wall of capillaries towards the centre, especially when shear rate is  low and 
red cell aggregation occurs.  As a result, a relatively cell-free plasma layer develops 
near the wall, and the RBC mean velocity is greater than the mean blood velocity 
(McWhirter et al., 2012). This causes two hydrodynamic effects known as the 
Fahraeus and Fahraeus–Linqvist effects which take place in the flow of blood when 
the diameters of micro-vessels in the vasculature are decreased from about 0.3 mm to 
10μm.   The first effect is the decrease in tube (small vessel)  haematocrit compared 
to the systemic (large vessel) haematocrit because of the unequal average flow rates 
of the RBC and plasma in small tubes.  The second is the decrease in apparent 
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viscosity of the blood as the tube diameter decreases, because of the decrease in 
haematocrit (Goldsmith, 1986).  
1.3.2.3  Blood flow and cell deformation in capillaries 
 The apparent viscosity increases again when the diameter decreases further 
(<10μm).  This phenomenon is called inversion Fahræus-Lindqvist effect 
(Whitmore,  1967). In these capillaries, the cells flow essentially in single file and 
their ability to deform and enter the vessel determines resistance to flow, along with 
the plasma viscosity.  The deformability of RBC is mainly determined by its 
membrane characteristics, and in pathological condition, a severe decline of RBC 
deformability can lead to raised flow resistance (Nash and Egginton, 1993). While 
viscosity of blood in large vessels is not usually affected  by WBC because of their 
low number, in capillaries WBC can hold up flow because they are much more rigid 
than RBC (Nash, 1991).  Thus WBC enter capillaries about 1000 times slower than 
RBC (Bagge, 1983).Activated WBC undergo changes in their cytoskeleton and 
become even more rigid, so that they may block capillaries in disease (Ernst and 
Matrai, 1986)  
1.3.3 Adhesion of leukocytes and platelets from flowing blood 
1.3.3.1 The Multi-step adhesion paradigm 
In order of leukocytes to carry out their immune functions, they need to travel 
from the blood through the endothelium into tissue.  Platelets must adhere to the 
walls of damaged vessels to play their role in prevention of blood loss.  In both 
cases, the cells must first adhere and then obtain signals which change their 
behaviour (Figure 1.4). 
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For leukocytes a multi-step adhesion cascade was first described in the 1990s 
(Butcher, 1990, Springer, 1994)(see Figure 1-4 A).   The process consists of 
overlapping steps: step 1: Capture, where leukocytes tether to the endothelial cells 
via specific fast-acting adhesion receptors; step 2: Rolling, where leukocytes tumble 
slowly on the EC until they are activated by chemoattractants on the endothelial 
surface; step3: Firm adhesion of the activated leukocytes to the EC luminal surface;  
step 4: Transmigration, where leukocytes travel over then through the EC and the 
basement membrane into the tissue.  Two pathways are possible when crossing EC; 
either between cell-cell junctions (paracellular pathway) or through the cell body 
(transcelluar pathway) (Ley et al., 2007).  Later studies showed that platelets also 
used a multi-step process where they first bind unstabley and flip over along the 
collagen surface  (Varga-Szabo et al., 2008).  (see Figure1-4 B).  They then become 
activated and firmly adhered.  Finally, they spread and start to bind other platelets, 
but do not migrate.  Molecular mechanisms underlying adhesion and activation are 
described in the following section. 
However, before adhesion can happen in the circulation, the leukocytes and 
platelets must come into contact with the vessel wall.  Both travel mixed with the 
more numerous RBC inside the blood vessels but are forced toward the vessel wall 
in a phenomena called margination (Goldsmith and Spain, 1984). This margination 
depends on cell size and the blood shear rate, and is described further in Section ( 
1.3.4.1)  The capture after margination is also dependent on the shear rate and shear 
stress at the wall, factors considered in Section(1.3.4.2) 
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1.3.3.2 Mechanisms of leukocyte adhesion 
EC activation is the starting point of the leukocytes adhesion cascade which 
occurs in post-capillary venules in inflammation (Springer, 1995, Butcher, 1990, 
Carlos and Harlan, 1994, McIntyre et al., 2003). Cytokines or inflammatory agonists 
such as thrombin upregulate expression of specialised receptors on the endothelial 
surface, including the selectins, P-selectin (CD62P) and E-selectin (CD62E). E-
selectin is expressed exclusively on endothelial cells, stimulated by TNF-α, 
interlukin -1 beta or bacteial endotoxin (Bevilacqua et al., 1987)(.  P-selectin is 
expressed on platelets and EC, where it is stored in Weibel-Palade bodies and can be 
rapidly mobilised by thrombin (Bonfanti et al., 1989).  At the vascular wall, 
leukocytes are captured by these specialized 'rolling' receptors, which have a rapid 
reaction rate with their glycoprotein ligands on the leukocytes (Lasky, 1992). The 
bonds also have rapid reverse rates, so that the leukocytes do not adhere firmly, but 
roll along, making and breaking bonds. L-selectin expression is restricted to 
leukocytes and it has a significant role in the recruitment of naive lymphocytes to 










Rolling leukocytes contact chemoattractant agents such as chemokines also 
presented by the activated EC (e.g., IL-8 which activates neutrophils) (Springer, 
1995).  This leads leukocyte integrins to be activated in turn by “inside-out” 
signalling, which changes the affinity of the integrins which moves the cascade to 
the next stage of firm adhesion.  The major leukocytes integrins at this stage are of 
the β2-family (αLβ2 and αMβ2; (see Section 1.3.3.5) and also α4β1-integrin.  The 
endothelial ligands to which leukocyte integrins bind are immunoglobulin gene 
superfamily (IgSF) members;  β2-integrins particularly bind intercellular adhesion 
molecule-1 (ICAM-1; CD54); α4β1-integrin binds vascular cell adhesion molecule-1 
(VCAM-1; CD106) (Phillipson et al., 2006).  When leukocytes adhere firmly to the 
endothelium, they migrate over, then through endothelium via intercellular junctions 
Figure ‎1-4: Leukocytes adhesion cascade (Adapted from Lecture Notes of Gerard 




by the interaction between integrins and their IgSF ligands in a process called 
transmigration. Several junctional proteins work together to complete this process 
such as CD31, CD99, and junctional adhesion molecules (JAMs).  Leukocytes may 
also penetrate into extravascular tissue by passing through EC instead of moving in 
between the junctions (Ley et al., 2007).  
A dynamic interaction between cell surface integrins and leukocytes actin 
cytoskeleton is required for the migration step. Leukocytes spread on the surface and 
transmigrate by lamellipodia formation at the leading edge.  The friction force 
generated at the front of the cell is adequately strong to pull leukocytes forward, 
while new attachments are made at the front and old ones reversed at the rear (Ley et 
al., 2007).  
These processes are similar for different types of leukocytes, although 
subsets may respond to different chemokines and utilise different integrins.  Notably, 
mononuclear cells (but not neutrophils) can use the interaction between α4β1- 
integrin and VCAM-1 to be captured from flow, as well as for firm adhesion after 
activation. 
1.3.3.3 Mechanisms of platelet adhesion 
                When collagen is exposed due to endothelial injury, platelets adhere and 
accumulate at the site of the injury to form a plug in the injured vessel and facilitate 
the coagulation cascades so that a stable clot is formed. During physiological 
conditions, platelets do not adhere to endothelium because the collagen and 
fibronectin are not exposed.  Platelet 
26 
 
adhesion is a coordinated process and happens in stages that are similar to leukocyte 
adhesion except that platelets adhere to the arterial subendothelium where shear 
forces are higher than in venules (see Section 1.3.4).   
Stages of tethering, rolling, activation and firm adhesion are seen. To start, 
von Willebrand Factor (vWF) binds to collagen and then binds to platelet 
glycoprotein (Gp) GPIb in an “on-and-off” manner  hich results in the formation of 
tethers which are multiple extensions of the platelet membrane (Dopheide et al., 
2002).  The platelet roll or flip along. In this step collagen and GPVI interact 
together in a low affinity bond (Varga-Szabo et al., 2008), which gives an activation 
signal so that adhesion is strengthened by the GPIa/IIa receptor (α2β1-integrin) 
(Rivera et al., 2009). The next step in activation is stimulated when platelets release 
thromboxane A2 and adenosine diphosphate, and /or when the vessel wall secretes 
tissue factor which activates thrombin (Varga-Szabo et al., 2008).  As a results the 
activation step is completed and firm adhesion is supported by the contact between 
GPIIb/IIIa (αIIbβ3-integrin) with fibrongen and vWF (Jackson, 2008).  At this stage, 
platelets also spread on the surface and bind to incoming platelets via αIIbβ3-integrin 
on each forming a sandwich with fibrinongen.  Large platelet aggregates may build 
up on the surface. 
1.3.3.4  Leukocyte-platelet interaction 
 During inflammation, both platelets and leukocytes may become activated 
and adhere to each other either in the blood or on damaged vessels.  The first 
adhesive contact between neutrophils or lymphocytes and platelets on a surface 
happens when P-selectin glycoprotein ligand 1 (PSGL1) on the leukocytes identifies 
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P-selectin on activated platelets  (Lalor and Nash, 1995, Piccardoni et al., 2001, 
Buttrum et al., 1993).  
 Conformational changes in αMβ2-integrin may take place as a result of 
neutrophil activation and also platelet-derived chemokines, to encourage firm 
neutrophil adhesion (Sheikh and Nash, 1996, Stone and Nash, 1999). For monocytes, 
ability to adhere is increased because of the platelets binding to β1- and β2-integrins 
on monocytes (Martins et al., 2006).For lymphocytes, platelets may help tethering to 
peripheral lymph nodes in high endothelial venules for homing during adaptive 
immune responses (Elzey et al., 2003).  Platelets and leukocytes may also form 
aggregates in the blood when platelets are activated (Rinder et al., 1991).  The first 
step is again mediated by P-selectin interacting with PSGL-1 (Maugeri N, 1994).   
The adhesion processes described above are of interest here because stem 
cells are widely believed to adhere from flow using similar mechanisms and 
receptors (Teo et al., 2012). Also, stem cell-platelet interaction has been suggested as 
a mechanism for capturing cells from the blood (Teo et al., 2012).  This is considered 
further in Section( 1.5.4.4) after some aspects of stem cell biology have been 
described.  Another common theme is the use of integrins for adhesion.  Leukocytes 
have specialised β2-integrins and platelets have αIIbβ3-integrin.  Most other cells do 
not have these integrins but do have other integrins used for adhesion to matrix.  
Thus the next section briefly reviews characteristics of integrins. 
1.3.3.5 Integrin adhesion molecules and their ligands 
                 In 1986, the expression “integrin”  as used to described a compound 
surface protein which was an essential element for the transmembrane link between 
the extracellular matrix (ECM) and the cytoskeleton of surface adherent cells 
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(Tamkun et al., 1986).  After that, integrins were realised to be a family of cell-
surface receptors that are structurally homologus transmembrane proteins. The 
molecules are identified as heterodimeric receptors that consist of non covalent 
linked α- and β-subunits (Hynes, 2002) (Figure1 5). 
There are 18 kno n α-subunits and 8 kno n β-subunits in the family of 
human integrins, with an I-domain which is the main ligand-binding site found in 
many of the α- subunits (Takagi et al., 2001). They are involved in cell-matrix 
binding as well as cell-cell binding, with different specificities arising from the 
different α- and β-subunit combinations.  The ligands of the different integrins are 
summarised in Figure 1-6.  
Different cell types express different integrins, although many cells share 
expression of the common matrix-binding integrins.  Nonetheless, some cells types 
have specific integrins which are not expressed on other cells; for instance, as noted 
above, leukocytes express unique β2 integrins (Kilshaw, 1999).  The first discovered 
integrin in humans  as αLβ2 (Sanchez-Madrid F, 1982) which is expressed on 
different immune cells including neutrophils, monocytes, lymphocytes and dendritic 
cells (Smith, 2008) and binds mainly to ICAM-1, ICAM-2 and JAM-A (Ostermann 
et al., 2002).  
A characteristic of integrins on leukocytes and on platelets is that they may 
exist in non-active, non-binding states on unstimulated cells.  When the cells are 
activated by agonists, inside out signalling causes change in the conformation of the 
integrins which increases their affinity (Luo et al., 2007). Integrins are not only 
considered adhesion molecules but also involved in a range of signalling functions 
(Danen and Sonnenberg, 2003).  On binding to ligand there is 'outside-out' 
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signalling, which modifies cell responses such as spreading in platelets and 

























Figure ‎1-6: Integrin family. Grouping of the integrin subunits in cells acccording to  




1.3.4 Effect of haemodynamics on adhesion 
The multi-step adhesion processes described above are adapted for 
recruitment of different cells from the blood (Watts et al., 2013).  Several of the steps 
are influenced by the blood flow and blood rheology described earlier.  Adherence of 
platelets and leukocytes with the walls of blood vessels is controlled by three main 
factors i.e. margination of these cells allowing them to come close to the wall of 
vessel, and shear rate and shear stress at the vessel wall which affect the 
effectiveness and stability of adherence.  This section considers how the initial steps 
of margination and initial attachment are influenced by the above factors and their 
link to cell and blood rheology: cell size and aggregation, haematocrit and blood 
viscosity.  This will enable later discussion of the adhesion of stem cells. 
1.3.4.1 Cell margination in blood - effects of cell size and shear rate 
Margination refers to a state during which platelets or leukocytes are 
displaced radially towards the walls of blood vessels by the RBCs flowing in the 
centre. Variation is observed in the degree of margination in different regions of the 
circulation and between margination of platelets and leukocytes (Palmer, 1967).   In  
suspensions flowing in tubes, particles tend to move away from the wall towards the 
centre.  In blood, different cellular blood components move away from the vessel 
wall at varying rates because of differences in their relative sizes. In increasing 
order, the tendency of different blood components to move away from the wall 
towards the vessel centre was found to be platelets < single RBC < leukocytes < 
RBC rouleaux (or aggregates) (Palmer, 1967). Distribution of different blood 
components is controlled by the rate with which they move towards centre. For 
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instance, due to their smallest tendency, platelets are more likely to be marginated 
(present on the periphery) than others and rouleaux are mostly found in the centre 
(Aarts, 1985).  
Margination also depends on shear rate because of its effects of RBC 
rouleaux which dissociate as shear rate increases.  Leukocytes are only marginated at 
low shear rate in blood, and if red cell aggregation is abolished using washed RBC 
instead of whole blood, their margination is lost even at low shear rate (Goldsmith 
and Spain, 1984). Platelets are however smaller than individual red cells, and even 
without rouleux formation and at high shear rate, they are marginated (Watts et al., 
2013).  
The presence of red cells is essential for margination, but margination of 
leukocytes and platelets occurs over a wide range of haematocrits, and similar 
numbers are found adherent to the upper or lower surfaces of adhesive tubes (Abbitt 
and Nash, 2003, Watts, 2015). However, at very low haematocrit (10%) in horizontal 
tubes, sedimentation of red cell aggregates and leukocytes did occur and few 
leukocyte were seen or adhered at the upper surface, although platelets did adhere 
(Watts, 2015).  This was presumably because sedimentation rate is strongly 
dependent on particle diameter.  If suspensions of leukocytes or platelets alone are 
perfused without red cells, the leukocytes sediment towards the lower surface and 
can adhere there, but platelets do not adhere efficiently presumably because they 
sediment slowly (Watts, 2015).  
Cells larger than leukocytes in the blood might fail to marginate even at low 
shear rate, if they are larger than rouleaux.  At the same time, the high sedimentation 
rate of large cells could make them to settle away from the upper surface but towards 
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the lower surface, to give an unequal distribution even when red cells are present. 
This has never been tested to our knowledge. 
1.3.4.2 Effects of  shear rate and shear stress, and cell size on cell attachment 
from flow 
The leukocyte adhesion cascade takes place mainly in post capillary venules, 
at low shear rates.  Platelet adhesion can occur in all vessels including arteries with 
high shear rate. Apart from margination described above, these findings appear to 
arise from the effects of shear rate and of shear stress on cells of different size (Watts 
et al., 2013). 
 Shear rates at the wall of a vessel affect the velocity of a cell before it is 
adherent and the wall shear stress affects the force on a cell if it adheres (see Figure 
1-7).  The velocity of the cells is proportional to its radius and the wall shear rate, 
while the force on an adherent cell is proportional to its radius squared and the wall 
shear stress (Goldsmith and Spain, 1984). The higher the velocity the lower the 
likelihood of the cell formaing an adhesive receptor-ligand bond, while the higher 
the force, the less likely that the bond will remain (Chen and Springer, 2001).  Thus 
one can expect decreasing formation and survival of adhesive bonds in high shear 
regions of the circulation, and for any region of the circulation, smaller cells will 
travel slower and experience less force. 
In blood flow, wall shear rate and stress vary greatly. In particular,across the 
circulation shear rates lie in the range of around 100-5000s‾¹ and shear stresses lie in 
the range of approximately 0.2-10Pa (Tangelder et al., 1988, Lipowsky, 1988). 
Moreover, leukocyte adhesion can be seen only in regions where shear rates are low, 
mostly located in post capillary venules. Conversely, platelet adhesion is mostly seen 
34 
 
in areas where there are high shear rates and stresses i.e. on the arterial side of 
circulation. This variation between the adhesion demonstrated by platelets and 
leukocytes can be linked to the difference in their sizes (Watts et al., 2013). Due to 
their small size, platelets move along the wall of vessel with near-wall flow velocity 
~four times lower in comparison with leukocytes. Additionally, the force exerted on 
the adhesive bonds is also lower by a factor of 16 due to the small size of platelets. 
Hence, it can be stated that although the adhesion receptors of platelets demonstrate 
similar intrinsic kinetics, they are able to adhere with walls of vessels over a broad 
range of shear rates and stresses (Doggett et al., 2002).  If a cell were twice the 
diameter of a leukocyte, it would be expected to travel twice as fast and experience 
four times more force for a given shear rate and stress. 
Researchers have carried out both in vitro and in vivo studies to study the 
influence of shear rate on adhesion. Isolated leukocyte suspensions have been used 
to study the influence of shear rate on leukocyte adhesion in vitro. Two comparable 
studies have been conducted to analyse adhesion behaviour  of leukocytes on human 
umbilical vein endothelial cells (HUVEC)  which were activated by cytokine- and 
subjected to different shear rates. A parallel plate flow chamber was used to develop 
shear rates (Lawrence et al., 1987, Lawrence and Springer, 1991). It was 
demonstrated by these two studies that the number of adhering cells reduced by a 
factor of 30  ith the increment in shear rate from 280 to 430s‾¹.  Abbitt and Nash 
studied the influence of shear rate on leukocyte adhesion in whole blood using a 
rectangular glass capillary coated with P-selectin as the surface for adhesion (Abbitt 
and Nash, 2003). It was found that there was a reduction in the number of adhering 
leukocytes with the increase in shear rate and few cells demonstrated adhesion when 
35 
 
the shear rate was above 280s
-1
.  Increased adhesion of rolling leukocytes with 
reduction in shear rates in mesenteric venules (diameter 25-40μm) of a cat has been 
demonstrated in vivo (Bienvenu and Granger, 1993, Perry and Granger, 1991). 
These researchers used an adjustable screw clamp on the arterial side of the 
circulation to alter the wall shear rate. It was also demonstrated that decrease in shear 
rate reduced the rolling velocity of the adherent leukocytes (Perry and Granger, 
1991).  
Adhesion of leukocytes and platelets in blood was compared by Watts et al. 
(Watts et al., 2013), over a range of shear rates, for capillaries coated with P-selectin 
or collagen.  As expected, they found that platelets adhered up to higher  shear rates 
than leukocytes.  Also, changes in red cell aggregation had opposite effects.  
Aggregation increased leukocyte margination and adhesion, but decreased platelet 
adhesion. The differences between leukocytes and platelets were attributed to 
differences in their size affecting velocity and force applied to cells at the wall, and 
also the effects of the cell-free layer that develops at the wall at low shear when 
aggregation is present. 
 In summary, studies on flowing leukocytes and platelets have described 
multi-step adhesion processes, identified key receptors for adhesion, and shown the 
importance of flow parameters and blood rheology.  Comparable studies have been 














Figure ‎1-7:   Schematic of effects of wall shear rate and shear stress on a platelet or 
leukocyte adhering to a vessel wall. 
 (Adapted from Lecture Notes of Gerard Nash, University of Birmingham; with permission).  
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1.4 Characteristics of EPC 
1.4.1 Isolation, culture and identification of human EPC 
Two methods have been used for isolating and culturing EPC from human 
blood, which result in early EPC (eEPC) and outgrowth endothelial cells (OEC).  In 
the first approach, mononuclear cells (MNC) from human peripheral blood or cord 
blood are collected and plated in dishes that are coated with fibronectin in a cell 
culture medium that contains fetal calf serum along with various endothelial growth 
factors (VEGF ,hEGF, R3-IGF-1, hFGF-B) (Ito, 1999, Hill and Goldspink, 2003). 
After 48 hours, the non-adhered cells are collected and subsequently cultured on 
another fibronectin-coated surface with the same medium, generating  round cells in 
colonies after 5 days. The cells isolated by this method are identified as early 
outgrowth EPC or colony-forming unit-EC (CFU-EC) (Yoder et al., 2007).  This 
method is simple but does not encourage the appearance of an EPC that can generate 
mature EC.  A number of proteins classically reserved for endothelial cells (von 
Willebrand factor, endothelial nitric oxide synthase, CD31, CD144, and vascular 
endothelial growth factor 2 receptor [KDR]) (Hassan et al., 1986, Schmeisser et al., 
2003) are expressed by monocytes which are derived from peripheral blood MNC 
when cultured on plates with fibronectin in media that contain endothelial growth 
factors. However, this method cannot be recommended for isolation of EPC since the 
resulting cells express CD45 suggesting they are of haematopoeitic lineage (Fadini et 
al., 2012).  
In the second  method, isolated MNC are seeded onto plates coated with 
collagen I.  The non-adherent cell population is removed within the first 24 hours in 
order to remove contaminating cells of leukocyte lineage, and the adherent 
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population is cultured. After about two to three weeks, colonies  arise from these 
cells and are recognized as endothelial colony-forming cells (ECFC) or late 
outgrowth EPC (Yoder et al., 2007).  These cells express CD31, VE-cadherein, and 
vWF  in the absence of CD14 or CD45, and are able to bind and internalize DiI-
acetylated-LDL. They thus express EC-markers and absence of monocyte features 
(Yoder et al., 2007).  Late outgrowth EPC were also found to have similar 
characteristics to cultured arterial endothelial cells (Brown et al., 2009).  Human 
EPC used in the current study were derived by the second method. 
1.4.2  EPC Mobilization and Recruitment 
When the body suffers from hypoxia and trauma, EPC mobilizing factors are 
produced such as colony stimulating factor, VEGF and basic fibroblast growth 
factor.  In the bone marrow this leads to increased  enzymatic activity of matrix 
metalloproteinases (Francisco and Dias., 2012). Activation of matrix 
metalloproteinase-9 promotes the transformation of membrane-bound Kit ligand to a 
soluble Kit ligand, leading to diversion of the hemangioblast to either hematopoietic 
precursor cells or EPC (Urbich and Dimmeler, 2004) .  During ischemic injuries 
such as a heart attack, EPC are mobilised and play a role in neovascularization and 
repair of endothelium by their capability to incorporate incorporate in new blood 
vessels and/or to produce proangiogenic factors (Cao, 2010).  It is proposed that the 
signal leading to EPC egress from bone marrow comes from a peripheral blood 
signal arising from chemoattractants from the site of injury (Hutter et al., 2004). In 
animal studies, increased circulating EPC number following ischemic limb or 
endothelium damage was also associated with the high levels of endogenous VEGF 




EPC need specific molecules to adhere and migrate from the blood. Adhesion 
molecules including P-selectin glycoprotein ligand (PSGL)-1 and β1-integrins on 
EPC may bind to endothelial receptors to allow capture and then firm adhesion 
(Langer et al., 2006). When  EPC interact with tissue-specific chemokines, they 
become activated and start integrin-mediated adhesion to endothelial vascular cells 
and finally transendothelial migration into sites of vascular and tissue remodeling 
(Francisco and Dias., 2012). Usually, the concentration of chemokines is greater in 
regions of tissues undergoing active remodeling (Francisco and Dias., 2012).  
A number of studies suggest that platelets play a role in the recruitment and 
differentiation of EPC.  (Langer et al., 2006) found that platelets could affect both 
EPC adhesion and chemotaxis.  In mice, surface-bound platelets used PSGL-1 and 
VLA-4 to capture EPC under high-shear flow conditions and promoted their 
differentiation, judged by development of endothelial markers vWF and  Weibel 
Palade bodies. Later studies identified stromal cell-derived factor 1α as a platelet-
derived chemokine promoting capture and differentiation of EPC in damaged arteries 
(Massberg et al., 2006, Stellos et al., 2008).  Human platelets also captured EPC 
from flow in vitro, and when P-selectin or P-selectin glycoprotein ligand-I (PSGL-I) 
was blocked, the platelets-EPC interaction was inhibited, but not when  
glycoproteins Ib-IX-V or IIb/IIIa was blocke (Lev et al., 2006).  
1.4.3  Differentiation of EPC 
EPC contribution to new vessel formation and remodeling, depends on three 
processes: differentiation into mature EC, direct incorporation into neovessels, 
and/or production of paracrine and/or juxtacrine signals which encourage 
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interactions with pre-existing EC (Francisco and Dias., 2012). EPC differentiation 
into EC can be subdivided into three steps: direct interaction bet een integrin α5β1 
and fibronectin   is essential in the initial steps of EPC differentiation (Urbich and 
Dimmeler, 2004); to regulate EPC proliferation and survival, growth factors 
including the VEGF family are required;  in order for differentiated EPC to function 
as mature EC, they must acquire the specific phenotype which depends on the 
regulation of the transcription factor HoxA, which regulates the expression of 
endothelial nitric oxide synthase, VEGFR-2 and vascular endothelial cadherin 
(Urbich and Dimmeler, 2004).  Currently, there is no exact characterization of when 
EPC turn into a mature EC in vivo, although the loss of CD133 followed by von 
Willebrand factor expression has been defined to the mark the formation of mature 
EC (Hristov et al., 2003).  
1.4.4 EPC function 
Bone-marrow derived endothelial cells are believed to be involved primarily 
in angiogensis, by direct generation of cells incorporated in the vessel wall and by 
releasing pro-angiogenic factors. The release of the angiogenic factor VEGF by EPC 
was first document by Rehman et al. (Rehman et al., 2003). Pro-inflammatory 
cytokines of varying profiles are also secreted by early growth EPC as well as late 
growth EPC (or ECFC),  and inhibition of such release is reported to be caused by 
statin treatment (Zhang et al., 2009). The role of mononuclear cells in neo-
angiogenesis induction and localization was investigated  in-vivo by Anghelina et al. 
(Anghelina et al., 2006). These cells took part through released angiogenic factors, 
and also produced enzymes which were responsible for matrix degradation.  
According to Krenning et al. (Krenning et al., 2009), EPC could act in a  similar 
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way. While formation of new blood vessels occurs when existing endothelial cells 
start sprouting and replicating, blood derived EPC were considered as facilitators and 
stimulant of this process.  Bone-marrow derived cells were also found to be involved 
in angiogenic repair processes and they may be the source of CD34 positive and 
CD41 negative cells which circulate in the bloodstream.  The role of reconstituted 
genetically marked bone marrow was supported by four different studies on animals: 
on collateral vessel formation in response to ischemia, on VEGF-stimulated 
angiogenesis and on tumour-induced angiogenesis.  Presence of bone-marrow 
derived cells as perivascular cells was documented in all of them  (Tibor 
Ziegelhoeffer, 2004, Rajantie et al., 2004, Zacchigna et al., 2008, Wickersheim A, 
2009).  
1.5 Characteristics of MSC 
1.5.1 Isolation, characterisation and differentiation of MSC from different 
tissues 
Isolation of MSC most commonly uses aspiration of bone marrow which is a 
relatively simple approach that can be applied in experimental models including 
mice. For initial MSC isolation, researchers have typically relied on the plastic 
adherence method, although minor modifications in the basic technique can lead to 
substantial differences in the phenotype and behaviour of the MSC obtained 
(Dominici et al., 2006).The minimum criteria to be fulfilled by a cell to be called as a 
human MSC (hMSC) was stated in a position paper published by the International 
Society for Cellular Therapy (ISCT) in 2006 (Dominici et al., 2006).  As per this 
statement, cells need to satisfy three conditions to be recognized as hMSC. These 
are: (a) expression of certain antigens on the cell surface, (b) demonstration of plastic 
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adherence and (c) ability to demonstrate tri-lineage differentiation i.e. osteogenic, 
chrondrogenic and adipogenic. The antigenic markers which are present on the 
surface of hMSC include CD73, CD90 and CD105. On the other hand, the  markers 
CD11b, CD14, CD19, CD45, CD79α and human leukocyte antigen-D related (HLA-
DR) must not be expressed by cells to be characterized as hMSC. However, a cell is 
not identified as an hMSC only on the basis of expression of these markers; 
fulfilment of the other two conditions is also necessary as these conditions prove to 
be the most suitable  for distinguishing hMSC from other extracted cells (Dominici 
et al., 2006).  
Thus, MSC must be capable of differentiating into different cell lineages 
including adipogenic, chondrogenic and osteogenic cells (Dominici et al., 2006). It 
has been reported  that human MSC differentiate into osteogenic lineages when they 
are incubated in growth medium containing fetal bovine serum (FBS), ascorbic acid, 
dexamethasone and β-glycerophosphate which amplify activity of alkaline 
phosphatase and deposition of calcium (Jaiswal et al., 1997, Pittenger et al., 1999).  
Alternatively, they differentiate into chondrongenic lineage when they are grown at 
high cell-density, exposed to transforming growth factor TGF-β in serum free 
medium. This treatment causes generation of greatly sulphated, cartilage-specific 
proteoglycans and type II collagen. Finally, when MSC grown in FBS containing 
medium supplemented with indomethacin, isobutyl methyl xanthine, insulin and 
dexamethasone differentiated into adipogenic cells as indicated by the appearance of 
lipid vacuoles with red O staining. However, all clonal populations are not capable 
of differentiating into these three lineages since certain MSC clones have been found 




Although researchers first discovered MSC in bone marrow, these cells were 
later identified in connective, adipose and muscle tissue of adult human beings 
(Friedenstein et al., 1974, Nathanson, 1985). Studies were carried out to find 
alternative sources of MSC since there occurs reduction in number and 
differentiation potential of MSC with age (D'Ippolito et al., 1999). Human umbilical 
cord blood (UCB) and veins, placenta, and amniotic fluid have been shown to 
contain MSC (Anker et al., 2004) (Panepucci et al., 2004). Besides these, numerous 
fetal tissues like spleen, lung, blood, liver and bone marrow are also  sources of 
MSC (Campagnoli et al., 2001, Anker et al., 2003). MSC have also been obtained 
from synovium as a population of adherent cells which demonstrated ability to 
differentiate into adipocytes, osteocytes and chondrocytes (De Bari et al., 2001).  
Those cells were able to make a contribution in regeneration of skeletal muscle in a 
nude mouse model (De Bari et al., 2003).  
Research in this thesis is based on comparison between MSC from three 
different sources i.e. MSC obtained from Wharton’s Jelly, MSC obtained from 
trabecular bone and MSC obtained from bone marrow.  
1.5.1.1 MSC and Bone Marrow 
Friedenstein et al (Friedenstein et al., 1970) described a bone marrow-derived 
fibroblast-like cell for the first time which later became the most extensively studied 
MSC which are sometimes regarded as the 'gold standard.  Bone marrow serves to be 
the main source of haematopoetic stem cells ( HSC) but non-HSC are responsible for 
sustaining the microenvironment required by HSC for their development and 
differentiation (Prockop, 1997). This bone marrow microenvironment, which is 
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known as hematopoietic niche, is largely supported by MSC (Pittenger and Martin, 
2004).  Physiologically, migration of MSC from BM to periphery is rare, and there 
are no protocols to induce the translocation. Therefore, direct MSC isolation from 
BM is the most successful method for MSC  preparation., and researchers have 
isolated MSC from several different species (Pittenger et al., 1999, Hatzistergos et 
al., 2010, Nardi NB, 2011). Isolation of MSCs from other cells in bone marrow 
aspirates involves three main steps: separation of non-nucleated RBC from nucleated 
cells using density gradient centrifugation; adherence of cells for culture onto plastic;  
utilization of trypsinization for separating monocytes from MSC.  Procedures for 
isolating and culturing MSC from different species are usually more or less same.  
Culturing of plastic adherent MSC has proven to be the most extensively used 
procedure for their isolation. 
While  bone marrow has been accepted as the chief source of MSC (Pittenger 
et al., 1999, Haynesworth et al., 1992), utilization of bone marrow-derived MSC is 
not recommended in all cases because of increased level of viral exposure and 
considerable reduction in number of cells and their ability to differentiate and 
proliferate with donor age. Moreover, the method of obtaining a sample of bone 
marrow is invasive and painful. For that reason, alternative sources of MSC can 
prove to be beneficial for improved clinical efficacy and greater accessibility 
(Stenderup et al., 2003, Zhang H, 2005). 
1.5.1.2 Trabecular Bone MSC 
Trabecular bone can also be considered as a source of MSC as  clinicians 
may use  fragments obtained from femoral heads as bone grafts. These bone 
fragments have been shown to contain mesenchymal progenitor cells, and usually 
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taken from individuals subjected to elective surgery for orthopaedic problems 
(Sakaguchi et al., 2005, Tuli et al., 2003).   MSC collected from trabecular bone 
from femoral heads that are fragmented mechanically demonstrate the characteristics 
which are required for therapeutic purposes i.e. ability to differentiate into multiple 
lineages (chondrogenic, osteogenic and adipogenic) and immuno-modulatory 
properties (see below). 
Initially, MSC were obtained from trabecular bone by digesting it with 
collagenase (Tuli et al., 2003). These MSC were collected from individuals subjected 
to surgery because of an osteoporotic hip fracture or individuals suffering from 
osteoarthritis, which could have been  changed inherently or due to the disorder and 
hence have different properties as compared to the cells taken from healthy iliac 
crest.  Such a comparison has been done by Sanchez-Guijo et al. (Sanchez-Guijo et 
al., 2009).  It was found that both sets of cells were similar in their multilineage 
differentiation potential, proliferation and immunophenotypes.  However, the MSC 
obtained from trabecular bone demonstrated increased expression of immature 
marker CD90, shorter expansion time through different passages and a greater 
proportion of cycling cells.  In another study washing MSC from trabecular bone  
gave a reduced differentiation capability compared to aspiration of MSC from the 
bone marrow in the same  elderly patients (Sanchez-Guijo et al., 2009). Culture 
expansion of cells under adipogenic conditions, osteogenic or chondrogenic 
conditions, all showed impaired differentiation form the former cells. Greater 
capability for differentiation was demonstrated if MSC were cultured with 1 ng/mL 
fibroblast growth factor 2 (FGF-2), which was taken to imply that MSC obtained 
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from trabecular bone of elderly individuals are not recommended for use as cell 
therapies for regeneration and bone repair unless they are grown with FGF-2.      
1.5.1.3 MSC from Umbilical Cords 
One vein and two arteries are present in the umbilical cord. Mucoid 
connective tissue termed Wharton’s jelly surrounds these vessels and contains  a 
network of collagen fibrils and glycoprotein microfibrils (Frank et al., 1983).  An 
outer epithelium derived from the surrounding amnion wraps the cord.  Since 1988, 
the umbilical cord blood has been employed as a source of MSC (Gluckman et al., 
1989).  Large numbers of hematopoietic stem and progenitor cells are found in the 
blood that remains in the umbilical vein after birth, which have been used as an 
allogeneic source for the treatment of several different genetic, oncologic, 
immunologic, hematologic and pediatric diseases (Gluckman et al., 1989, Kim et al., 
2002). Non-hematopoietic stem cells are also present, including MSC (Kogler et al., 
2004, Greschat et al., 2008).  Ho ever, Wharton’s jelly is a source of numerous 
stromal cells which may further differentiate to give rise to adipocytes, chondrocytes 
and osteoblasts (Wu et al., 2009, Baksh et al., 2007).  A distinct cell population of 
Wharton's jelly mesenchymal stromal cells showed stemness phenotype and may 
have been depositied during fetal migration (Wang et al., 2008).  Alternatively, these 
MSC may indeed be primitive stem cells generated from mesenchyme, embedded 
within the matrix of the cord. These MSC may play roles during gestationt through 
the release of proteins such as mucopolysaccharides, extracellular matrix proteins 
and glycoproteins which form a gelatinous ground substance to prevent the cord 
vessels from strangulation (Bongso and Fong, 2013).  MSC isolated from young 
donors tend to be more proliferative and immunosuppressive that those isolated from 
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adult donors and this may be attributed to the robust stemness and immune 
properties of fetal MSC (Kim et al., 2013).  
 Isolation of MSC can be achieved by explant culture of small pieces of cord 
or by enzymatic digestion (Salehinejad et al., 2012, Seshareddy et al., 2008).  The 
latter method generated nearly three times more cells per 1g of cord compared to the 
former method (Yoon et al., 2013), although the time taken by cells to double their 
number was longer for WJMSC obtained through enzymatic digestion (Han et al., 
2013). Additionally, MSC obtained from explants showed greater viability, perhaps 
because growth factors are discharged from tissue pieces in the culture (Yoon et al., 
2013, Sobolewski et al., 2005). Among these growth factors, bFGF is of significance 
since it controls self-renewal and accelerates chondrogenic and osteogenic 
differentiation of MSCs if present in the culture media (Tsutsumi et al., 2001, 
Auletta et al., 2011). 
1.5.1.4 Comparison of MSC from different sources 
In comparison with bone marrow, the umbilical cord offers benefits for use 
as a source of human stem cells (HSCs).  The umbilical cord is typically viewed as 
medical waste, and unlike bone marrow aspiration, it is collected through a painless, 
safe and simple technique after delivery.  Additionally, cord collection does not 
involve technical and ethical issues  and cord MSC are more primitive as compared 
to cells obtained from other sites and may thus be a preferable source of MSC for 
therapy (Wu et al., 2009, Lu et al., 2006, Wu et al., 2007).  On the other hand, it has 
been claimed that the rate of successful isolation of MSC from cords is smaller 
(63%) than  from bone marrow (100%) (Kern et al., 2006).    Moreover, allogenic 
transplantation of cord cells does not require a perfect match of the human leukocyte 
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antigen type (HLA), since there are less chances of immunological reactions to be 
induced by these cells as compared to cells taken from BM (Park et al., 2007).  
Large numbers of cells are usually needed in transplantation for clinical 
applications.  Regrettably, the number of MSC that can be collected from BM is very 
small. Reports indicate that the yield generated from bone marrow is only 0.001-
0.01% of mononuclear cells (Pittenger et al., 1999). On the other hand, yield 
obtained from 1g of adipose tissue was 5x10
3
 stem cells, about 500 times higher than 
for bone marrow (Fraser et al., 2006). According to another report, isolation 
efficiency demonstrated by Wharton’s jelly  as as high as 1-5x10
4
 cells/cm of cord 
(Weiss et al., 2006).  Comparing MSC obtained from bone marrow, adipose tissue 
and Wharton’s jelly, the last demonstrated greatest potential of proliferation (Amable 
et al., 2014).   It has also been demonstrated that MSC obtained from different 
tissues exhibit variable potential for differentiation into different cells. For instance, 
MSC from adipose were better more capable of differentiating into adipocytes than 
those from skin (Al-Nbaheen et al., 2013). In addition, MSC collected from cords 
were more capable of differentiating into chondrocytes as compared to the MSC 
collected from bone marrow (Sakaguchi et al., 2005, Wang et al., 2009). In 
comparison with MSC obtained from adult tissues, those obtained from fetal tissues 
demonstrated greater capability of differentiation into endothelial cells and 
cardiomyocytes (Kim et al., 2013). 
The above comparative studies are pre-clinical, in vitro investigations.  
Clinical trials  to analyse efficacy and safety of the therapeutic agent must employ a 
particular kind of MSC, but tyopically it is not known which type of MSC is most 
suitable for a particular therapy.  For that reason, research studies continue to 
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investigate different characteristics and potentials of MSC from different sources.  
For example, Hsieh and co-workers conducted a study to compare the ability of 
MSC collected from BM and WJ for regenerating infarcted myocardia (Hsieh et al., 
2013). According to them, WJ-MSC were more neurogenic, neuroprotective and 
angiogenic because of differences in their secretome. In addition, a pre-clinical trial 
of myocardial infarction in rats was conducted by Naftali-Shani and colleagues 
during which they used human stromal cells collected from different origins, 
particularly right atrium, subcutaneous fat, pericardial fat and epicardial fat (Naftali-
Shani et al., 2013). It was found that the greatest quantities of inflammatory and 
trophic cytokines were discharged in vitro by hMSC obtained from right atrium and 
pericardial fat. These hMSC also demonstrated increased levels of heart recovery in 
vivo. Such studies continue to be important for identifying the most suitable tissue-
derived mesenchymal stromal cells for a specific regenerative treatment.     
1.5.2. Functions of MSC 
1.5.2.1 MSC for Tissue Regeneration 
MSC can be of great significance for healing tissue damage owing to their 
distribution in a wide range of tissues, their differentiation potential and the 
reparative effects noticed when MSC are infused in pre-clinical and clinical models 
(Wei et al., 2013).   It is widely accepted that there are roles for MSC in tissue 
growth, healing of wounds and maintenance of the cell supply to compensate for the 
cells lost due to apoptosis and pathology.  Due to these roles, researchers and 
clinicians have used  MSC for treating degenerative disorders and tissue injuries. 
Clinical indices of liver function have been shown to improve after infusion of 
autologous bone marrow mesenchymal stem cells in individuals who are suffering 
50 
 
from liver failure or liver cirrhosis due to hepatitis B (Chapel et al., 2003, Kharaziha 
et al., 2009). Bone marrow MSC are also capable of bringing about significant 
therapeutic outcomes in musculoskeletal system. Reports indicate their efficiency in 
healing of burn-induced skin defects, bone damage due to osteonecrosis, diabetic 
critical limb ischemia and periodontal tissue defects (Lu et al., 2011, Yamada et al., 
2006, Rasulov et al., 2005). Pre-clinical studies indicate that hMSCs can be used for 
treatment of myocardial infarction and damaged cornea (Lee et al., 2009, Roddy et 
al., 2011).  Utilization of MSC for treatment of damaged tissues such as spinal cord, 
brain (Zeng et al., 2011) and lung (Ortiz et al., 2007),  involves similar activity . 
Moreover, the engraftment of haematopoietic stem cells can be complemented by co-
transplantation of MSC (Chapel et al., 2003).  
1.5.2.2 MSC for Immunomodulation 
Prevention of graft versus host disease by MSC in transplanted patients 
indicated that MSC have the potential for immunomodulation, and it has been found 
that they are also capable of acting against innate immunity (Sohn and Gussoni, 
2004, Fiorina et al., 2009). Accordingly, MSC are capable of reducing inflammatory 
responses, decreasing generation of ROS and thereby delaying apoptosis of activated 
neutrophils (Huang et al., 2009), and of causing suppression of NK cell responses 
(Zuk et al., 2002).  Monocytes are also prevented from differentiating into dendritic 
cells by MSC as they amplify secretion of anti-inflammatory cytokines (IL-10) and 
decrease generation of pro-inflammatory cytokines like TNF- α (Tomar et al., 2010, 
Houlihan et al., 2012). It has also been shown that MSC influence the survival, 
proliferation and effector functions of T cells thereby modulating development of 
adaptive immune responses connected to chronic inflammatory disorders (Krampera 
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et al., 2013, Morikawa et al., 2009). MSC also demonstrate cell-to-cell contact 
leading to modulation of immune responses, through several different proteins are 
expressed on the surface of MSC. For instance, Jagged-1, the notch ligand present on 
hMSC plays a role in suppressing activation of T cells (Liotta et al., 2008).  
In our laboratory, we showed MSC and endothelial cells communicate with 
each other  via soluble mediators to up-regulate production of IL-6 by MSC (Luu et 
al., 2013). This caused a reduction in the response of the endothelial cells to 
inflammatory cytokines and recruitment of leukocytes.   These studies suggest that 
MSC delivered in the blood and coming into contact with endothelial cells would 
enagage in 'cross-talk' that would be anti-inflammatory. 
There are thus a number of reports which indicate therapeutic use of MSC in 
pre-clinical animal models of immune diseases. MSC have proven to be effective in 
inhibiting graft-versus-host disease in individuals subjected to bone marrow 
transplantation (Muller et al., 2008, Prasad et al., 2011). These are of great 
significance especially for those patient with steroid resistance (Kebriaei et al., 2009, 
Wu et al., 2011, LeBlanc et al., 2008) Moreover, MSC reduced inflammation in 
patient with Crohn’s disease and systemic lupus erythmatosus (SLE) thereby 
decreasing damage to bowel and kidneys via inducing regulatory T cells (Sun et al., 
2010, Carrion et al., 2010, Ciccocioppo et al., 2011).  Due to their immediate 
immunomodulatory effects (Honmou et al., 2011), bone marrow MSC have been 
shown to be capable of improving amyotrophic lateral sclerosis, multiple sclerosis 
(Karussis et al., 2010, Connick et al., 2011, Choi et al., 2010, Honmou et al., 2011) 




1.5.3 Therapeutic administration of MSC - local vs. systemic delivery 
The site used for administration of MSCs for therapeutic purpose can 
influence the route taken by cells to reach the desired destination (Boltze et al., 
2015). For therapy, MSCs can be administered through intracardiac (IC), intra-
arterial (IA), intraperitoneal (IP) or intravenous (IV) injection. Although intravenous 
administration is least invasive, greater engraftment rates were demonstrated by IA 
and IC administration as compared to IV administration in  models of myocardial 
infarction (Barbash et al., 2003, Freyman et al., 2006, Walczak et al., 2008). They 
administered radiolabelled cells  in models with brain injury and found that IA 
injection in the extracranial right internal carotid artery (near target) led to greater 
homing of cells in the brain as compared to IV injection in the femoral vein. 
Walczak, et al, demonstrated that IA injection near the desired organ gave better 
results than IV injection at a distant point (Walczak et al., 2008). In cases of IV 
administration, MSC  accumulated in filtering parts of the body such as the spleen, 
liver or lung, but this accumulation was reduced in cases of IA injection (Barbash et 
al., 2003, Kraitchman et al., 2005, Sackstein et al., 2008). However, there was a 
greater chance of microvascular occlusions with IA injection (Walczak et al., 2008), 
a condition known as passive entrapment. In cases of IA and IC administration, 
greater number of MSC were able to reach and engraft at an ischemic site as the cells 
bypassed the lungs.  
IP administration of MSC is occasionally used. It was used it to administer 
MSC to foetuses in mice with muscular dystrophy as IV injection was considered to 
be inappropriate for this particular case (Chan et al., 2007). The donor cells were 
detected in muscular as well as non-muscular tissues. Finally, one can also use the 
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method of local delivery by injection of MSC directly into the target site. Beggs et 
al. administered Dil-labelled MSCs into baboons through IV injection but could not 
detect cells in limb muscles (Beggs et al., 2006). On the other hand, when they 
injected the cells directly into the muscle, DiO labelled MSCs could be detected 
there (Beggs et al., 2006). However, Muschler et al.reported that this method is not 
feasible in most clinical cases because it is too invasive, particularly in the brain or 
heart (Muschler et al., 2004). Moreover, locally injected cells may die prior to their 
role in healing because of limited supply of oxygen and nutrients.     
Since intravascular infusion is the most common form of therapy, it is 
important to understand the mechanisms by which MSC might be delivered to the 
microcirculation, become adherent to the walls of blood vessels and subsequently 
migrate through them.  It is also useful to consider whether endogenous MSC can 
circulate 'normally' in the blood. 
1.5.4. MSC circulation and recruitment to tissue 
1.5.4.1 Circulation of endogenous MSC 
The ability of MSC to circulate in the blood under physiological steady-state 
condition is controversial since the available literature contains reports with quite 
contrasting results. There are some reports which indicate existence of MSC in 
blood; though only very low levels of circulating MSC have been mentioned in these 
reports (Kuznetsov et al., 2001). A number of other studies indicate absence of any 
circulating MSC (He et al., 2007). It is quite difficult to harvest adequate quantities 
of circulating MSC at steady-state conditions owing to the requirement of obtaining 
blood through venepuncture. This process, theoretically, might discharge small 
numbers of connective tissues cells or pericytes into the collected blood or into the 
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circulation.  da Silva Meirelles et al. (Meirelles et al., 2006) failed several times in 
deriving a long-term culture of MSCs from blood accessed through the portal vein, 
which would have a lower chance of contamination of blood with pericytes and other 
connective tissue cells. Isolation of MSCs will be significantly influenced by the 
technique used to mobilize MSC in the peripheral blood, culturing methods and 
methods used to avoid and get rid of contamination. Heterogeneous expression of 
markers has been demonstrated by MSCs taken from peripheral blood. In particular, 
fibroblast-like stem cells isolated from blood of four different mammals proved to be 
adherent and demonstrated adipogenic and osteogenic potential (Kuznetsov et al., 
2001). These  isolated stem cells were different from hMSC isolated from bone 
marrow in the sense that they lacked endoglin and Stro-1 (Kuznetsov et al., 2001). 
MSCs have also been isolated from peripheral blood during a study carried out by 
Tondreau et al. (Tondreau et al., 2005). They used preselection methods for CD133+ 
cells in G-CSF-mobilized peripheral blood. According to Rochefort et al. (Rochefort 
et al., 2006), such stem cells were capable of differentiation into neuronal/glial cells, 
chondrocytes, osteoblasts and adipocytes. 
 
Perhaps of greater interest here is that greater levels of MSCs were detected 
in peripheral blood cells isolated from injured mice (injury causing intimal 
hyperplasia) in comparison with the controls i.e. mice without injury (Wang et al., 
2008). This finding is in accordance with the observation that peripheral blood levels 
of G-CSF and VEGF are also increased in the case of injury.  MSC obtained from 
injured mice demonstrated greater potential of differentiation as compared to those 
obtained from healthy mice:  when MSC from injured animals were cultured up to 
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ten passages, they demonstrated capability of trilineage differentiation in vitro (Karp, 
2009).  
1.5.4.2 Administration of MSC to the blood and subsequent fate 
If exogenous MSC are injected into the blood, they may get arrested non-
specifically in microvessels or get recruited inside the vasculature of the desired 
tissue and then  transmigrate across the endothelium in a process termed MSC 
homing by analogy to the behaviour of leukocytes (Karp, 2009).   However, in 
contrast to the well-established mechanisms of  adhesion and migration which 
characterize leukocyte homing, a discrete mechanism for MSC homing is not well 
established.  In practice, the available literature is deficient in data elucidating the 
final position of MSC after administration, so that it is difficult to determine whether 
the cells have been localized (captured inside vessels) or homed (subjected to 
targeted adhesion and transendothelial migration (Karp, 2009).  Nevertheless, there 
are a number of studies evaluating the adhesion molecules expressed by MSC and 
the cells' adhesive and migratory capabilities, described below. 
Non-specific localisation or capture in arterioles or capillaries may occur 
because of the size of the MSC which are larger than leukocytes (for human cells, 
diameter about 20µm vs <10µm) (Luu et al., 2013).  Indeed, when rat MSC 
(diameter 23µm) were infused into rats iliac artery, >90% became trapped in the first 
pass through  microvessels of the rat cremaester observed directly by intravital 
microscopy (Toma et al., 2009).  This study also showed that they blocked 10µm 
pore filters in vitro at pressures when mononuclear leukocytes cells did not.  In other 
animal models, MSC infused into systemic veins have been found to locate in large 
numbers in the lung  (Fischer et al., 2009, Kang et al., 2012). Mechanically-trapped 
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cells might still adhere to endothelium and migrate through it, and so adhesive and 
migratory behaviour would still be important in this situation. 
1.5.4.3 Adhesion molecules and mechanisms supporting MSC recruitment 
If the homing concept is correct, tissues would need to recruit circulating 
MSC from the flow to ensure effective delivery to damaged sites. For this purpose, 
MSC have on their surface a number of different adhesion molecules shared by 
leukocytes. These adhesion molecules include CD24, CD29 (β1-integrin), CD44 and 
CD49a-f (α1-α6-integrin) (Chamberlain et al., 2007), although other studies found 
no CD24 (Ruester et al., 2006). Adhesion molecules which are found on endothelial 
cells are also expressed by MSC. These molecules include vascular cell adhesion 
molecule-one (VCAM-1), intercellular adhesion molecule-one (ICAM-1) and 
intercellular adhesion molecule- two (ICAM-2) (Majumdar et al., 2003).  
It seems that the number and type of adhesion molecules found to be present 
on MSCs may be influenced by the source of MSCs and method used for their 
isolation and culture. For example, adhesion molecules expressed by hMSCs at 
passage 4 and passage 6 were found to be different (Aldridge et al., 2012). There was 
a linear relationship between passage number and the expression of CD49, but a 
decrease in the expression of CD44 was noted at passage 6.  However, other reports 
indicated no difference between the  molecules expressed by hMSCs at passages 3, 5 
and 7 e.g. CD73, CD90, and CD105  (Lo Surdo and Bauer, 2012). In relation to the 
origin of hMSCs, it was found that adhesion molecules expressed by hMSCs isolated 
from bone marrow and those isolated from adipose tissue differed.  Differences in 
expression were noted for cell adhesion molecules  CD49d (Integrin alpha4), CD54 
(ICAM-1), CD34, and CD106 (VCAM-1)  with large variation in CD106 (VCAM-1) 
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and CD54 (ICAM-1) (De Ugarte et al., 2003).   It is therefore likely that the source 
and methods of isolation and expansion must be taken into consideration while when 
evaluating adhesive properties of  MSC adhesion. The comparison becomes even 
more complicated if it is made between cells isolated from different species (such as  
humans, rats and mice) as different species demonstrate different profiles of some 
adhesion molecules (Chamberlain et al., 2007).  The substantial heterogeneity of 
MSC within an isolated population adds to the above-mentioned complications. The 
potential for differentiation, for example, varies between different cells of the same 
population (Pevsner-Fischer et al., 2011) While our knowledge about the 
mechanisms giving rise to this intrapopulation variation is still deficient, it has been 
established that intrapopulation variation  exists in terms of expression of adhesion 
molecules. For instance, only 50% of the MSC population from hMSC was found to 
express CD49d (Aldridge et al., 2012).  
Several mechanisms involving different  adhesion molecules have been 
proposed for recruiting flowing MSC to the vasculature. During a study on hMSC 
recruitment to the vasculature in mice, Rüster and colleagues (Ruester et al., 2006) 
found that P-selectin and the  α4β1-integrin/VCAM-1  played a major role in 
recruitment in venules. In comparison with the wild type controls, the P-selectin-/- 
mice demonstrated a lesser degree of MSC rolling in the ear venules. The function of 
other adhesion molecules was also investigated through in vitro studies that made 
use of endothelial cells as substrate for the adhesion. During a flow-based assay, the 
number of MSC demonstrating adherence decreased considerably when P-selectin 
 as blocked on the TNFα-treated endothelial cells (Ruester et al., 2006) . However, 
it was found that MSCs neither expressed P-selectin glycoprotein ligand-1(PSGL-1; 
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CD162) nor the alternative P-selectin ligand–CD24 on their surface. This implied 
that MSC expressed an alternative P-selectin ligand (Ruester et al., 2006) .  In the 
same study, adherence of MSC to the TNFα-treated endothelial cells was found to be 
reduced after blocking α4β1-integrin or VCAM-1 to a similar degree to each other, 
showing a role for this pathway (Ruester et al., 2006).   It should be noted that in 
these studies, flow was reduced to a very low shear tress (-) to allow attachment 
followed by an increase in flow to 'washout'.  In another study, low numbers of MSC 
adhered to cytokine-treated EC after prolonged perfusion at 0.1Pa, also through 
VCAM-1 (Segers et al., 2006).  
In a recent study from our laboratory (Luu et al., 2013) MSC were also 
perfused over EC treated with TNF.  It was found that MSC adhesion was negligible 
at a wall shear stress of 0.05 Pa, which resembles the low end of venular shear.  If 
the flow was decrease to 0.01 Pa to allow attachment, then washed out at 0.05 Pa, 
adhesion could be detected on stimulated, but not unstimulated EC (Luu et al., 
2013).  MSC adhered in large numbers if allowed to remain stationary in contact 
with EC for 30min before washout at 0.05Pa.  Chamberlain et al. (Chamberlain et 
al., 2011) also found little adhesion of perfused MSC to endothelial cells unless flow 
was stopped and the cells allowed to settle before washing out. These data suggest 
that attachment of flowing MSC in intact vessels would be rare under normal 
circulatory conditions, but that MSC could adhere to endothelium only if already 
arrested or trapped (Chamberlain et al., 2011).  
 A wide range of different cells express the glycoprotein CD44 on their 
surface, which can act as a ligand to allow adhesion via several other molecules 
including hyaluronan (Aziz et al., 2000). Its role as a ligand for P-selectin has also 
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been reported (Alves et al., 2008), and it may be the ligand for P-selectin expressed 
by MSC. Studies indicate that hematopoietic cell E-/L-selectin ligand (HCELL) is 
capable of binding with E-selectin  (Dimitroff et al., 2000, Burdick et al., 2006). 
HCELL is a specific glycoform of CD44 which is considered to be one of the most 
powerful ligands for E-selectin (Dimitroff et al., 2000) (Burdick et al., 2006). It has 
been reported that trafficking of human MSC to murine bone marrow is mediated by 
HCELL (Avigdor et al., 2004). While MSC express CD44 molecules heavily on 
their surface, it was found that MSC adhesion was not decreased by blocking E-
selectin on endothelial cells (Ruester et al., 2006). However, other researchers have 
found CD44 on hMSC to interact with E-selectin (Thankamony and Sackstein, 
2011).  
Herrera and colleagues (Herrera et al., 2007) demonstrated that mMSC were 
recruited to the renal microcirculation of mice after acute renal failure (ARF), in a 
process  here CD44  as required. They isolated mMSC from CD44−/− or CD44+/+ 
animals and then  administered into mice suffering from ARF. CD44+/+ mMSC 
were detected in the ARF animal’s renal circulation. On the other hand, the renal 
vessels of mice without ARF did not contain CD44+/+mMSC.  Likewise, when the 
researchers administered ARF animals  ith mMSC taken from CD44−/−animals, the 
administered cells were not detected in the renal microcirculation, implying that 
recruitment of mMSC required CD44 expression (Herrera et al., 2007). The 
recruitment was specific for CD44 expressed by MSC and when CD44 activity was 
inhibited through antibodies or treatment of the cells with hyaluronic acid, it also 
resulted in decreased renal localization of MSC (Herrera et al., 2007).CD44 was 
probably not the only receptor required for recruiting MSC into the renal 
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environment, because even in the case of blocked CD44, damaged tissues 
demonstrate a greater level of MSC recruitment compared to the tissues with no 
damage (Herrera et al., 2007). The molecular mechanisms involved in the mouse 
MSC recruitment to the heart were investigated in animals suffering myocardial 
infarction (Ip et al., 2007 ). Upregulation of several genes was recorded in the heart 
after infarct and these included the genes for VCAM-1, ICAM-1 and E-selectin. 
Recruitment of mMSC in the infracted myocardium decreased considerably when 
mMSC  ere treated  ith antibody against β1-integrin.   Blockade of α4β1-integrin 
(CD49d/CD29)  did not affect recruitment, and the particular α-integrin subunit 
 orking in this process  as not identified, although the presence of α9-, α6 and α8-
integrins were demonstrated (Ip et al., 2007 ).  
Given their inefficient adhesion from flow, surface modification of MSC has 
been used to try to improve homing.  Various techniques have been used to modify 
MSCs membrane, including delivery of sialyl Lewis X (SLeX), a mediator of 
leukocyte rolling.  hMSCs were fused with biotinylated lipid vesicles which enabled 
streptavidin-linked SLeX to bind. The authors noted an increase in MSCs rolling on 
P-selectin at a shear  stress of 0.05 Pa (Sarkar et al., 2010). Similarly, biotinyl-N-
hydroxy-succimide was fused to hMSCs and successfully bound to free amine 
groups. The authors noted again that this enabled streptavidin-linked SLeX to be 
bound to the surface which again led to an increase in MSCs rolling on P-selectin 
(Sarkar et al., 2008). This technique was later used in vivo to improve 
hMSCrecruitment  to inflamed mouse ear (Sarkar et al., 2011).  Directing MSC 
homing by using enzymatic modification techniques has been attempted. For 
example, the surface receptor CD44 was modified by enzymatic treatment to bind to 
61 
 
E-selectin. This conversion enhanced hMSC bone marrow homing in vivo (Sackstein 
et al., 2008).   
Another technique of surface receptor modification is genetic manipulation 
where the adhesion and homing receptors can be overexpressed.  For instance, 
genetic modification of CD44 to form the variant HCELL noted above, was found to 
increase adhesion from flow and transmigration of MSC through endothelial cells 
(Thankamony and Sackstein, 2011). Overexpression of CCR1 (chemokine (C-C 
motif) receptor 1) increased chemotaxis by MSC when stimulated by CCL5 
(chemokine (C-X-C motif) ligand 5) (Huang et al., 2010). In addition, 
overexpression of CCR1 enhanced engraftment after intra-myocardial injection in 
ischemic mouse heart studies.  The overexpression of CXCR4 improved MSC 
homing in myocardial infarction rat model (Bang et al., 2012). On the other hand, 
overexpression of CXCR4 and CXCR7 did not enhance MSC homing in a mouse 
renal injury model (Gheisari et al., 2012). These findings suggest that different 
techniques may be required to enhance MSCs homing depending on the target tissue 
(Cheng et al., 2008).  While genetic modification  has the potential to be a tool to 
promote MSC homing, unpredicted negative effects on cellular function may be 
problematic. For example, overexpression of survival genes (such as Akt) can lead to 
risk of tumourgenesis (Phillips and Tang, 2008).  
 Even though, collagen and fibronectin are  considered one of the major 
proteins in the Extra Cellular Matrix (ECM), their role in human MSC integrin 
receptors binding is not fully addressed.   
Studies of MSC adhesion to collagen and fibronectin are rare. There is only limted 
study which has addressed the binding between BMMSC and collagen. Study 
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conducted by Lan CW et al who studied the adhesive behaviour of osteoprogenitor 
cells isolated from bone marrow (BMSCs). They showed that these cell adhere twice 
more to the surface when the surface is coated with collagen under flow condition, 
Also, They noticed when they flush all marrow cells by shear stress of 1.10 dyne/cm, 
25% of cells which are adhered to collage coated surface remained attached to the 
surface despite the flush force which indicate the strength of the adhesion (Lan et al., 
2003). 
 Regarding collagen, a study was conducted to investigate the adhesive 
behaviour of BMMSC by using Collagen nanofibers scaffold. The authors reported 
that over 45% of BMMSc adhered efficiently to collagen which coated with 
nanofibers (Chan et al., 2009). additionally, studies on Murine bone marrow cells 
(BMC) revelled again higher MSC adhesion to collage coated surfaces (Vandersluijs 
et al., 1994).   
 In case of on fibronectin protein, Ogura N et al. (2004), found that fibronectin 
stimulated adhesion, spreading and growth of human BMMSC (Ogura N, 2004).  In 
addition, Veevers et al. (2011) found a receptor, α5β1-integrin, which support cross 
talk between growth factor receptor and integrin receptor signals on fibronectin 
(Veevers-Lowe et al., 2011).  This interaction between cell and fibronectin led to a 
chain of actions which caused greater phosphorylation of PDGFR-β and 
subsequently promoted the adhesion and migration of the human BMMSC. They 
noted that collagen types I or IV had little effect on PDGFR-β activity compared to 




1.5.4.4 The role of platelets in recruitment  of MSC 
Platelets have been reported to be involved in recruitment of MSC in both in 
vitro and in vivo models.   In a flow-based adhesion assay, Langer and co-workers 
(Langer et al., 2009) noticed an increase in the recruitment of hMSC to human 
arterial endothelial cells when the EC were pre-incubated with platelets. In 
particular, pre-incubation with platelets caused greater hMSC adhesion in 
comparison with the activation of EC with IL-1β. In vivo studies generated results 
which were in accordance with these findings. hMSC adhesion was found to be 
decreased considerably in a murine model with carotid artery injury after treatment 
with anti-GPIb and platelet-depleting antibody. It  as also demonstrated that αvβ3-
integrin blockade decreased the adhesion of platelets to immobilized hMSC (Langer 
et al., 2009).  In a rat model of pulmonary arterial hypertension, infused rat MSC 
protected again a rise in right-sided blood pressure and cardiac hypertrophy (Jiang L 
et al., 2012). MSC were found in the lung, and their adhesion there was reduced by 
blockage of P-selectin and of GpIIbIIIa. The same receptors were found to support 
attachment of MSC along with platelets to collagen in an in vitro flow assay.  It was 
concluded that platelets mediated MSC homing to the lung.  In a recent study, there 
was preferential trafficking of infused MSC to an inflamed vs control ear, but this 
was decreased if platelets were depleted from the blood (Teo et al., 2015). Direct 
observation of microvessels showed MSC adherent along with platelets and 
neutrophils.  The above studies strongly suggest that MSC will interact with platelets 
in blood and that this interaction will modify their behaviour in vivo. 
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1.5.4.5 Transmigration of MSC 
Transmigration of MSC through the endothelium  has not been investigated 
widely.  In a flow assay, adherent murine MSC spread and appeared to migrate 
across murine aortic endothelial cells over 1-2 hours (Chamberlain et al., 2011).  In 
that study, the MSC could also transmigrate across an endothelial monolayer on a 
porous filter over a 16 hour period.  In a static assay, (Steingen et al., 2008), 
transmigration of hMSC occurred via non-activated endothelial monolayer through 
interaction bet een α4β1-integrin and VCAM-1. Over about 60 minutes MSC 
embedded in the endothelial monolayer, and after 240 minutes, the endothelial 
monolayer released the integrated MSC allowing them under the monolayer.  Teo et 
al (Teo et al., 2012) observed transmigration of a proportion of adherent MSC 
through endothelial monolayer in about 1 hour, with adhesion and transmigration 
increased if the endothelial cells had been treated with TNF.  In contrast , the time 
for transmigration of leukocytes is 5-20 minutes (Ley et al., 2007).  The difference 
from the transmigratory pattern of leukocytes might be linked to the utilization of 
non-activated endothelium  or the lack of transmigratory potential in the MSC. For 
instance, considerably decreased transmigratory activity is demonstrated by 
lymphocytes on non-activated endothelium because relevant adhesion molecules are 
not present on the surface.  However, the available literature indicates that 
transmigration of MSC is regulated by MSC-endothelium interactions specific to 
these cell types, and that this process needs to be investigated in detail under 




Migration across filters has also been studied without an endothelial layer.  In 
studies of migration across 8µm pore filters coated with Matrigel, MSC from cord 
blood migrated slightly more efficiently than those from bone marrow in response to 
chemokine CXCL12 or hepatocyte growth factor (Son et al., 2006).  It was also 
noted that the number of MSC migrating decreased with increasing passage number.  
Others found that coating the under-side of an 8µm pore filter with fibronectin 
promoted migration of human bone marrow MSC (Veevers-Lowe et al., 2011).  
Migration was further increased by addition of platelet-derived growth factor, and 
migration was inhibited by blockade of α5β1-integrin. 
1.5.4.6  Outstanding questions in MSC recruitment 
 The studies of EPC, MSC, of leukocyte and platelet adhesion and of blood 
rheology described above raise various questions related to adhesion of flowing 
progenitors and the behaviour of MSC if infused into blood. 
 The leukocyte and platelet adhesion cascades have been well documented, 
and some reports suggest EPC and  MSC follow a similar multi-step process to 
leukocytes.  However, this literature is not extensive or all in agreement in relation to 
MSC in particular.  One of the shortcomings of the literature is the lack of studies 
which cover the effects of haemodynamic and blood rheological factors on MSC 
adhesion.  It is not clear whether MSC will marginate in blood, over what range of 
shear rates they can adhere, and how important their large size is compared to 
leukocytes and platelets.  There is doubt whether they can adhere to endothelial cell 
receptors from flow and little information on whether they can bind to the matrix that 
may be exposed in a damaged vessels, as platelets do.  On such surfaces, it is not 
known whether they can go through steps of  rolling, stopping, spreading and 
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migrating.  Most studies of MSC adhesion, spreading and migration have used static 
rather than flow assays.  
 Recent studies suggest MSC may interact with platelets as EPC were 
reported to  earlier, but how they interact in flowing blood is unclear, as are the 
receptors that may support their interaction.  This makes it difficult to predict how 
MSC might behave if injected into the blood for therapy.  In addition, most studies in 
this area have only used  MSC from bone marrow, and is not known how adhesion 
and recruitment and interaction with blood might vary between cells from different 
tissues, as other behaviours do. 
The above topics need  further investigation, comparing MSC from different sources, 
in dynamic models and including  presence of blood.  Clarification is also needed as 











1.6 Hypothesis and aims 
 The hypotheses in this thesis are that the adhesive and migratory behaviour of 
MSC varies between cells from different tissues, and that their adhesion from flow 
will be affected by presence of blood and interaction with cells in it.  Thus, we 
hypothesise that different MSC may be vary in how they will behave if injected into 
the circulation, and these differences may affect their use as a therapy. 
Therefore, the main aims of this thesis were: 
 To compare the adhesion of  EPC to MSC from different sources to different 
surfaces  (such as matrix proteins and endothelial receptors) under different 
flow conditions  in vitro. 
 To evaluate the ability of different MSC to spread on  different surfaces, and 
migrate . 
 To compare adhesion in blood to adhesion of isolated cells and evaluate 
interaction with platelets. 
 To evaluate receptors supporting cell adhesion in the different circumstances. 
Our initial intention to compare EPC and MSC was not extended beyond the studies 
of dynamic adhesion because of the need to focus on a specific cells and the relative 
lack of information on MSC behaviour in vivo (where EPC naturally circulate but 
MSC do not). 
 The overall aims were to provide better understanding of the impact of the 
physical factors on the adhesion behaviour of different types of MSC. This 
understanding will give insights into the behaviour of MSC in the circulation which 

















 The study was carried out after ethical approval from the Science, 
Technology, Engineering and Mathematical Ethical Review Committee of the 
University of Birmingham.  
2.1  Cell derivation and culture 
2.1.1 Basic cell culture 
 
 Endothelial progenitor cells (murine cells line or primary cells from umbilical 
cord blood) and mesenchymal stem cells (from bone marrow, trabecular bone or 
umbilical cord Wharton's jelly) were used in this study.  Their sources  are detailed 
below and culture media listed in Table 2.2.  All cell cultures  were performed  under 
sterile conditions, using a Class II microbiology safety cabinet. Culture media were 
filtered by Minisart 0.2 um single-use filter units (Sartorius Stedim Biotech, UK) 
before use.  Reagents to be used in the culture were pre-heated to 37 ᴼC using a 
heating box (Thermo Scientific, Town, County/State) for  minimum of 30 minutes.  
Cells were retrieved from cryo-preserved aliquots (see below), thawed rapidly, and 
grown to approximately 80% confluence in tissue culture flasks (25cm² or 75 cm²; 
Cellstar, Dorset, UK) maintained at 5% C02 and 37 ᴼC in a Heraeus incubator 
(Therm Fisher Scientific, Leicestershire, UK). A 25cm² culture flask (T-25) was 
used initially for growing cells from cryopreserved stock, and 75 cm² flasks (T-75) 
were used for expanding cultures. 
2.1.2 Subculture and cryopreservation of cells 
 
 To detach cells, they  were first washed using 3ml ethlenediaminetetraacetic 
acid solution (EDTA) and then  0.25% trypsin-EDTA solution was added for 4 
minutes (both from Sigma-Aldrich Co., UK).  The detached cells were diluted and 
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washed once using culture medium in a 15ml conical tube centrifuged at 400g for 5 
minutes.  The supernatant was removed and 3ml of fresh medium was added for cell 
suspension. The cells were either placed in a single T-75 (if taken from a T-25 flask) 
or divided between 3 different T-75 flasks (if taken from a T-75 flask) and then 
incubated at 37 ᴼC 5% C02 until they reached 80% confluence.  They were then 
either passaged again, cryopreserved or used in an assay. 
 For cryopreservation cells were dettached and washed as above, and re-
suspended in ice-cold Cryo-SFM freezing medium (PromoCell GmbH, Germany; 
1ml per T-25 flask). This suspension was transferred to an ice-cold cryovial 
(1ml/vial), placed at -80⁰C overnight, and then transferred to liquid nitrogen storage. 
2.1.3  Origin and derivation of endothelial progenitor cells (EPC) 
2.1.3a Murine EPC line  
 
 Murine foetal lung mesenchyme-derived mEPC (MFLM-4) were obtained 
from Seven Hill Bioreagents (Ohio,USA). mEPC were culture in Dulbecco's 
Modified Eagle Media (DMEM) with supplements (see Table 2.2). They were 
observed daily by microscope and the culture medium changed every 48h until 
passage or use. 
2.1.3b Primary EPC from human umbilical cord blood 
 
 Human hEPC were isolated from umbilical cord blood as described by 
Ingram et al. (2004). Umbilical cord blood was collected in citrate phosphate 
dextrose by the Human Biomaterials Resource Centre  (University of Birmingham) 





 and aliquots of 5ml placed on the top of 5 ml of 
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Histopaque 1077 and centrifuged at room temperature at 2500 for 30 mins.  The 
mononuclear  cells were collected from the plasma-Histopaque interface and washed 
3 times with PBS, re-suspended in 15 ml of cEPC culture media see Table 2.2, 
placed in a T-75 flask coated with 0.1 mg/ml rat tail type 1collagen (Becton 
Dickinson;UK) and cultured at 37 ᴼC 5% C02.  The medium was changed after 
24hours and then every 2-3 days thereafter. Endothelial cells colonies appeared 
between 14 to 22 days of culture.  The cells were then detached and transferred to a 
T25 flask and cultured and passaged as described above. 
2.1.4 Origin and derivation of mesenchymal stem cells (MSC) 
2.1.4a Bone marrow MSC (BMMSC) 
 
 Human bone marrow-derived MSC were from Lonza (Lonza Ltd., Basel, 
Switzerland) who provided  instructions for  culture which were strictly followed. 
The  recommended basal medium and the supplements needed for the culture are 
shown in Table 2.2.  Cells delivered frozen were thawed and expanded to passage 3 
(counting those supplied as passage 1) and then frozen in aliquots as described in 
Section (2.1.2).  Passage 3 aliquots were thawed and expanded, and used between 
passages 5-7. 
2.1.4b Trabecular bone MSC (TBMSC) 
 
 Trabecular bone chipping samples were provided by Dr A Thomas, Dr 
Andrew Filer and Dr Mark Pearson, taken from the femoral heads removed during 
hip surgery at the Royal Orthopaedic Hospital (Birmingham).  Before placing the 
samples into the T-25 culture flask with LG DMEM growth media Table 2.2, the 
bone pieces were cut into 2-3mm bits. The flasks were then incubated at 37°C, 5% 
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CO2. Depending on the donor, the time for achieving a confluent flask varied, but the 
average was about one and a half months  from when the material was initially 
separated.  After about 2 weeks, the BMSC could be observed adhered to the flasks 
after migration from the bone fragments.  Finally, the bone fragments were removed 
from the flask, cells were transferred to a T-25 flask and  passaged as described 
above. 
2.1.4c Umbilical cord Wharton's jelly (WJMSC) 
 
 Umbilical cords were collected by the Human Biomaterials Resource Centre  
(University of Birmingham) after informed consent.   For exposing the blood 
vessels, the cord was first cut into 5cm pieces and then each of the pieces was sliced 
longitudinally. After cutting out the vein and two arteries , the remaining tissue was 
cut into 3 pieces and placed in 50ml falcon tubes with 10ml of PBS (with calcium 
and magnesium chloride) and 50U/ml hyaluronidase (Sigma) and 1mg/ml 
Collagenase type 2 (C6885; Sigma). The samples were incubated for 5 hours at 37°C 
on a rotor. 
 To remove large pieces, the sample was diluted 1:10 in PBS and passed 
through a 70µm pore filter (BD Bioscience). The cell suspension was centrifuged, 
and the cell pellet re-suspended in culture media (DMEM Low Glucose; see Table 
2.2) and  seeded  in T-75-flasks . The medium was replaced every 2 or 3 days. The 






2.2 Characterisation of MSC  
 
 All MSC were characterized and fulfilled the criteria established by the 
International Society of stem cells therapy (2006).  They expressed CD90, CD73 and 
CD105 and lack expression of CD34, CD45, CD14 or CD79alpha ,CD19 CD11b and 
HLA-DR surface molecules, and were able to differentiate in vitro to adipocytes, 
chondroblasts  and osteoblasts,  
2.2.1 Surface characterisation 
 
 Accutase was used to detach MSCs (Lonza and UC). Then, the mixture was 
resuspended in 1ml of FACS buffer  (PBS awith 1% BSA).    MSC were isolated, 
counted and aliquots of 5x10⁴ cells were transferred to FACS tubes. The FACS 
tubes were spun at 400g for 5 minutes and the pellet was resuspended by adding 
100ul of FACS buffer. MSC phenotyping cocktail, antibodies against chosen 
integrins or  isotype controls (all 2.5µl; Table 2.3) were added for 20 minutes in the 
dark in the fridge. FACS buffer was used to wash the samples by adding 3ml, and 
then samples were spun for 5 minutes at 400g. cells were resuspended in 300ml of 
FACS buffer and the tubes were kept in ice until analysis. Samples were fixed in 1% 
Formaldehyde in PBS if the analysis was carried out after 24 hours.  For comparison, 
leukocytes were isolated from fresh blood (CD45+, CD20+ and CD14+ cells) and 
endothelial cells from umbilical cords (HUVEC; gift of Hafsa Munir). 
 The principle of flow cytometry depends on the light scattering and 
fluorescence features of single cells. Briefly, inside the flow cytometer chamber; 
labelled cells pass thorough a beam of laser light.  The intensity of light scattered by 
the cells or of fluorescent light is measured. The data is displayed in histograms 
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representing the size of the cells and their level of expression of labelled molecules. 
FACS samples were analysed using a Cyan flow cytometer(Dako) and Summit 4.3 
software was used to anlayse the data. 
 
2.2.2 Cell count and size 
 
 MSC counting and size measurements were done with several different 
techniques:  cellometer, Coulter counter and light microscopy. 
2.2.2a Cellometer 
 
 Cells in suspension were analysed using a Cellometer Auto T4 (Nexcelom 
Bioscience Ltd, Manchester, UK). The device incorporates a microscope and camera 
system that automatically measures and identifies the cells, considering their 
morphology, size and brightness using pattern recognition software and bright field 
imaging.The cell concentration and diameter were determined.  The disposable 
counting chambers of the cellometer enclosed two independent chambers of 
controlled height. A single channel pipette was used to transfer 20 µl cell suspension 
into each chamber  hich  as then placed in the device’s imaging slot. The data  ere 
calculated automatically and displayed on a linked PC screen. 
2.2.2b Coulter Counter 
 
 The counting and sizing of the cells was also been done using a Z™ Series 
Coulter Counter (Beckman Coulter, Buckinghamshire, UK). The cells were diluted 
typically 1:1000 in a conductive fluid (ISOTON II diluent;Beckman Coulter), and 
1ml was sucked  through a glass aperture with electrodes either side.   The change in 
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conductance registered as an increase in voltage as each cell passed through the 
aperture.   The number and size of the voltage pulses were analysed, to give the 
concentration and cell diameter  distribution, based on calibration with beads of 
known diameter.  Electronic 'gates' were set to count all MSC between 7-27 µm or 
only those 12-27 µm.  The Coutler counter could also be used  to count platelets (see 
Section 2.3.2) in the gate between 1-4µm (i.e platelets). 
2.2.2c Microscopy 
 
  Images collected by phase-contrast microscopy during and after cell adhesion 
assays (see Section 2.4.3)  were analysed offline using Image-Pro software (Media 
Cybernetics Inc., Maryland, USA). A computer mouse was used to draw around cell 
outlines and the programme calculated the surface area and the diameter of the circle 
with equivalent area as measures of size.  The size of images was calibrated using an 
image of a graticule with lines marked every 10µm.  In some cases, MSC were 
allowed to settle on a glass slide, and microscopic images were captured and 
analysed in the same way. 
 
2.3 Blood cells 
2.3.1 Blood collection 
 
 Blood was collected by venepuncture into sodium citrate 3.2-3.8% as 
anticoagulant in a mixture of 1:9.  Blood donors were healthy adult volunteers who 
gave written informed consent.  Blood was handled according to the Health and 
Safety Policy (UHSP/22/BTVR/14) of the University of Birmingham.  
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2.3.2 Preparation of platelet-rich plasma (PRP) or isolated platelets 
 
 To prepare PRP, blood was centrifuged at 200g for 20 minutes, and the PRP 
retrieved without disturbing the packed cells. For the isolation of platelets,  25ml of 
blood  as added to 25ml Tyrode’s buffer  ith 5mM glucose. The  cells  ere 
centrifuged for twenty minutes at 200g at room temperature. A Pasteur pipette was 
then used to remove the PRP without disruption of the buffy coat and red blood 
cells. The platelets were washed three times in Tyrodes's buffer with added 
protacyclin (PgI2)(Cayman Chemical Company, Michigan, USA), 5ul by 
centrifugation for ten minutes at 1000g.  Platelets were finally resuspended in 4ml 
Tyrode’s buffer containing glucose and counted using the Coulter counter (Figure 
2.2.1).  Platlets were diluted to  2x10
8
/ml in Tyrode’s buffer and left for 30 minutes 
before use. 
2.4 Flow-based adhesion assays 
 
Flow-based assays were used to examine the adhesion of cells under different flow 
conditions in vitro.  Cells  were perfused through glass capillaries (microslides) 
coated with different substrates  and cell behaviour under different flow rates 
assessed. The experimental plan is shown in   Figure 2. 1 (flow system diagram)  and 
Figure 2.2 (experimental plan).  
2.4.1 Preparation of coated microslides 
 
 Microslides are open ended glass capillaries (50mm tubes) (CamLab, 
Cambridges shire, UK) having the dimensions of 0.3mm height and 3mm width and 
a rectangular cross section. In order to provide a surface for binding of proteins, the 
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microslides were coated with 3-amino-propyltri-ethoxysilane (APES) as described 
(rCooke et al., 1993). The microslides were  kept in nitric acid solution (70% in 
distilled water) for one day and then washed with distilled water ten times in a 50ml 
conical tube Excess water was removed by inverting the tubes over tissue paper. 
Next, the tubes were filled with 30ml acetone twice and with 4% APES in acetone 
twice. Next the microslides were covered with 30ml of 4% APES. The conical tubes 
were inverted three times followed by overnight incubation at room temperature. 
Microslides were then washed twice with 30ml acetone and twice with 30ml distilled 
water. After every wash the tubes were inverted 3 times. Finally, the washed 
microslides were dried on Whatman blotting paper (Whatman Plc), placed in an 
oven at 37
o 
C for one hour and finally autoclaved. 
 Microslides were coated with required proteins: recombinant human or 
murine P-selectin at 10μg/ml  in PBS (Sigma); E-selectin at 25μg/ml,50 μg/ml or 
100 μg/ml  in PBS; 20μg/ml human plasma fibronectin (Sigma) in PBS; 500µg/ml 
equine tendon collagen Horm collagen (Axis-Shield). As a control, separate 
microslides were filled with 50ul of PBS. All microslides were incubated for two 
hours at 37°C. Follo ing incubation, microslides  ere flushed by dra ing up 500μl 
of 1% bovine serum albumin (BSA) in PBS. Finally, the microslides were filled with 
1% BSA to block non-specific protein binding sites and were incubated overnight in 
the fridge. 
 To test the quality of the APES coating, PRP (see section 2.3.2)  was  drawn 
into a treated microslide and kept for 45 minutes in an incubator at 37⁰C with 5% 
CO2.  If a confluent monolayer of platelets was formed at the microslide surface, the 
APES coating procedures was considered successful. 
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2.4.2 Flow system  
 
 The flow system was set up as in the Figure 2.2 The coated microslide was 
glued to the centre of a glass microscope slide. Double-sided sticky tape was  used to 
wrap both ends of the microslide. Next, one end of the microslide was connected via 
silicon tubing to an electronic valve which was connected to two syringe barrels 
filled with either wash buffer or a cell sample. An electronic syringe pump (Harvard 
Apparatus) was connected at the other end of the microslide which was then 
positioned  under a phase contract microscope equipped with a CCTV camera linked 
to a video recorder. A heating box enclosed the flow system to maintain the 
temperature constant at 37°C.  
 The syringe pump was set to deliver a chosen flow rate and hence wall shear 
rate, w, calculated using the equation: 
w = 6.Q/w.h
2 
where w = width of the microslide , h =height of the microslide and Q = volumetric 
flow rate (reference ).  Typically flow rates of 0.048, 0.95 and 0.191ml/min were 
used, equivalent to wall shear rates of 18, 35,70s
-1
 respectively.  
To conduct an adhesion assay, cell free medium was first washed through the 
microslides and then cell suspension or blood (see below) was perfused through the 
microslides for four minutes, followed by washout of non adherent cells until the 










Figure 2-‎1-2: Experimental design  for flow Adhesion assay 
 
2.4.3 Adhesion assay for isolated MSC  
 
 Before the MSC isolation, the flow system was set up as described in section  
2.4.2.The microslides were coated with  BSA, Fibronectin, P-selectin, E-selectin or 
collagen as described in section 2.4.1. 
 Trypsin EDTA solution was used to dettach the MSC from the culture flask 
as described in Section (2.1.2). The cellometer was used for counting the number of 
cells and they were suspended at a density of 5x10
5/
ml in culture medium.
 
The 
sample was perfused through the microslide for two minutes prior to starting video 
recording. To allow analysis of the speed of cells passing over the surface, the cells 
flowing at the lower surface of the microslide were then recorded for  two minutes 
through a CCTV camera which was connected to a time-lapse video recorder. The 
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field of view was changed every 30 seconds during the recording,.The microslide 
was washed out after the 4 minute perfusion of cell suspension using cell-free 
medium, to eliminate remaining unbound cells. Recording of ten random fields of 
view along the microslide's centreline was done to allow counting of adherent cells.  
In some experiments, recordings of adherent cells were repeated  at intervals to 
analyse cell spreading. All recordings were analysed offline using Image-Pro v7 
software (Media Cybernetics Inc., Maryland, USA).  
2.4.3a Cell adhesion 
 
 The number of adherent cell was counted in each of the the ten fields 
recorded after washout.  The counts were averaged and normalised per mm² using 
the known dimensions of the field of view which was calibrated using a micrometer 
graticle. The counts were then expressed as cells/mm²/10
6
 perfused, based on the 
known concentration and volume perfused in 4 minutes.  Finally, adhesion was also 
expressed as a  percentage of all cells perfused, assuming adhesion was uniform over 
the lower surface of the microslide, with area 150mm
2
. 
2.4.3b Cell velocity 
 
 The  video recordings of cells passing over the surface during inflow were 
played back frame-by-frame; recordings were at 50 frames per second, so each frame 
advance  as 0.02s. The visible area’s  idth  as 750µm. The number of frames that 
a cell took  to cross the screen was counted and multiplied by 0.02s to calculate the 
'time of flight'. The width was divided by this figure to calculate the speed of the 




2.4.3c Cell spreading 
 
 Images gathered at the end of washout and at intervals afterwards were 
analysed as described in Section 2.3.2c so that the area of cells could be calculated as 
an index of cell spreading.  Cells were also counted and divided into those that were 
phase-bright and rounded and those that were phase dark and 'spread', so that 
percentage of cells spread could be calculated.  In some experiments, at the end of 
washout a single field was recorded continually for 35min to follow the time course 
of spreading for individual cells.   
2.4.4 Adhesion Assay for MSC in blood 
 
  MSC were detached as stated in Section (2.1.2)and re-suspended in 10ml 
PBSA. Cell Tracker Green (Life Technologies) was added to  have 5µM, and the 
cells were incubated at 37°C in dark for 1h. The cells were then washed with PBSA 
and re-suspended at a concentration of 1.5 x 10
5
 per ml in whole blood in CPDA 
anticoagulant (Citrate phosphate dextrose adenine (1:9) (CPDA; Sigma). Following 
this, the in vitro adhesion assay was performed  as  stated in Section 2.4.3.  Washout 
of blood and non-adherent cells took longer than when using isolated MSC.  
However, once cleared, adherent cells were counted as above. 
 In some experiments with microsides coated with fibronectin, whole blood 
was perfused through the microslid for 4 min at a wall shear rate of 35s
-1
. The 
microslide was then washed out with PBS without Ca+2 and Mg+2 so that a platelet 
monolayer was left on the surface (see Results). When desired, to fully activate the 
deposited platelets, 10μM thrombin receptor activating peptide (TRAP); PAR-1 
receptor-specific peptide (SFLLRN; Alta Biosciences, Birmingham, UK). was then 
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added for 30 min. Then isolated MSC at concentration of 5x10
5
/ml were perfused 
through the microslide coated with platelets for 4 min and adhesion analysed as 
before. 
2.5 Aggregation of MSC with platelets 
 
 The principal of the Chrono-log Born Aggregometer is based on changes in 
light transmission. In brief, when platelets aggregate, the sample light transmission 
increases. Since there is slight variation in plasma among donors, each donor’s 
Platelets Poor Plasma (PPP)  was used to set a reference value. When an agonist is 
added, the change in the transparency between PPP (platelet poor plasma) and PRP 
(Platelets Rich  Plasma) is tracked by the system.  
 The variations of light transmission are plotted in graph format: 0% represent 
no variation in transparency from when the sample began, which means no platelet 
aggregation. Whereas 100% represents a huge variation in transparency which 
indicates platelets clump together which in turn allows more light to pass through the 
sample.   
 MSC were detached as described in Section (2.1.2) except that the pellet was 
resuspended in culture medium to achieve the density of 2x10
6
/ml. Washed platelets 
were isolated from human blood sample and resuspended in tryrodes buffer at 
2x10⁸/ml as descrided in Section 2.3.2.  400 µl of platelet suspension was transferred 
into a glass tube containing a magnetic flea. The tube was then placed in the 
aggregometer (Chrono-log,Labmedics, Manchester,UK) with a magnetic stirrer 




Following two minutes of agitation, 100ul of MSC suspension was added to the 
platelet and the cells were agitated for a further 10 minutes, during which time the 
light transmission was recorded.  As an agonist, in some experiments Horm collagen 
was added either alone or with MSC (see Results). As a positive control, 1 unit/ml of 
thrombin (sigma,poole,UK) were add to platelet suspension to assess the platelet 
response. Finally, the sample suspension was transferred from the aggregometer and 
fixed with 1% formaldehyde.  Fixed samples were examined under phase-contrast 
microscope for morphological changes such as clump formation.  
2.7 MSC migration Through 8µm pore filters 
 
 1% BSA,  human plasma fibronectin (20g/ml) or Horm collagen (500μg/ml), 
was used to coat the surface of 8µm-pore transwell filters (BD falcon) either from 
the bottom or from the top. In order to coat the top, 50µl of the protein solution was 
placed inside the filter, followed by incubation for two hours at 37°C. Following 
incubation, excess proteins were removed and 1% BSA was used to wash the filter. 
In order to coat the bottom of filters, they were flipped upside down and then the 
protein solution was pipetted  as a 'bead' followed by incubation for two hours at 
37°C and rinsing with BSA. Coated filters were placed into 24 wells plate which 
contained 700 µl of culture media. 
 MSC were detached as described in Section (2.1.2) and resuspended in 
freshly prepared growth medium to achieve a cell density of 1.4x10⁵ cell/ml. After 
adding 200ul of cell suspension to the upper chamber, the system was incubated for 
24 hours at 37
o
C. After incubation, the medium was collected from above the filters 
and from the 24 well plate.  The top and bottom surfaces of filters were washed once 
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with 200 µland 700µl PBS respectively, with the wash medium added to the 
collected samples from above and below the filter. Trypsin-EDTA solution was then 
used to detach cells from upper and lower surfaces of the filter, and these cells were 
added to the wash samples to obtain final 'TOP' and BOTTOM' cells in known 
volumes. These isolated cells were added to  20ml PBS in a Coulter Counter sample 
cup (Sarstedt) containing 2% formaldehyde. The numbers of fixed cells in the TOP 
and BOTTOM samples were counted  using a Coulter counter  (see Section (2.2.2b).  
Percentage migration was calculated as: 
BOTTOM/(TOP+BOTTOM) x 100%. 
2.8 Treatment of MSC or blood with function-blocking antibodies 
 
 Isolated MSC were treated with function-blocking antibodies (10µg/ml) 
against integrins or isotype-matched controls for 10min at room temperature.  They 
were then analysed in adhesion assays (Section 2.4), either as isolated cells or after 
they were added to whole blood.   In some experiments, MSC were added to whole, 
blood which had been pre-treated with antibody against the platelet receptors 
GPIIb/IIIa or Gp1b for 30 min at room temperature.  The antibodies used are listed 
in Table (2.3) 
2.9 Statistical analysis: 
 
 Data are shown as mean ± SEM of (n) replicate experiments using different 
culture samples on different occasions.  Statistical analysis was performed using 
Minitab 17 software (Minitab Inc.).  Effects of multiple treatments or conditions 
were analysed using a general linear model analysis of variance (ANOVA) and 
where appropriate post hoc comparisons between treatments or to control were made 
86 
 
using the Bonferroni test or Dunnett test respectively.  Single treatments were 





Table 2-‎1-: List of General Reagents 
Reagent Supplier Application 
Histopaque  
 






Cells Washing  
 















Gibco Invitrogen  
 
Culture media  
DMEM Gibco Invitrogen  EPC culture media 
 
10% Fetal Calf Serum 
(FCS) 
Gibco Invitrogen  
 
 





Gibco Invitrogen  
 













Cell culture antifungal drug 
Trypsin  
 
Gibco Invitrogen  
 
Cell Dissociation reagent 
0.1 µg.ml
-1
 Basic fibroblast Gibco Invitrogen  EPC growth factor 




Gibco Invitrogen  Cord EPC isolation 
20 %FBS hyclon  Lonza Cord EPC isolation 
MSCGM(BulletKit) Lonza   MSC basal medium and 
growth media  
DMEM Low Glucose            Biosera                                    WJMSC culture media  











Table 2-2: List of Culture Media 
Cell Type Medium Supplier 
mEPC Dulbecco's Modified Eagle 
Media (DMEM),10% Fetal 
Bovine Serum, 100µg/ml 
Penicillin, 250µg/ml. 
Amphotericin B , 200µmol 
Glutamine and 10µl Basic 





 Fetal Bovine Serum 
(Sigma) Penicillin (Sigma)  
Streptomycin (Sigma)  
Amphotericin B ( 
Invitrogen)  
Glutamine (Sigma)  
Basic fibroblast growth 











recombinant in a 
buffered BSA saline 
solution, 5µg/ml. 













n-B  250µg/ml 




Recombinant  R 
Insulin- Like  
In LONZA endothelium 
cells culture medium 
2MV, CC-3156 with 

























WJMSC DMEM Low Glucose, 
10% Fetal Bovine Serum 




DMEM Low Glucose; 
(Biosera)  
Fetal Bovine Serum 
(Sigma) 
 Penicillin (Sigma)  
Streptomycin (Sigma) 
 
BMMSC MSCBM Mesenchymal 
Stem Cell Basal Medium  
and MSCGM hMSC 
SingleQuot Kit 





MSCBM hMSC Basal 
Medium and MSCGM 
hMSC SingleQuot 
Kit(Lonza) 
TBMSC DMEM Low Glucose, 
10% Fetal Bovine Serum 
and 1% Penicillin,1% 
Streptomycin. 
 
DMEM Low Glucose, 
(Biosera)  
Fetal Bovine Serum 
(Sigma) 





















Table2-1: List of Monoclonal antibodies. 




BD Pharmingen  Integrin β1 identification 
β3-integrin/ anti-human 
CD61 (SZ21; mouse 
IgG1) 
 
BeckmanCoulter Integrin β3 identification 
α v-integrin/ anti-human 
CD51 (mAb L230) 
EnzolifeSciences Integrin α v identification 
αᴠβᴣ /(23C6 mouse IgG1) 
 





Gift; Cell Tech, Slough, 
UK 
 
Integrin α 4 identification 
GPIIb  Platelets Integrin(receptor 
for fibrinogen and von 
Willebrand factor 
GPIIb/IIIa (CD41) Eli Lilly Platelets Integrin(receptor 
for fibrinogen and von 
Willebrand factor) 
IgG1-FITC Dako  Isotype control 
CD44 APC BD Bioscience hMSC  
CD73 FITC BD Bioscience  
CD90 Bv421 BD Bioscience  
CD105 PerCp-Cy 5.5 BD Bioscience  
CD166 PE BD Bioscience  
CD146 APC BD Bioscience  
CD45  Leukocytes marker 
CD20  B cell marker 
 
CD14  macrophages , neutrophils 
markers 
CD34  hematopoietic and vascular 
progenitor cells marker 


























Chapter 3 : COMPARISON OF ADHESIVE PROPERTIES OF 

















Based on the concept that infused EPC and MSC may be used to treat a 
variety of conditions such as vascular injuries and chronic inflammation, this chapter 
compared the potential ability to adhere from flow of isolated progenitor cells: 
mouse EPC cell line (mEPC), primary human cord blood EPC (hEPC),  and primary 
MSC from bone marrow (BMMSC), Wharton's jelly (WJMSC), and trabecular bone 
(TBMSC). In order to investigate the effect of flow on adhesive behaviour of these 
cells on various surfaces, we used  the flow adhesion assay  illustrated in Section 
2.4.3. We compared adhesion to surfaces coated with receptors that would be 
presented by inflamed endothelium (P-selectin and E-selectin) or by damaged vessel 
wall (collagen and fibronectin), to 'control' surfaces coated with albumin alone.  In 
this chapter, the isolated progenitor cells were perfused over the coated surfaces at 






.  Higher rates were initially tested as 
well, but no adhesion was seen.  The number of adherent cells of each cell type at the 
different surfaces was counted and expressed as a percentage of all those perfused, as 
described in Section 2.4.3a. We also measured velocity  of non-adherent cells in the 
flow near the surface of P-selectin and albumin in order to study whether there was 
weak adhesion or 'rolling' on P-selectin compared to free flow for albumin.  Finally, 
we investigated whether cell size influenced behaviour.  As described in Section 
2.2.2, the diameter of cells flowing near the wall of a vessel is expected to affect 
their velocity and forces exerted on them.  It is possible that larger cells would 
adhere less well.  Therefore, we measured the size of MSC as whole populations and 
of the adherent MSC.   
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These studies thus aimed to improve our understanding of the dynamic 
adhesion property  of different types of progenitors cells from  a flowing suspension 
onto matrix or inflamed vessels. 
3.2 RESULTS 
3.2.1 Comparison of the adhesion of different flowing progenitor cells to 
endothelial or matrix receptors 
We first investigated the adhesive properties of two different types of EPC,  
mEPC mouse cell line and hEPC from cord blood.  Figure 3.1A shows the behaviour 
of human cord EPC for different surfaces. We noticed that when we flowed hEPC 
over collagen at 18s
-1
, about 50% of the perfused cells adhered. By increasing wall 
shear rate to 35s
-1
, the percentage of adhesion was reduced to less than 10%, while at 
70s
-1
, less than 5% adhered. When we perfused hEPC over fibronectin at 18s
-1
, 
around 20% adhered, and the numbers decreased to similar levels to those seen on 




.  When we flowed  
EPC over P-selectin at 18s
-1
, we noticed a just detectable but very low percentage of 
adhesion. When the shear rate was increased to 35s
-1
, the percentage of adhesion was 
decreased, while at 70s
-1
, we completely lost the adhesion.  Finally, for BSA 
(control), no hEPC were observed adhered to the surface at any shear rate.  
Figure 3.1B shows the behaviour of mEPC under the same conditions. We 
noticed that  mEPC adhered to collagen or fibronectin at similar levels and with 
similar effects of varying wall shear rate.  When we flowed mEPC over P-selectin, 




, but not at 70s
-1
.  Again, for BSA, no 




In summary, hEPC or mEPC could adhere to matrix proteins from flow better 
than to P-selectin, which showed levels just above background for BSA.  Adhesion 
tended to be higher for collagen than fibronectin, but this trend was not statistically 
significant. 
In Figure 3.2, we used the same assay conditions to study the adhesion 
behaviour of three different MSC types: WJMSC, BMMSC, TBMSC. Figure 3.2A 
shows that when we flowed WJMSC over collagen at 18s
-1
, around 30% adhered. By 
increasing shear rate to 35s
-1
, we lost more than half of the adhesion, and at 70s
-1
, the 
percentage of adhesion declined to under 5%. We noticed that when we flowed 
WJMSC over fibronectin at 18s
-1





, adhesion reduced in a similar manner to collagen.  Finally, on P-
selectin  or BSA, no WJMSC were observed adhered to the surface at any shear rate  
In Figure 3.2B, when BMMSC were perfused over the same surfaces, we 
observed similar effects of shear rate and lack of adhesion to P-selectin or albumin.  
Adhesion to collagen and fibronectin tended to be lower than those for WJMSC but 
effects of shear rate were similar. We saw occasional cells attached to P-selectin at 
the lower shear rates. 
Figure 3.2C shows adhesion data for TBMSC tested in the same way.  The 
trends were similar to those for the other MSC, but the levels of adhesion to collagen 
and fibronectin appeared to be lowest overall.   
In Summary, all types of MSC adhered to collagen or fibronectin from flow, 
but not to P-selectin or albumin.  Adhesion again tended to be higher for collagen 
than fibronectin, but this trend was not statistically significant. Adhesion tended to 
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be in the order WJMSC>BMMSC>TBMSC.  To test this more directly, we re-
plotted the data in Figure 3.3. to compare the three different cells type. 
In Figure3.3A, we compared the adhesive properties of WJMSC, BMMSC, 
and TBMSC on collagen; we found that WJMSC bound at significantly higher levels 
than BMMSC or TBMSC, while the  difference in binding on collagen between 
BMMSC and TBMSC was not statistically significant. In figure 3.3B, we compared 
the adhesive properties of WJMSC, BMMSC and TBMSC on fibronectin; we found 
that WJMSC bound at significantly higher levels than BMMSC or TBMSC.  Again, 
the difference in binding on fibronectin between BMMSC and TBMSC was not 
significant.   
 In Figure 3.4 we have re-plotted the whole adhesion data to compare effects 
of shear rate on adhesion of all the progenitors cells to the different surfaces. On 
collagen and fibronectin surfaces, MSC tended to bind better than EPC. However, 
for P-selectin, we noticed that EPC bound to the surface at higher levels than MSC, 
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Figure ‎3-1:  Adhesion of A. hEPC, B. mEPC to different surfaces: effects of wall 
shear rate. 
EPC were perfused for 4 min at 37⁰C over collagen, fibronectin, P-selectin or 
albumin at  wall shear rates of 18, 35 or 70s
-1
. Data are the mean ± SEM from three 
to four experiments.  Overall, in A and in B, ANOVA showed significant effects of 
wall shear rate and of adherent substrate  (p<0.01 in all cases).  *=p<0.05; 
**=p<0.01 for post-hoc comparison of adherent substrates including all values for 
shear rate by Bonferroni test. 
97 
 







W a l l  s h e a r  r a t e  ( s
- 1
)
C o l l a g e n
F ib r o n e c t i n
































































W a l l  s h e a r  r a t e  ( s
- 1
)







































Figure ‎3-2: Adhesion of (A)WJMSC, (B)BMMSC, (C)TBMSC  to different 
surfaces: effects of wall shear rate. 
Wharton's jelly, bone marrow and trabecular bone MSC  were perfused for 4 min at 
37⁰C over collagen, fibronectin, P-selectin or albumin at  wall shear rates of 18, 35 
or 70s
-1
. Data are the mean ± SEM from three or four experiments.  Overall, in A, B 
and C ANOVA showed significant effects of wall shear rate and of adherent 
substrate  (p<0.01 in all cases).   *=p<0.05; **=p<0.01 for post-hoc comparison of 
adherent substrates including all values for shear rate by Bonferroni test.
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Figure ‎3-3: Comparison of Adhesion of WJMSC, BMMSC and TBMSC  to (A) 
collagen or (B) fibronectin. 
MSC were perfiued for 4 min at 37⁰C over collagen or fibronectin at wall shear rates 
of 18, 35 or 70s
-1
. Data are the mean ± SEM from three or four experiments.  
Overall, in A and in B, ANOVA showed significant effects of wall shear rate and of 
cell type (p<0.01 in both cases).   *=p<0.05; **=p<0.01 for post-hoc comparison of 







Figure ‎3-4: Comparison of adhesion of different types of endothelial progenitor 
cells and mesenchymal stem cells on (A) collagen, (B) fibronectin or (C) P-
selectin.  
Cells were perfused for 4 min at 37⁰C over collagen, fibronectin or P-selectin at wall 
shear rates of 18, 35 or 70s
-1
. Data are mean values. Numbers of experiments are the 





3.2.2 Near-wall velocities of different progenitor cells 
 Since the binding to P-selectin was lower than we expected from literature 
reports, we also measured the velocity of cells near the surfaces to see if we could 
detect weak adhesion or 'rolling', compared to non-adhesive albumin.  Figure 3.5A 
compares velocities for P-selectin and BSA for hEPC. As expected, cell speed 
increased with increasing shear rate. The graph also  illustrates a significant effect of 
adherent surface, with flowing cells slowed down slightly for P-selectin compared to 
albumin, which may indicate there is a weak rolling interaction. Figure 3.5B shows 
very similar behaviour and trends for mEPC.  Overall, the EPC flowed about 15% 
slower for P-selectin than albumin. 
 Figure 3.6 shows near-wall velocities of the different types of MSC on 
collagen, fibronectin, P-selectin and BSA. The velocities of WJMSC, BMMSC, and 
TMSC increased with shear rate but showed no effect of surface.  Since flowing cells 
were not slowed down, it appears that no rolling occurred.  
 We also carried out experiments where EPC or MSC were perfused over E-
selectin.  In  2 experiments with each type we used different E-selectin 
concentrations 20µg/ml, 50µg/ml and 100µg/ml at the same shear rates as above.  
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Figure ‎3-5: Velocity of (A) Human cord EPC (B) mouse EPC perfused over 
different surfaces: effects of wall shear rate. 
EPC were perfused for 4 min at 37⁰C over P-selectin or albumin at wall shear rates 
of 18, 35 or 70s
-1
. Data are the mean ± SEM from three or four experiments.  
Overall, in A and in B, ANOVA showed significant effects of adherent substrate and 
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Figure ‎3-6: Velocity of (A) WJMSC (B) BMMSC and (C)TMSC perfused over 
different surfaces: effects of wall shear rate. 
MSC were perfused for 4 min at 37⁰C over collagen, fibronectin, P-selectin or 
albumin at  wall shear rates of 18, 35 or 70s
-1
. Data are the mean ± SEM from three 
or four experiments.  Overall, in A, B and C, ANOVA showed significant of wall 
shear rate (p<0.01 in each case) but not of adherent substrate. 
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3.2.3 Comparison of diameters of different MSC and effect on adhesion 
 Three different methods were used to measure cell diameters during 
preparation or  during adhesion assays : Coulter counter (see Section 2.2.2b); 
Cellometer (see Sections 2.2.2a); microscopy and image analysis (see Section 
2.2.2c).  To test whether they yielded the same results, we compared measurements 
for identical samples of cells.  Table 3.1A shows diameters of BMMSC in 
suspension measured by Coulter Counter or Cellometer.  The results were nearly 
identical.  Table 3.1B compares values for cells settled in a microslide, with diameter 
measured by microscopy, compared to a sample of the same cells measured by 
Cellometer.  The value for the Cellometer was consistently larger than ImagePro 
analysis by 5±1%. 
 Based on the above, to investigate the effect of cell size on adhesion, we 
compared the mean diameters of BMMSC, WJMSC, and TBMSC before perfusion 
(by Cellometer) and after they had adhered to collagen or fibronectin (by microscopy 
and ImagePro).  Table 3.1C shows the data, with the microscopy values multiplied 
by 1.05 to allow for the systematic difference between the methods as noted above.  
From this Table, we found that smaller-size cells were adhered to collagen compared 
to the original sample, and smaller-size cells were adhered to fibronectin compared 
to the original sample.  Moreover, smaller cells adhered to fibronectin compared to 
collagen, although this trend was not statistically significant.   
 We also tested whether cell diameter (measured by Cellometer) was linked to 
the velocity of non-adherent cells flowing near the wall of microslides for different 
samples of WJMSC prepared on separate occasions.   Figure3.7A shows the average 
velocity of WJMSC measured at different shear rates on two different surfaces P-
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selectin and 1%BSA. At a wall share rate of 70s
-1
, we found that cell velocity 
increased when cell diameter was greater,   whereas, at low shear rate of 18s
-1
, the 
trend was not seen.  In figure 3.7B, the  relation between cell size and velocity is re-
plotted for the data pooled from the different shear rates. Figure3.7A showed that 
velocity was dependent on shear rate and cell diameters.Linear regration showed that 





















Table ‎3-1: Measurement of cell diameter: comparison of methods, and of 
adherent cells with original perfused sample. 
 
‎3-1A. Comparison of cell diameter measured by Cellometer or using Coulter 





Isolate 1 19 19.1 
Isolate 2 17.4 17 
Isolate 3 20 20 
mean 18.8 18.7 
SEM 0.8 0.9 
 
 
Table ‎3-1.B: Comparison of cell diameter measured by Cellometer or using 




Isolate 1 23 21.6 
Isolate 2 24 23.2 
Isolate 3 24 22.8 
mean 23.7 22.5 
SEM 0.3 0.5 
 
 
Table ‎3-1.C. Comparison of diameters of cells adherent to different surfaces 




sample(µm)   
Size of Adherent 
cells (µm) 
onCollagen* 
Size of Adherent 
cells (µm)  
onFibronectin** 
BMMSC 22.3 ± 0.9 18.9 ± 4.2 16.8 ± 4.2 
WJMSC 20.3 ± 1.2 17.8 ± 1.2 15.9 ± 1.2 
TBMSC 19.3±0.3 15.8 ± 1.3 15.4 ± 3.9 
 
Diameter of the original sample was measured by Cellometer.  Diameter of adherent 
cells was measured using ImagePro software and digitised images. Data are mean ± 
SEM from 3 experiments where different MSC were perfused over collagen or 
fibronectin.   
*ANOVA showed for comparison of collagen adherent and original sample, no 






Figure ‎3-7: Velocity of WJMSC perfused over P-selectin or albumin at different 
shear rates: effect of mean diameter of the perfused cells. 
MSC were perfused for 4 min at 37⁰C over P-selectin or albumin at wall shear rates 
of 18, 35 or 70s
-1
. Data are from a single experiment under each condition for 4 
different samples of WJMSC with different mean diameters.  In B, data are mean ± 
SEM for the 3 different shear rates and two surfaces, for each sample.  In A, 
ANOVA showed significant ofwall shear rate (p<0.01) and diameter (p<0.05) but 
not of adherent substrate.In B,Linear regretion of mean velocity vs diameters was not 
statiscally significant (P0.10) 
**ANOVA showed for comparison of fibronectin adherent and original sample, no 







 In this Chapter, we compared adhesive behaviour of flowing EPC and MSC 
on different surfaces, and then analysed whether the diameter of MSC affected their 
adhesion.  The main new findings were that the cells could adhere from flow to 
collagen or fibronectin, and surprisingly, that adhesion was more effective on the 
matrix proteins than selectins.  This was particularly the case for MSC, which 
adhered to collagen better than fibronectin, with very few adhering to albumin.  
MSC and EPC adhesion decreased the higher the wall shear rate, and they could 
adhere up to a wall shear rate of 70s
-1
 but not above this level.  All adhesion counted 
was stationary.  There was evidence of slowing down of EPC flowed over P-selectin 
compared to albumin, suggesting a very weak 'rolling' interaction.  MSC did not 
slow down on P-selectin, and also either stopped or flowed at full speed on matrix 
proteins.  Once attached, cells adhered firmly, with little subsequent detachment 
when exposed to 70s
-1
  shear rate.  The MSC that adhered were on average smaller 
than the population perfused, suggesting that smaller cells adhered better. The 
velocity of non-adherent MSC was greater, the bigger the mean diameter of the cell 
sample perfused. 
 EPC adhesion from flow has been more widely studied than MSC adhesion.  
EPC circulate in the blood and need to be captured from flow to carry out repair or 
angiogenesis functions.  They were studied here for comparison to MSC which 
would not normally be expected to circulate unless injected for therapy.  We 
observed that cord EPC and mouse EPC could adhere to P-selectin at shear rates at 
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the lo  end for the venous circulation.  Others have found that selectins and β2-
integrins can mediate adhesion of flowing EPC to endothelial cells or purified 
receptors ((Hristov et al., 2003) and to platelets (Langer et al., 2006, Stellos et al., 
2008). Surprisingly, we found that the EPC adhered better to collagen or fibronectin 
than P-selectin.  This suggests that these cells might bind to exposed matrix protein 
better than inflamed endothelial cells in vivo. This might  be consistent with the 
general understanding of EPC involvement in angiogenesis, in damaged tissue at 
least. 
 We found that WJMSC, BMMSC and TBMSC adhered  to collagen 
significantly more than  to fibronectin, compared to nearly zero adhesion on P-
selectin, E-selectin or albumin.  In addition, WJMSC adhered the most efficiently, 
while BMMSC adhered more than TBMSC.  However, all showed similar shear rate 
dependence, with adhesion very low at 70s
-1
 and not detectable above that level.  
Since MSC are naturally stromal cells not found in the circulation, it may not be 
surprising that they adhered less than EPC to P-selectin.  However, they would be 
expected to bind to matrix proteins in their natural tissue, likely through integrin 
receptors.  This is investigated further in Chapter 6.  The cells are very large, about 
20µm in diameter, which is larger than most capillary diameters.  It is thus likely that 
MSC would be trapped in small vessels even without adhesion (Karp, 2009).  
However our results suggest they could adhere to damaged vessels where matrix was 
exposed.  They would then need to spread and or migrate to take part in tissue repair.  
This behaviour is considered in Chapter 4. 
  Studies  of MSC adhesion from flow to matrix have been rare. To our 
knowledge only one study has addressed the binding between BMMSC and 
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collagen.  The authors reported that there were no adherent MSC on a collagen 
surface at shear rate of 1000s
-1
 (Jiang L et al., 2012).  This is consistent with our 
finding which show that we lost cell adhesion when we increased shear rate from 
70s-1 to 100s-1. 
 Our data is in agreement of a study conducted by Lan CW et al who studied 
the adhesive behaviour of osteoprogenitor cells isolated from bone marrow 
(BMSCs). they showed that these cell adhere twice more to the surface when is 
surface is coated by collagen under flow condition, interestingly enough they noticed 
when they flush all marrow cells by shear stress of 1.10 dyne/cm, 25% of cells which 
are adhered to collage coated surface remained attached to the surface despite the 
flush force which indicate the strength of the adhesion (Lan et al., 2003). Moreover; 
another study was conducted to study the adhesive behaviour of BMMSC by using 
Collagen nanofibers scaffold. they reported that over 45% of BMMSc adhered 
efficiently to collagen coated nanofibers (Chan et al., 2009). additionally, studies on 
Murine bone marrow cells (BMC) revelled again higher MSC adhesion to collage 
coated surfaces (Vandersluijs et al., 1994).   
   This is the first study to compare dynamic adhesive behaviour of  MSC 
from different sources, and to show they can adhere to both collagen and fibronectin 
from flow.  Variation between the adhesion behaviour of different MSC could be 
attributed to the source and/or the isolation and culture techniques.   This assumption 
is based on the findings of Aldridge et al. (2012)  who suggested that the expression 
of adhesion molecules on MSC are affcetd by their source and the isolation method 
(Aldridge et al., 2012).  The high WJMSC adhesion compared to BMMSC on 
collagen and fibronectin may be linked to differences in regeneration ability. WJ 
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MSC have been shown to be more neurogenic and angiogenic than BMMSC, 
possibly also linked to differences in their secretomes (Hsieh et al., 2013).  
Regarding the low adhesion of TBMSC compared to WJMSC and BMMSC, we 
suggest this difference may be due to the fact that TBMSC were obtained from aged 
patients undergoing knee replacement.  Coipeau et a. (2009) suggested that  MSC 
were modified inherently because of the burden of the diseases .  Information about 
MSC homing and mobilization may still be conflicting because of the difficulty in 
isolating and identifying native MSC.  Laboratories may base studies on culture-
expanded MSC which may lack some cell adhesion molecules or chemokine 
receptors which contribute to MSC homing.  However, therapeutic use of MSC is 
likley to require such expansion, and cells used here were cultured for from 5 to 7 
passages.  
 Previous studies have looked at adhesion of flowing MSC to endothelial cells 
or purified endothelial receptors.  Indeed, MSC have been proposed to use a multi-
step process to cross endothelium similar to  leukocytes  (Chamberlain et al., 2007) 
(Henschler et al., 2008).  On  a P-selectin or E-selectin surface, we noticed almost no 
adhesion when using WJMSC, BMMSC or TBMSC even when wall shear rate was 
reduced to 18s-1. However, Ruster et al  suggested that there were interactions with 
P selectin and between MSC integrins and VCAM-1 when human MSC bound to EC 
that had been treated with tumour necrosis factor-α (TNF) (Ruester et al., 2006).  In 
the same study the authors found that MSC expressed neither P-selectin glycoprotein 
ligand-1(PSGL-1; CD162) nor the alternative P-selectin ligand–CD24 on their 
surface (Ruester et al., 2006). In agreement to our studies, they did not find a role for 
E-selectin for adhesion to EC (Ruester et al., 2006).   It should be noted that in this 
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study, adhesion occurred only at a very low flow (0.01Pa wall shear stress, 
equivalent to about 14s-1 wall shear rate), and remained when flow was increased.  
Others perfused rat MSC over TNF-treated EC for 2 hours and observed adhesion at 
higher shear rates, again attributed to VCAM-1 (Segers et al., 2006).  In another 
study, murine MSC did not bind to murine EC from flow, but did adhere when held 
stationary for 10min before flow increased (Chamberlain et al., 2011).  
Subsequently, Aldridge et al. (2012)  found that blockade of β1-integrins or of CD44 
did reduce adhesion of human MSC to liver sinusoidal endothelial cells (Aldridge et 
al., 2012). However, again, in this model the authors stopped the flow temporarily 
for 5 minutes to allow enough time for MSC to bind to HSEC, before re-applying 
flow.  In our laboratory, BMMSC bound to HUVEC under stationary conditions 
even without stimulation of EC (so that P-selectin or VCAM-1 should not be 
expressed), and then remained adherent if flow was imposed (Luu et al., 2013).  We 
did find that at very low wall shear rate (14s-1), we could detect some adhesion if the 
EC were treated with TNF or IL-1, but did not investigate what receptors were used.  
Other studies in our lab suggested that flowing MSC could not adhere to purified 
VCAM-1 (G. Nash, unpublished observations).  Thus the mechanisms and 
circumstances under which MSC can bind to intact EC in the circulation remain in 
doubt (Karp, 2009).  The effects of blood cells themselves on MSC adhesion are 
investigated in Chapter 5. 
 In other studies, scientists have been purposely manipulating MSC to express 
selectin surface receptors or ligands to enhance MSC adhesive properties, again 
implying that 'native' MSC do not capably bind to selectins (Sarkar et al., 
2010).Improving MSC homing may be an important step to support the therapeutic 
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effects of MSC. One of the techniques which has been widely used is cell surface 
modification which increases sialyl Lewis X (SLeX) because of its role in leukocyte 
rolling (Teo et al., 2012). Another technique used for cell surface modification is the 
application of biotinylated lipid vesicles which are fused to MSC to bind 
streptavidin-linked SLeX (Sarkar et al., 2011). We suggest that manipulation may 
not be necessary for frankly damaged vessels but may be necessary to increase 
recruitment to intact EC even if  inflamed. 
 The highly significant reduction in adherent cells  noticed with increased wall 
shear rate, suggests that shear rate and stress play critical roles in EPC and 
MSCadhesion.  This is also the case for leukocytes and platelets, but adhesion occurs 
at higher shear rates the smaller the cells (upto about 300s-
1
 for leukocytes and  
>1000s
-1
 for platelets) (Watts et al., 2013). At high shear rate conditions, the contact 
time between cell adhesion molecules  and surface substrate is shortened which 
subsequently decreases likelihood of forming a receptor-ligand bond.  In addition, 
the force caused by shear stress increases, tending to break bonds that do form.  
Here, cells were barely slowed down by P-selectin, so that a two step adhesion did 
not appear to occur.  On the matrix proteins, all cells appeared to come to an abrupt 
halt and they did not then move, except to spread gradually. 
 There has been no research study the role of stem cell diameter in adhesion. 
Watts et al. reported that cell size, margination, and a cell-free layer influenced the 
adhesive abilities of platelets and leukocytes (Watts et al., 2013). They showed that 
platelets were able to adhere at high shear rate and they attributed this to their small 
size which subsequently minimized the force experienced and their velocity. Also, 
they suggested that  leukocytes were not able to adhere at high shear rate but could 
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be recruited in venules. As expected, we found cell velocity near the wall increased 
the bigger the cells, and with increasing shear rate.  The velocity measured here at 
70s-1 was about 800µm.s-1 which is what is expected for about 10µm radius (see 
Section 1.3.2.3  ).  The values for leukocytes at a shear rate of 280s-1 where 
adhesion is just retained on P-selectin was about 1400µm.s-1, which is what is 
expected for about 5µm radius.  Thus the relative velocities of the two cells is  what 
might be expected from MSC being double the size of leukocytes.  Interestingly, 
force goes up with radius squared for a given shear stress (see Section 1.3.1.3)   This 
may explain why the limiting velocity for leukocytes is higher, because at that 
velocity or shear rate of 280s
-1
, the force should be similar to MSC at 70s
-1
 (because 
of their doubled radius compared to leukocytes).  It seems that the shear sensitivity 
of MSC can be largely explained by their size versus leukocytes, which may be 
surprising as the leukocytes are using a specialised capture receptor, selectins, that 
act quickly, while the MSC are binding to unspecialised matrix receptors.  This 
subject is considered again in Chapter 6 where mechanisms of attachment were 
investigated. 
 Another factor in vivo is margination.  During inflammation, fibrinogen 
production increases, accompanied by decline in venous flow rate and increase in red 
cell aggregation, which leads to margination enhancement for leukocytes and 
increased adhesion (Watts et al., 2013).  Margination is dependent on cell size, with 
larger cells tending to move inward in the flow more.  MSC are much larger than 
platelets or leukocytes, and it is not clear what might happen to large MSC in 






 MSC from several sources showed little adhesion to selectins from flow, but 
did adhere to collagen or fibronectin. This adhesion was surprisingly effective 
considering their large size and the expectation that they are not adapted for adhesion 
from the circulation in the same way as leukocytes are.  Our results confirm that the 
cell adhesion cascade is affected by cell diameter, but also depends on the nature of 
the receptors and ligands.  Our surface-coating system is very useful to study the 
efficiency of MSC delivery and the results suggest that MSC will bind better to 
damaged vessels than inflamed vessels.  Whether MSC can specifically home 
remains unclear, although our results might suggest they can e.g., in wound healing.  
While many could get physically trapped in the microcirculation  in vivo, they might 











































4.1  INTRODUCTION 
 
If MSC are deposited in a damaged vessel, cell adhesion and spreading on 
extracellular matrix (ECM) are essential for cell motility, migration into tissue and 
survival.  Cell spreading is the initial kinetic process following adhesion.  Cell 
spreading ability is advantageous to the cell, as demonstrated by cell culture pioneers 
who established the importance of cell-substrate contact area (Folkman and 
Moscona, 1978).  They suggested that the contact area was a determinant of cell 
proliferation capabilities (Folkman and Moscona, 1978).  Moreover, others showed 
spreading to determine the fate of the cell, with failure leading either to a dormant 
state (Stoker and Rubin, 1967) or  cell death (Chen et al., 1997). The active 
mechanisms which control cell spreading behaviour are not fully understood.  As 
cells adhere to the  surface, they become flattened and deformed. At the molecular 
level, the initiation of a signalling cascade is caused by the binding between cellular 
integrins and the matrix (Hynes, 2002). The signalling events trigger a series of 
morphological changes of the cell and subsequently produce contractile forces which 
can support migration (Huttenlocher and Horwitz, 2011).  
In the current chapter, we set out to investigate the behaviour of MSC after 
they had adhered to matrix proteins from flow. Contact area was measured as a 
function of time for different cell types captured on different surfaces. Subsequently, 
we measured the ability of the MSC to migrate through porous filters with different 
coatings.  The goal was to compare the behaviour  of BMMSC,WJMSC and TBMSC 





To investigate cell spreading, we used phase-contrast microscopy during and 
after perfusion of MSC in the cell adhesion assays described in Chapter 3.  This 
enabled us to monitor quantitatively the dynamics of spreading of individual cells. 
The cell behaviour was analysed offline using Image-Pro software as described in 
Section  2.4.2c. Spread cells were defined as large cells with extensive visible 
filopodia (microspikes) and showing changes from phase-bright to phase-dark 
appearance (see e.g., Figure 4.1). Non-spread cells were  phase-bright, smaller round 
cells with little or no membrane protrusions. We considered partially phase-bright 
and phase-dark cells, as spreading cells. Degree of spreading was characterised by 
measuring the area of the cells.  To investigate cell migration, MSC were allowed to 
settle and adhere on 8µm pore Transwell filters which had been coated either from 
the bottom or from the top with collagen, fibronectin or albumin.   MSC were 
incubated for 24 hours at 37
o
C, and cells retrieved from top or bottom of the filter by 
trypsin and counted  using a Coulter counter.   
4.2 RESULTS 
4.2.1 Rate and degreee of spreading of MSC on collagen or fibronectin 
Figure 4.1 shows  phase contrast images of the  spreading behaviours of three 
different cell types; (A) WJMSC, (B) BMMSC, and (C) TBMSC at different time 
points on collagen.  The cells were perfused over the collagen for 4 minutes followed 
by washout of non-adherent cells.  They are representative of multiple images taken 
at different sites in the microslide at each time, and were used to quantify the 
changes in the proportion of cells spread with time. The images at 5 minutes (i.e., 
after 1min of washout) show that all types of adherent cells attached to collagen 
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surface showed no sign of spreading. The cells appear small and round  with little 
membrane protrusion. At time point 15 minutes,  the membrane of some BMMSC 
started to deform and protrude, whereas  WJMSC and TBMSC remained round with 
little change.  At  25 minutes, some BMMSC had spread out completely while 
WJMSC and TBMSC had started showing some changes in their cells membrane. 
By 35 minutes, most BMSC, TBMSC and WJMSC had spread. 
Figure 4.2 shows  similar images for cells adhered to fibronectin.  Again, at 
time point 5 minutes, adherent cells showed little sign of spreading. At time point 15 
minutes, however,  the membrane of  WJMSC, BMMSC and TBMSC had started to 
deform and spread cells were evident.  At 25 minutes and at 35 minutes,  nearly all 
BMSC and TBMSC and WJMSC were completely spread.   
Quantitative data derived from the microsope images for percentage spread 
with time are shown in Figure 4.3.    Comparison of the percentage of spreading  of 
WJMSC, BMMSC, and TBMSC on collagen is shown in Figure 4.3A.  At time point 
5 minutes, all cell types showed zero percentage spreading. At time point 15 ,25, 35 
minutes, there was steady progressive spreading, with BMMSC spreading 
percentage being consistently and significantly greater than WJMSC and TBMSC, 
which were similar to each other. This data shows that BMMSC spread more 
efficiently on collagen compared to the other cells types. 
Figure 4.3B shows similar date for progressive spreading on fibronectin. 
Taken as a whole, it is evident that MSC spread more rapidly and effectively on 
fibronectin compared to collagen.  At time point 15 minutes, 95% of BMSC had 
already spread while about 50% of WJMSC and TBMSC had spread. At later time 
points , BMMSC and TBMSC continued to spread, with TBMSC reaching 100% 
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spreading and WJMSC reaching a value of about 80% by 35 minutes. Overall, 
BMSC spreading   was faster compared to WJMSC or BMSC. Interestingly, 
WJMSC and TBMSC behaved similarly in the first 15 minutes, after which TBMSC 
showed faster spreading behaviour than WJMSC.  
To gain further insight into the kinetics of spreading, in separate experiments, 
individual fields were recorded after washout and the area of the same cells 
repeatedly measured over time.  Figure 4.4 shows phase contrast images of the size 
of adherent cells for (A) WJMSC, (B) BMMSC, and (C) TBMSC on a collagen  
surface.   Figure 4.5 shows phase contrast images of the size of adherent cells  on a 
fibronectin surface. Figure 4.6 illustrates how the phase contrast images of a single 
adherent cell at different time points were analysed using Image-pro software.  
Figure 4.7 compares the cells area measurements of WJMSC, BMMSC, and 
TBMSC on collagen and fibronectin at different time points.   In Figure 4.7A, on a 
collagen surface, it can be seen that all cell types showed progressive increase in cell 
area with time.  Overall, the order of areas was BMMSC>TBMSC~WJMSC, with 
the data showing statistically significant difference in cell size between BMMSC and 
TBMSC.  
In Figure 4.7B, on a fibronectin surface, again, all cell types showed increase 
in area with time.  However, on fibronectin  BMMSC and TBMSC had similar large 
areas, and both were significantly greater in area than WJMSC.   Comparing the 
surfaces, it was evident that the BMMSC and TBMSC spread to larger final sizes on 
the fibronectin than collagen, while WJMSC reached similar sizes on each surface.  




In summary, fibronectin tended to support more efficient spreading of MSC 
than collagen.  BMMSC spread more rapidly, in great numbers and to a greater 
extent than WJMSC.  TBMSC had an intermediate behaviour.  Because of the clear 
differences in the more widely studied types of MSC, from bone marrow and 
Wharton's jelly, and the poor proliferation potential of TBMSC, subsequent studies 






















Figure ‎4-1: Phase contrast images of spreading of (A) WJMSC (B) BMMSC 
and (C) TBMSC on collagen 
Images recorded at 5, 15, 25 and 35 minutes after the start of perfusion for 4 minutes 
at a wall shear rate of 35s
-1
. Images are from separate fields in an  experiment 








Figure ‎4-2: Phase contrast images of spreading  of (A) WJMSC (B) BMMSC 
and (C) TBMSC on fibronectin. 
Images recorded at 5, 15, 25 and 35 minutes after the start of perfusion for 4 minutes 
at a wall shear rate of 35s
-1
. Images are from separate fields in an  experiment 
representative of 3 others with similar results. 
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Figure  4-3: Comparison of the percentage of adherent WJMSC,  BMMSC and 
TBMSC spread with time on A. collagen, B. fibronectin.  to different surfaces  
(A) on collagen and (B) on fibronectin surface: 
Images were analysed at 5, 15, 25 and 35 minutes after the start of perfusion for 4 
minutes at a wall shear rate of 35s
-1
.  Data are mean ± SEM from 3-4 experiments.  
For combined data from A and B, ANOVA showed significant effects  of cell type 
and substrate on percentage of cells spreading  (p<0.01 in all cases).  *=p<0.05; 
**=p<0.01 for post-hoc comparison of cell types, combining values for all time 






Figure ‎4-4:  Phase contrast images of (A) WJMSC (B) BMMSC and(C)TBMSC 
adherent to collagen, with the same field followed over time. 
Images recorded at 5, 15, 25 and 35 minutes after the start of perfusion for 4 minutes 
at a wall shear rate of 35s
-1
.  For each cell type, images are from a single fields in an 




Figure ‎4-5: Phase contrast images of (A) WJMSC (B) BMMSC and(C)TBMSC 
adherent to fibronectin, with the same field followed over time. 
Images recorded at 5, 15, 25 and 35 minutes after the start of perfusion for 4 minutes 
at a wall shear rate of 35s
-1
.  For each cell type, images are from a single fields in an 






Figure ‎4-6: Measurement of the area of individualWJMSC on Fibronectin 
surface. 
Images at  5, 10, 25 minutes after the start of perfusion for 4 minutes at a wall shear 
rate of 35s
-1
. Individual frames were digitised and analysed using ImagePro 
software. 
After 5 min  After 10 min  After 25 min  
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Figure ‎4-7: Comparison the areas of WJMSC, BMMSC and TBMSC spread on 
A. collagen or B. fibronectin for different times. 
Images were analysed at 5, 10 and 25 minutes after the start of perfusion for 4 
minutes at a wall shear rate of 35s
-1
.  Data are mean ± SEM from 3-4 experiments. 
For combined data from A and B, ANOVA showed significant effects  of cell type, 
substrate and time on cell area.  *=p<0.05; **=p<0.01 for post-hoc comparison of 






4.2.2 Migration of MSC through porous filters coated with collagen or fibronectin 
 
We compared migration ability for BMMSC and WJMSC using Transwell 
filters with 8 µm diameter pore. The filters were first coated on the top or the bottom 
with fibronectin or collagen.  BSA was used as a control protein.  The filters were 
subsequently immersed in culture medium which contained FCS, so that all surfaces 
were effectively 'blocked' with albumin. Comparisons were thus mainly examining 
the effects of adding collagen or fibronection to BSA on either the upper or lower 
surface.   
In these experiments, the original samples and the cells retrieved from the 
above and below the filter were counted using a Coulter counter which also 
measured their diameter. We noticed that the diameter of the retrieved cells was 
smaller compared to the original sample. (See figure4.11). We thus analysed the 
migration for the whole population (7-27µm) and for the larger population (12-
27µm) separately, to see if there was a link between size and migration.  
Figure 4.8 compares Transwell migration for BMMSC and WJMSC after 
coating filters with collagen, fibronectin or albumin alone.  In Figure 4.8A, data are 
shown for top-coated filters and analysis of all cells (gated from 7-27 µm). In Figure 
4.9B, data are shown for top-coated filters and analysis of cells between 12-27 µm in 
diameter.   Figures 4.9C and D show results for the same analyses but where the 
bottom of the filter was coated.  For albumin coating alone, about 20% of MSC 
migrated across the filter in 24h.  Fibronectin coating tended to increase migration 
compared to albumin.  However, collagen coated on top gave a similar migration to 
albumin, while collagen coated on the bottom gave a higher migration than albumin.  
Overall, there was a higher level of migration for the WJMSC than for the BMMSC, 
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with this difference more clearly apparent for the filters with a bottom coating.  
There was also a tendency to observe a higher degree of migration when the smaller 
sized cells were included in the analysis.   
To make the comparison between coating the top or bottom of filters clearer, 
the data are re-plotted in Figure 4.9 as Top vs. Bottom, separately for the different 
cells.  It is evident that coating the bottom gave greater migration.  This effect was 
stronger for the WJMSC then the BMMSC.  It was again noticeable that the 
percentage migration was greater when the smaller sized cells were included in the 
analysis.  For example, Figure 4.10 compares directly the results for all cells vs. 
larger cells only, for  MSC migrating  on filters with the bottom coated with 
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Figure ‎4-8: Transwell migration: comparison between BMMSC and WJMSC 
for filters pre-coated on the top (A,B) or bottom (C,D), with collagen, 
fibronectin or albumin. 
Data were analysed for all cells detected by the Coulter counter (A,C), or for only 
larger cells with diameter above 12µm (B,D).  Migration was allowed for 24hrs at 
37°C. Data are mean ± SEM from 3 experiments. ANOVA showed that there were 
significant effects on migration of cell type in C and D (p<0.01 in each case) and of 
coating substrate in A, B and C  (p<0.05 in all cases).  +=p<0.05 for post-hoc 
comparison of adherent substrates including values for both cell types, by Bonferroni 
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Figure ‎4-9: Transwell migration: comparison between coating the top or 
bottom of filters with collagen, fibronectin or albumin for BMMSC (A,B) or 
WJMSC (C,D). 
Data were analysed for all cells detected by the Coulter counter (A,C), or for only 
larger cells with diameter above 12µm (B,D).  Migration was allowed for 24hrs at 
37°C. Data are mean ± SEM from 3 experiments. ANOVA showed that there were 
significant effects of  the surface coated (Top vs. Bottom; p<0.01 in all cases).  
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Figure ‎4-10:  Transwell migration: comparison between  all cells detected by 
the Coulter counter (7-27µm diameter) and larger cells (12-27µm diameter), for 
BMMSC (A) or WJMSC (C). 
Migration was allowed for 24hrs at 37°C. Data are mean ± SEM from 3 experiments. 
ANOVA showed that there were significant effects of cell size on migration (p<0.01 
for each MSC type).  *=p<0.05, ** = p<0.01 for comparison by Bonferroni text. 
 


















Figure ‎4-11: :   cells size diameter distributionA original sample and B the cells retrived 
from below the filter after 24hours incubation: the original samples and the cells retrieved 
from the below the filter were counted using a Coulter counter which also measured their 







Having studied adhesion of MSC to matrix proteins, collagen and 
fibronectin, the next aim of this thesis was to compare the subsequent behaviour of 
BMMSC, WJMSC, and TBMSC.  This would be relevant to their fate when 
deposited in damaged tissue and might reveal the factors which affect their role 
there. To do that, we studied their spreading behaviour on collagen and fibronectin, 
and then their migration through filters coated with these proteins.  
Firstly, on collagen, BMMSC spread more efficiently and faster than 
WJMSC and TBMSC, which behaved similarly. On fibronectin BMSC also spread 
faster compared to WJMSC or TBMSC, although all cell types approached 100% 
spread with time.  On both surfaces, BMMSC spread to cover a larger area than the 
TBMSC and WJMSC.  We noticed an interesting findings regarding the spreading 
behaviour of TBMSC on fibronectin, which behaved similarly to WJMSC until 
about 15 minutes, but then TBMSC spread faster and to a larger area than WJMSC.  
On collagen the WJMSC and TBMSC behaved nearly identically. The behaviour on 
fibronectin might relate to differences in signals from the adhesive interaction with 
this protein (see below).  Overall, spreading was more efficient, more rapid and to a 
greater area on fibronectin than on collagen. 
These findings are consistent with those  of  Ogura N et al. (2004), who 
found that fibronectin stimulated adhesion, spreading and growth of human BMMSC 
(Ogura N, 2004).  In addition, Veevers et al. (2011) found a receptor, α5β1-integrin, 
which supported cross talk between growth factor receptor and integrin receptor 
signals on fibronectin (Veevers-Lowe et al., 2011).  This interaction between cell 
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and fibronectin led to a chain of actions which caused greater phosphorylation of 
PDGFR-β and subsequently promoted the adhesion and migration of the human 
BMMSC. They noted that collagen types I or IV had little effect on PDGFR-β 
activity compared to fibronectin.  Neither of these studies evaluated MSC from other 
sources, and so we have shown for the first time there are cell-specific variations in 
spreading as well as adhesion, in addition to substrate-specific variations. 
The potential therapeutic uses of MSC may depend on their ability to migrate 
into tissue as well as adhere and spread on the surface.  We thus assessed migration 
across 8µm pore filters coated with different proteins, either on the upper or lower 
surface.   We limited our studies to use of BMMSC and WJMSC, as TBMSC were 
difficult to obtain and proliferate, and have not been widely studied or used in 
therapies.  We discovered several interesting trends.  In contrast to spreading, 
WJMSC were more effective in transmigration then BMMSC on all surfaces.  When 
the top of the filter was coated, there were was little difference between coating with 
collagen or albumin, but coating with fibronectin encouraged migration slightly.  
When the bottom was coated, there was greater migration overall than if the top was 
coated, and both collagen and fibronectin increased migration compared to albumin.  
Interestingly, the effect of coating the bottom of the filter appeared to be greater for 
WJMSC than BMMSC. When the bottom was coated, this showed the greatest 
difference between the cells.  Finally, we unexpectedly observed that there was a 
greater spread in cell size after migration then in the original cell population, with a 
greater proportion of small cells (diameter <12µm) observed. These smaller cells 
showed more efficient migration.  Thus, larger cells may migrate less easily through 
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gaps than smaller ones, although this applied to both types of MSC, which had 
similar diameters. 
To our knowledge, this is the first comparison of the ability to migrate for 
MSC from different sources on different surfaces. Our findings could be linked to 
the study noted above by Veevers et al. (Veevers-Lowe et al., 2011), who found that 
binding to fibronectin promoted signalling through PDGFR-β and trans-filter 
migration when the bottom side of the filter was coated.  They found that the 
interaction  ith fibronectin  as dependent on α5β1-integrin and not αvβ3-integrin.  
They also found that binding to collagen did not induce the same level of signalling 
as fibronectin.  However, we found similar migration for collagen or fibronectin 
coating of the lower side, although coating of the upper side with fibronectin did 
promote migration more than collagen.  The wider potential importance of such 
observations was illustrated by studies of knockout mice deficient in genes encoding 
PDGFR-β; these died at late embryonic stages because of failure of mural cell 
recruitment (Lindahl et al., 1997).  Others have shown that migration of 'multi-potent 
stromal cells' and fibroblasts are also promoted on fibronectin, but through effects on 
epidermal growth factor-receptor (EGFR) (Wu et al., 2011) (Maheshwari et al., 
1999).   Cell migration typically consists of protrusion at the front, followed by 
adhesion there and detachment at the rear (Ridley et al., 2003).  Activation of EGFR 
induces a signal network which promotes the front lamellipod protrusion and 
dynamic changes in adhesion (Wells A, 2006). The current transfilter assays lack 
ability to study these dynamic processes in detail, although the assays of adhesion 
and spreading did follow kinetics of the early events. 
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The role of migration following systemic infusion of MSC for therapeutic 
uses is challenging to characterize, and there is limited data on MSC adhesion and 
migration mechanisms in vivo.  There have been a number of studies of migration 
through endothelial monolayers in vitro. The mechanisms by which leukocytes 
adhere and go through the endothelium barrier to integrate into the tissue haves been 
widely studied (Ley et al., 2007) (Woodfin et al., 2010). While it is believed that the 
process may be similar for MSC, there is limited data to support this.  Schmidt et al. 
(Schmidt et al., 2006) showed slow integration and then migration of MSC through 
an endothelial cell monolayer over about 2 hours.  Steingen et al. (Steingen et al., 
2008) reported that MSC migrated through and under  endothelial cells stimulated 
with cytokines in 2-4 hours, assisted by VCAM/α4β1-integrin interaction. They 
showed that the degrading enzyme MMP-2 was generated during penetration of the 
endothelium.  Chamberlain et al  (Chamberlain et al., 2008) showed that murine 
MSC adherent to murine aortic endothelial cells (MAEC) produced microvillous 
processes (filopodia) which then were extended to form pseudopodia in multiple 
directions, and slowly moved into and under the endothelial monolayer, again in 
hours.  In this study, the authors also found that chemokines CXCL9, CXCL16, 
CCL20 and CCL25 promoted transmigration of MSC through MAEC cultured on 
filters over 16 hours.  Several studies have shown expression of chemokine receptors 
on human MSC (Chamberlain et al., 2008) (Ringe et al., 2007), and there are 
common chemokine receptors between leukocytes and MSC (Minguell et al., 2001). 
In our studies of transmigration, endothelial cells were not present and we did 
not add chemokines, but we did find a high proportion of WJMSC could migrate 
across filters when the bottom was coated.  BMMSC did show an effect of coating 
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the lower surface on migration, but not as strong as for WJMSC.  It is possible that 
migrated cells released chemotactic factors when adherent on the lower surface 
which attracted those on top, and that WJMSC were more effective in this respect.  
There were however several differences in adhesion and spreading that may explain 
differences in migration, which may be the key event in recruitment in vivo.  It is 
also possible that signalling through integrin receptors noted above, is different for 
the different types of MSC.  Investigation of the roles of specific integrins in the 
adhesion, spreading and migration behaviour seen here might help explain 
differences between cells and between coating proteins.  Studies of the integrins 
required for adhesion are described in Chapter 6. 
Bringing together the results from this Chapter and Chapter 3, we can 
consider the links between adhesion, spreading and migration for the different MSC.  
Comparing BMMSC and WJMSC for which we have the most complete data, 
WJMSC adhered in greater numbers from flow.  BMMSC spread  more efficiently 
and quickly, but WJMSC migrated in greater numbers, especially when the lower 
surface was coated.  Thus, spreading does not appear to promote migration.  In 
general, migration speed depends on strength of attachment but also the ability to 
detach in a regulated manner, with the regulation of formation and loss of integrin 
bonds being critical factors (Ridley et al., 2003, Huttenlocher and Horwitz, 2011). 
Too strong an attachment may slow migration.  The adhesion we measured here 
shows ability to support capture from flow, and this may not be the same as the 
adhesion developed after attachment, and not be closely linked to migration which 
starts some time after capture.  Thus the spread cells may become too strongly 
attached to move quickly.  In vivo it is difficult to predict which of the above 
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properties will be more important for therapy.  WJMSC should be more effectively 
captured in damaged tissue and migrate faster into the tissue.  On the other hand, 
BMMSC may spread and integrate into the wall faster if e.g., mechanically trapped 
in small vessels.  Further studies in flow models coated with endothelial cells, or by 
intravital microscopy, might be able to answer these questions about the 
effectiveness of the different MSC. 
4.4 CONCLUSIONS  
The cell adhesion, spreading and migration assays described here have 
provided information on behaviour of MSC that may be relevant to their recruitment 
to blood vessels and tissue if injected into the blood.  We found clear differences in 
behaviour of MSC that are used in current research and therapy, from bone marrow 
and Wharton's jelly.  Trabecular bone is less frequently used to obtain MSC, and 
TBMSC behaved similarly to the WJMSC. 
The studies described show the most complete comparison of adhesive and 
migratory behaviour of different MSC to date.  However, they also raise questions 
about the mechanisms supporting adhesion and migration, and whether the adhesive 
behaviour would be the same if the MSC were added to blood.  The latter question is 


















Chapter 5 ADHESION OF MSC TO MATRIX PROTEINS FROM 
















 Studies described in Chapter 3 showed that MSC could bind to matrix 
proteins, collagen and fibronectin, but not selectins, at wall shear rates up to about 
70s
-1
, and suggested that the different MSC tested adhered in the order 
WJMSC>BMMSC>TBMSC.  Having studied the spreading behaviour and migration 
of adherent cells on the different matrix proteins, we decided next to evaluate 
adhesion from flowing blood, to see if the same order of adhesion occurred or 
whether presence of other cells altered behaviour. 
 There are no studies of adhesion of MSC from flowing blood in the literature 
to our knowledge.  Adhesion from blood would be more relevant to the situation 
when MSC are used for therapy by injection into the circulation.   It is known that 
margination in the blood stream is important for adhesion of leukocytes and platelets 
(Abbitt and Nash, 2003, Watts, 2015), and it is not clear whether this would happen 
with large cells like MSC.  For instance, for leukocytes, slow flow and red cell 
aggregation promote margination, but for platelets, these conditions are not so 
effective (Watts, 2015). Since this thesis was started, some studies have been 
reported that suggest BMMSC may bind to platelets in blood and be deposited in the 
microcirculation with them (Langer et al., 2006, Teo et al., 2015)In addition, it has 
been reported that MSC can bind to platelets stuck to collagen (Jiang L et al., 2012).  
Thus interaction with platelets might affect adhesion from blood. 
 In this chapter, we compared adhesion form isolated MSC to adhesion for 
MSC in whole blood  perfused over the coated surfaces at a wall shear rate of 35s
-1
. 
The number of adherent cells of each cell type of MSC was counted for the different 
surfaces  and expressed as a percentage of all those perfused, as described in Section 
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2.4.3a.  Results from these experiments led us to also investigate the ability of 
flowing MSC to bind to platelets that had been deposited onto fibronectin from 
blood and binding of MSC to platelets in platelet-rich plasma (PRP).  For the latter,  
as described in Section 2.5,  MSC were added to the PRP in a platelet aggregometer  
and changes in light transmission recorded before the cells were fixed and examined 
under phase-contrast microscope for morphological changes such as clump 
formation.  
 These studies thus aimed to improve our understanding of the behaviour of 
MSC in blood and the role of blood flow and other blood cells such as platelets in 
MSC dynamic adhesion properties. 
5.2 RESULTS 
5.2.1 Comparison of the adhesion of WJMSC, BMMSC and TBMSC added to 
whole blood 
 In Figure 5.1, the adhesion of WJMSC, BMMSC and TBMSC are compared 
when they were added to blood at a fixed count and perfused over collagen or 
fibronectin.  For comparison, data for adhesion of isolated cells at the same shear 
rate are included.  Figure 5.1A shows the adhesion on collagen; we found that after 
flowing WJMSC, BMSMC, and TBMSC with whole blood, the percentage of 
adhesion was much decreased compared to adhesion of isolated cells in culture 
media. Also, by comparing the adhesion of the three MSC, the Figure shows that the 
adhesion of WJMSC within blood was much higher than that of BMMSC or 
TBMSC.   In fact, we only saw occasional fluorescent BMMSC or TBMSC adhered 
to collagen.  For WJMSC we saw large clumps of cells with several MSC in them 
(Figure 5.2 ) and on close examination we could also see fluorescent platelets and 
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leukocytes which had taken up dye.  After washout of blood, we used phase contrast 
microscopy to examine these clumps and observed small platelet clumps or 'thrombi' 
(Figure 5.2). Thus, only WJMSC adhered to collagen effectively in blood.  They 
appeared to be associated with platelets, and also bound together by them.  
Leukocytes were also adherent, probably also binding to the platelets. 
 Figure 5.1B shows the data for adhesion on a fibronectin surface; we found 
that after flowing WJMSC, BMSMC, and TBMSC with whole blood, no adhesion 
was detectable.  When we washed out the blood, however, we noticed that the 
surface of the fibronectin was covered by spread platelets in a monolayer (see Figure 
5.3).  We also saw leukocytes rapidly rolling across this surface during washout (see 
Figure 5.4)  These platelets did not form aggregates or build up of 'thrombi' as seen 
on a collagen surface. It appeared therefore that although MSC, especially WJMSC, 
might bind to platelets, they did not bind to the platelets on the fibronection.  It was 
possible that the platelet coating also inhibited the MSC binding to the fibronectin 
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‎5-1:Comparison of the adhesion of WJMSC, BMMSC and TBMSC suspended 
in culture medium or in whole blood from flow to (A)collagen  or (B) 
fibronectin.   
MSC were perfused at a wall shear rate 35s
-1
 for 4 minutes before washout and 
counting of adherent MSC.  In both A and B, ANOVA showed that there was a 
significant effect of cell type and of suspending medium (p<0.01 for cell type; 
p<0.05 for suspending medium).  Combining data for A and B for blood only, 
ANOVA showed a significant effects of adherent surface (p<0.05). *=p<0.05; 
**=p<0.01 for post-hoc comparison of cells type with data for the two media 
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combined, by Bonferroni test.  
 







‎5-2: Images of WJMSC and platelets adhered to collagen from whole blood. 
A,B. Phase contrast images taken with 20X or 40X objective.  
C.  Fluorescent and,D phase contrast images of a single WJMSC-platelet aggregate.  
Yellow arrow is pointing to WJMSC,Red arrow is pointing to Platelets and Black aroow is 
pointing to White bloos cells . 
 
 5-3: Phase contrast image of  platelets adhered to fibronectin from whole blood 
after WJMSC with whole blood (1.5 x 10
5
/ml) were flown on fibronectin surface 
at rate 35s
-1




 5-4:  Leukocytes rolling across platelets monolayerduring washout, picture was 








5.2.2  Adhesion of flowing isolated MSC to platelets deposited on fibronectin 
 
 Based on the surprising results described above, we conducted a different 
experiment where isolated WJMSC, BMMSC, and TBMSC were flowed over 
platelet monolayer surfaces which had been deposited onto fibronectin from whole 
blood.  Interestingly, adhesion was restored for all the MSC types (Figure 5.5A).   
The adhesion percentage was again in the order WJMSC>BMMSC>TBMSC.  Since 
these platelets were presumably not fully activated (not forming aggregates from 
blood), we repeated the test after TRAP had been perfused to activate platelets in the  
monolayer.  Interestingly, we noticed an increase in the adhesion percentage of all 
MSC compared to 'unactivated' platelet monolayers  (Figure 5.5B). Since the platelet 
monolayers were not perfectly confluent, some adhesion could have been to 
fibronectin itself (see e.g., Figure 5.6).  The effect of platelet activation thus helped 
show that adhesion was also platelet-specific.   
 These results raised the question why MSC had not bound to the platelets on 
the surfaces in the whole blood experiments, when the platelets were deposited on 
collagen or fibronectin, except the WJMSC for collagen. We considered the 
hypothesis that if activation was not required to bind platelets to MSC, they might 
bind in the blood and form a 'barrier' to adhesion to the platelets on the surface. This 
barrier would not operate if the platelets bound to the MSC were themselves 
activated (e.g., those bound to WJMSC and not the other MSC), as then cross-



















































































‎5-5: Comparison of the adhesion of WJMSC, BMMSC and TBMSC suspended 
in culture medium to platelets adhered to fibronectin after washout of blood.   
Platelets were (A) unstimulated, or (B) TRAP was perfused over them before 
perfusion of MSC.  MSC were perfused at a wall shear rate 35s
-1
 for 4 minutes 
before washout and counting of adherent MSC.  In A and B, ANOVA showed that 
there was a significant effect of cell type on adhesion (p<0.01 fin each case). 




‎5-6: Phase contrast image of platelets adhered to fibronectin from whole blood, 
before and after perfusion of  isolated WJMSC at conc  (1.5 x 10
5
  /ml)for 4 min 






5.2.3 Further studies of direct binding between MSC and platelets 
 We thus investigated the binding of platelets directly to MSC when they were 
mixed with PRP in a platelet aggregometer.  Figure 5.7A,B shows the aggregation 
results for PRP alone when thrombin or collagen were added as agonists, as positive 
controls.  In Figure 5.7C,D we show a typical aggregation response between PRP 
and WJMSC. We noticed a slight gradual increase in light transmission, or slight 
increase in 'aggregation' after adding WJMSC. After adding WJMSC we also tried 
adding collagen.  We noticed a strong aggregation response.  In Figure 5.7E,F we 
show a typical aggregation response between PRP and BMMSC. BMMSC caused a 
just detectable change in light transmission.  When collagen was added, there was an 
increase in the aggregation response.  
 These results suggested an interaction with platelets that was greater for 
WJMSC than BMMSC, but did not provide clear evidence.  When we observed cells 
retrieved from the aggregometer is was evident that aggregation of WJMSC did 
occur when they were mixed with PRP, and that platelets could be observed attached 
to individual cells (Figure 5.8).  With collagen added, large multi-MSC aggregates 
could be observed.  We could also see aggregates with BMMSC, especially when 
collagen was added (Figure 5.9), but overall, aggregates were smaller than for 
WJMSC. 
 To obtain further evidence of interaction between MSC and platelets, we 
tried a 'reverse' experiment.  WJMSC were injected into microslides and allowed to 
settle and adhere for 2 hours.  Then blood was perfused over the MSC, followed by 
washout.  Platelets could be observed attach to the sparse MSC (see e.g., Figure 
5.10).  However, the MSC tended to round up and we could not show consistent 
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attachment through this method.  Since completion of experiments described in this 
thesis, others in our laboratory made a simpler 'static' assay with MSC deposited on 
tissue culture dishes to which PRP was added and allowed time to settle.  The MSC 
remained spread and platelets adhered to the WJMSC but far fewer to the BMMSC 












‎5-7: Printouts from a platelet aggregometer showing platelet aggregation 
(decrease in absorbance or increase in transmitted intensity of light). 
A,B.  Aggregation responses to Thrombin (0.1 U/ml) or collagen (2 μg/ml) added to 
PRP.C,D.  Aggregation responses to 2x10⁶/ml WJMSC without or with added 
collagen (2 μg/mL).E,F.  Aggregation responses to 2x10⁶/ml BMMSC without or 
 ith added collagen (2 μg/mL). The results are presented as percentage aggregation, 
with 100% equivalent to transmission through PP . The tracings shown are from an 
experiment repesentative of 3 others with similar results. Arrowheads mark the 






















‎5-8: Phase contrast image of WJMSC after stirring with A. PPP;  B. PRP;  
C. PRP + collagen. 
The smaller pictures show higher magnification of MSC in PRP. red arrow is pointing to platelet. 
 
‎5-9: Phase contrast image of BMMSC after stirring with A. PPP;  B. PRP;  































‎5-10: Phase contrast image of WJMSC adhered to a microslide before and after 
perfusion of whole blood. 
A simpler 'static' assay with MSC deposited on tissue culture dishes to which PRP was 
added and allowed time to settle.  The MSC remained spread and platelets adhered to 
the WJMSC. 
‎5-11: Phase contrast and fluorescence images of MSC adhered to a culture dish.  
Platelets in PRP were stained with rhodamine and added to MSC. The platelets were 
allowed to settle for 30 minutes and then non-adherent platelets were washed off.  




5.3 DISCUSSION  
In  this chapter we demonstrated for the first time the adhesive behaviour of 
flowing MSC when added to whole blood.  WJMSC, BMSMC and TBMSC were 
compared when perfused over surfaces coated with matrix proteins.  We 
demonstrated that MSC within whole blood adhered to collagen or fibronectin much 
less than isolated MSC.  Indeed, there was no detectable adhesion to fibronectin, and 
on collagen, only occasional adherent BMMSC and TBMSC were seen.  In the case 
of WJMSC, we observed clumps of cells, some large with several MSC, which 
included platelets and occasional leukocytes. Thus, only WJMSC adhered to 
collagen effectively in blood, and they were associated with platelets, and also bound 
together by them.  On the protein surfaces themselves, small 'thrombi' of platelets 
were adhered to collagen, and a nearly confluent layer of spread platelets, without 
thrombi, were found on the fibronectin. 
In subsequent experiments on the fibronectin surface, after whole blood had 
been perfused and washed out, we found that isolated MSC adhered to the platelet 
monolayer, in the order WJMSC>BMMSC>TBMSC. Since MSC could bind to 
platelets, and they could also bind to fibronectin or collagen alone (see Chapter 3) it 
was puzzling why they were not seen attached to the these surfaces from blood, 
except for WJMSC and collagen.  To investigate further, we added WJMSC or 
BMMSC to PRP and examined aggregation in a platelet aggregometer which stirs 
the suspension at high speed.  Both MSC aggregated slightly with platelets, and 
larger aggregates of MSC with platelets were formed if collagen was added;  in each 
case WJMSC formed larger aggregates than BMMSC.  Other experiments were done 
to test adhesion of platelets from blood to MSC on a surface.  Although platelets 
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were observed attached to MSC, behaviour of the MSC was not reproducible.  
Recently, others in our laboratory have continued investigation based on these 
results.  They showed that unstimulated platelets in PRP could bind to MSC on a 
surface, again with WJMSC binding more platelets than BMMSC (Husain, Sherif 
and Nash, unpublished observations).  In addition, MSC/platelet aggregation studies 
have been repeated but with slow mixing speeds.  These studies showed strong 
aggregation of platelets induced by WJMSC (judged by change in light transmission) 
but not by BMMSC (Sherif and Nash, unpublished observations).  Taken together, 
the above results indicate that all MSC can bind platelets, but that WJMSC bind in 
greater number and more importantly, activate platelets so leading to formation of 
aggregates that include the MSC. 
Our hypothesis based on the above is illustrated in Figure5.13.  MSC bind 
platelets on their surface when flowing in blood; only for WJMSC, these platelets 
become activated and adherent for other platelets.   For collagen, the surface is also 
coated with activated platelets.  The WJMSC-platelet conjugates bind to these 
platelets and multicellular aggregates develop.  The BMMSC or TBMSC are 
shielded with non-activated platelets and do not form platelet-platelet attachments 
onto the collagen.  For fibronectin, the surface is coated with unactivated platelets, 
and these do not bind the MSC whether coated with activated or unactivated 
platelets.  In other words, activation is not required to bind platelets to MSC, and so 
they form a 'barrier' to adhesion to the platelets on the surface. This barrier does not 
operate if the platelets bound to the MSC are themselves activated (e.g., those bound 




The limited literature relevant to these studies supports the existence of 
MSC-platelet interactions and their relevance in vivo.  Teo et al.  (Teo et al., 2012) 
demonstrated that in mice, injection of endotoxin into the ear caused preferential 
recruitment of infused human BMMSC to microvessels in that ear. However,  
platelet depletion led to a decrease in this MSC homing, and direct observation 
showed MSC present with platelets and neutrophils in the inflamed vessels. In 
another study, Langer et al. (Langer et al., 2009) reported attachment of platelets and 
infused human BMMSC to the damaged carotid artery of mice, and again, there was 
a decrease in MSC adhesion when  platelets were depleted.  Jiang et al. (Jiang L et 
al., 2012) found that rat BMMSC  infused into a rat model of pulmonary arterial 
hypertension became located in the pulmonary blood vessels and that the number 
was reduced for animals treated with antibodies against P-selectin or an inhibitor of 
GpIIbIIIa.  They also studied adhesion of MSC to platelets which were adhered to 
collagen.  Under static conditions or flow, MSC bound to the platelets adhered to the 
collagen, but not to collagen alone.  The flow experiments were carried out at a 
much higher shear rate (1000s
-1
) than in our studies.  The deposition of MSC was 
reduced by treatment with the same antibodies against P-selectin or an inhibitor of 
GpIIbIIIa. 
Each of the above studies used BMMSC, and none directly observed 
behaviour in blood.  Thus they do not clearly test the hypothesis outlined in Figure 
5.11.  It is not clear in vivo which cells adhered first.  The results may suggest that 
adhered platelets captured perfused BMMSC, but it is also possible that platelets 
adhered to BMMSC assisted their trapping in microvessels.  In vivo, attachment may 
have been to endothelial cells rather than collagen or fibronectin. 
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The observation of a monolayer of spread platelets on a fibronectin surface is 
in agreement with a study by B Savage et al. (B Savage - ‎1996), who showed that 
platelets in flo ing blood arrested on fibronectin surface through αIIbβ3-integrin 
(GPIIbIIIa). They also described a monolayer without aggregates.  It is well known 
that platelets adhere to exposed collagen by (vWF) and (GPIb) initially, with firm 
adhesion and aggregation following through GpIIbIIIa explaining the presence of 
platelet clumps (Dopheide et al., 2002). We saw that during the wash out step some 
leukocytes rolled on the platelet monolayer on fibronectin.  We also found 
leukocytes attached to the aggregates on collagen. These findings are expected from 
previous observations of leukocyte-platelet adhesion in our laboratory (Buttrum et 
al., 1993, Butler et al., 2007)and may not be linked to the presence of MSC.   Rinder 
et al. (Rinder et al., 1991) reported that  platelets and leukocytes may also form 
aggregates in the blood when platelets are activated, and it is also possible that 
WJMSC-platelet aggregates could bind leukocytes in the blood as well as on the 
surface. 
These experiments are the first to show that flowing MSC can be marginated 
in blood. (see figure5.12)  The adhesion observed for WJMSC was on the upper 
surface of the microslide and so it cannot have been due to sedimentation.   Even 
when there was no adhesion, fluorescent MSC added to the blood could be seen 
flowing near the upper surface.  Thus, although MSC are larger than leukocytes, they 
can still be marginated by aggregated red blood cells at the low shear rates used in 




Figure‎5-12: Fluorescent image ofstained MSC marginated by the red blood 




 The results described may be relevant to the behaviour of MSC if infused for 
therapy.  Adhesion to the vessel wall may be unlikely for BMMSC or TBMSC for 
vessels with intact endothelium or even in damaged vessels with exposed matrix.  
WJMSC might be able to adhere to damaged vessels along with platelets.  There is 
also the possibility that WJMSC could cause thrombus formation in the blood and 
that this could block microvessels.  Infused MSC are cleared from the blood and 
many become stuck in the lungs (Fischer et al., 2009, Kang et al., 2012) These 
results suggest that trapping is likely to be mechanical and not adhesive.  However, if 
aggregates formed with platelets, MSC would be trapped more quickly.  Others have 
observed BMMSC stuck in small vessels in inflamed tissue (Teo et al., 2012) with 
platelets.  It is possible the BMMSC carried the platelets there, or that the platelets 






‎5-13: Hypothesis regarding behaviour of MSC and platelets adhering from 
flow.  
For perfusion over collagen (A), the surface coated with activated platelets. 
BMMSC is shielded with non-activated platelets and do not form platelet-platelet 
attachments onto the collagen while WJMSC-platelet conjugates bind to these 
platelets and multicellular aggregates develop. For perfusion over fibronectin (B), 
the surface is coated with unactivated platelets, and these do not bind theBMMSC 





Although all MSC could bind to collagen or fibronectin, and also were able 
to adhere to platelets, under blood flow only WJMSC showed large clumps of cells 
with several MSC, platelets, and leukocytes on a collagen surface.  It appears that 
WJMSC are able to activate platelets as well as bind them, leading to the build up.  
Differences in behaviour might arise because of different adhesion molecules on the 
MSC, such as integrins, or because WJMSC present some other activating agent to 
platelets.  To study the basis of MSC interactions with matrix proteins and with 
platelets, and mechanisms underlying the behaviour in whole blood, we next studied 
effects of antibodies able to block possible receptors (Chapter 6).  We considered the 
assay where MSC attached to platelets which had been deposited from blood onto 
fibronectin the best to study mechanisms of the MSC-platelet adhesion, since the 























Chapter 6  MECHANISMS OF ADHESION BETWEEN MSC, 
















 Platelets play an important role in haemostasis by being the primary agents in 
forming the initial thrombotic plug (Davi and Patrono, 2007) and in inflammation 
can assist in leukocyte recruitment  (Nash, 1994). The results in Chapter 5 suggest 
that platelets can also interact with MSC and influence MSC adhesion in blood.  
However, the mechanism that control that interaction is not well defined. 
Structurally, the platelet membrane carries a glycocalyx which act as an exterior 
coat, through which glycoprotein receptors are presented which control platelet 
adhesion (Cooper et al., 1976). The major adhesive receptors are the glycoprotein 
(GP) Ib-IX-V complex and GPIIbIIIa (also called αIIβ3-integrin). When collagen is 
exposed due to vascular injury, there will be immediate platelet binding between 
GPIb and its ligand vWF which binds from the blood onto collagen. Then, platelets 
bind to collagen via  GPVI and α2β1-integrin, which stabilizes the adhesion and 
triggers GpIIbIIIa activation which attaches to vWF, fibrinogen and fibronectin to 
further stabilise adhesion to the matrix and also induced platelet-platelet adhesion, to 
form the platelet plug (Varga-Szabo et al., 2008).  Platelets can also bind from 
flowing blood onto fibronectin at low shear rates using  GpIIbIIIa as the main 
receptor, but also α5β1-integrin (Beumer et al., 1994).  
 In addition to platelet adhesion, integrin family members support adhesion of 
many cells to extracellular matrix, and include receptors classified as  collagen- or 
fibronectin-binding, as shown in Figure6-1 Section 1.3.3.5. Our result in Chapter 5  
showed that isolated MSC could bind to collagen and fibronectin in the order 
WJMSC>BMMSC>TBMSC. In blood, however, we only observed clumps of 
WJMSC with platelets on collagen, even though we showed all MSC could bind to 
164 
 
deposited platelets.  To investigate the adhesive interactions that caused these results, 
we decided next to determine receptors which supported adhesion between WJMSC 
or BMMSC,  platelets and matrix proteins using selective function-blocking 
antibodies.  Use of TBMSC was limited by our inability to culture reliably beyond 
passage 3 and by their slow growth rate, and they were excluded from the studies of 
adhesion mechanisms. 
 First, we compared adhesion of two isolated cells WJMSC and BMMSC 
perfused over surfaces coated with collagen and fibronectin at a wall shear rate of 
35s-1, with or without antibodies against different integrins. Next, we flowed 
isolated WJMSC and BMMSC over platelet monolayer surfaces which had been 
deposited onto fibronectin from whole blood.  Again, antibodies against integrins 
were tested.  In whole blood assays we first tried to inhibit platelet adhesion to 
collagen in whole blood by: 
 (i) blockade of platelet GPIb-IX-V complex by antibody againt GP1b 
 (ii) blockade of platelet GPIIbIIIa by using abciximab  
Finally, antibodies against integrins with or without anti-platelet antibodies were 
tested. 
The adhesion assays were as described in Section 2.4, and antibody treatments as in 







We first investigated mechanisms of adhesion of isolated MSC to collagen 
(Figure 6.1) or fibronection (Figure 6.2).  Figure 6.1A shows that when isolated 
WJMSC  ere treated  ith antibody against β1- or βᴣ-integrin, the number of  
adherent  MSC was reduced by nearly 50% compared to untreated controls, and 
when  both antibodies were used, there was a slightly greater reduction. However, 
there was great variation between experiments and the reduction was not 
statitistically signficant (e.g., p=0.072 for anti-β3-integrin).   In Figure 6.1 B, when 
isolated BMMSC  ere treated  ith antibody against β1- or βᴣ-integrin, or both, the 
number of  adherent  cells was significantly decreased compared to control cells. 
Also,  hen isolated BMMSC  ere treated  ith antibody against β1-integrin, we 
observed further significant reduction in number of adherent cells compared to non 
treated cells.  Overall, it appears that MSC adhered to collagen using both  β1- and 
βᴣ-integrins.  For BMMSC there  as evidence that αvβᴣ-integrin was the particular 
βᴣ-integrin used, but surprisingly, antibody against αv-integrin was not effective. 
In Figure 6.2A, when isolated WJMSC were treated with antibody against 
β1- integrin, the number adherent from flow on fibronectin was greatly and  
significantly decreased compared to control cells. Also, when isolated WJMSC were 
treated  ith antibody against βᴣ-integrin, there was a slight but non-significant 
reduction in number of adherent cells. However, interestingly, we noticed that after 
treatment  ith antibody against βᴣ-integrin, adherent MSC lost the ability to spread 
on the fibronectin surface compared to non-treated cells and remained nearly round 
(see Figure 6.3). After treatment with anti-αᴠβᴣ-integrin, we detected significant 
decrease in number of adherent cells compared to controls, and this was also the case 
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 hen cells  ere treated  ith antibody against αᴠ-integrin.  Figure 6.2B shows results 
when isolated BMMSC were treated with the same antibodies.  Results were similar 
to those for WJMSC.  Anti β1-integrin reduced adhesion significantly but anti β3-
integrin had less effect, with borderline statistical significance (p=0.058).  
Treatments with anti-αᴠβᴣ-integrin or anti-αᴠ-integrin both significantly and 
markedly reduced adhesion.  Overall, it appears that MSC adhered to fibronectin 
mainly through β1-integrins.  Results for   βᴣ-integrins were inconsistent, with 
antibody against αv-integrin or αvβᴣ-integrin being effective but anti-βᴣ-integrin not.  
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 6-1:Effects of antibodies against different integrins on adhesion of (A). 
WJMSC, (B).BMMSC to collagen. 
MSC were  treated with antibodies and perfused at a wall shear rate of 35s
-1
 for 4 
min.  Data are mean ± SEM from 3-6 experiments (except for antibody against αvβ3 
tested on 2 occasions).  Not all antibodies were tested in all experiments, but 
untreated controls were used in every experiment.  *=p<0.05; **=p<0.01*for 
comparison to untreated control by paired t test. 










































* * * *
* *
B






































‎6-2: Effects of antibodies against different integrins on adhesion of (A). 
WJMSC, (B).BMMSC to fibronectin. 
MSC were treated with antibodies and perfused at a wall shear rate of 35s
-1
 for 4 
min.  Data are mean ± SEM from 3 experiments. **=p<0.01 for comparison to 
untreated control by paired t test. 














Figure ‎6-3 Effect‎of‎antibody‎β3-integrin on WJMSC on fibronectin.   
Images captured from phase contrast recordings during an adhesion assay. Antibody 
against β3-integrin caused adherent WJMSC to lose their ability to spread on 




Next we investigated the mechanism of adhesion of MSC to platelets 
deposited from whole blood onto a fibronectin surface.  Figure 6.4A shows results 
when isolated WJMSC were treated with antibodies against β3-,β1- or αv-integrins 
before being perfused over the platelets.  It also shows the effects of adding 
antibodies against GpIIbIIIa  to the blood before perfusion over the fibronectin and 
washout, with or without anti-β1-integrin added to the MSC.  We detected >90% 
reduction in the number of adherent WJMSC compared to controls when the cells 
were treated with  anti-β1-integrin, and a smaller but significant effect of anti-β3-
integrin.  Treatment of MSC with anti-αv-integrin also reduced adhesion.  When the 
Untreated 
Antibody against β3-integrin 
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blood was treated with anti-GpIIbIIIa, there were adherent platelets but only a few  
MSC adhered to them.  The platelets were not spread but rounded, and we noticed 
that the MSC rolled across them picking up platelets (see e.g., Figure 6.4B).  When 
the blood was treated with anti-GpIIbIIIa and MSC with anti-β1-integrin, adherent 
MSC were not seen (Figure 6.4A).  In similar experiments for isolated BMMSC 
treated with anti-β1-integrin, adhesion was 22 ± 10% of the value for untreated 
controls (mean ± SEM, n=3, p<0.05 by paired t test).  In 1 or 2 experiments with 
each,  anti-β3-integrin or  anti-αv-integrin showed partial inhibition of adhesion of 
BMMSC, while anti-GpIIbIIIa caused almost complete loss of adhesion. Overall, 
MSC binding to platelets required β1-integrin, and β3-integrin played a smaller role.  
When platelet adhesion to fibronectin was inhibited by anti-GpIIbIIIa, there was 
little adhesion of MSC to the fibronectin, although the MSC could bind to platelets. 


































































Figure ‎6-4: Effects of antibodies against different integrins on 
adhesion of WJMSC to platelets deposited from whole blood onto 
fibronectin 
A. Adhesion when MSC were  treated with antibodies and perfused at a 
wall shear rate of 35s
-1
 for 4 min.  In experiments with anti-GpIIbIIIa, the 
antibody was added to the blood to prevent platelet-platelet binding 
before it was perfused over fibronectin.  Data are mean ± SEM from 3 
experiments. *=p<0.05, **=p<0.01 for comparison to untreated control by 
paired t test. 
 
B. Phase-contrast microscope image of fibronectin surface after perfusion 
of blood in the presence of antibodies against GpIIbIIIa, during perfusion 






Next, the effects of adding antibodies to whole blood along with MSC and perfusing 
together over collagen was tested.  Similar inhibitory experiments were not done on 
fibronectin as no adhesion was observed in controls.  Figure  6.5A shows the effect 
on WJMSC binding to collagen in the presence of whole blood, when whole blood 
was treated with anti-GP1b or anti-GpIIbIIIa.  WJMSC again adhered in clumps to 
collagen.  The number was reduced by anti-GpIb and almost totlally inhibited by 
anti-GpIIbIIIa.  Interestingly,  the adherent WJMSC after anti-GP1b treatment did 
not form clumps; instead we noticed single cells surrounded by platelets (see figure 
6.6A). Figure 6.5B and 6.5C show results from similar experiments with with 
BMMSC and TBMSC respectively.  As before, very few of these cells showed 
binding to collagen in whole blood, and when the blood was treated with anti-GP1b 
or anti-GpIIbIIIa, we saw close to zero adhesion.  Examining the surface of the 
collagen after blood perfusion alone and washout, we saw platelet aggregates as 
expected on collagen, and smaller numbers of individual platelets with either anti-







































































































































Figure ‎6-5: Effects of antibodies against different platelet receptors on adhesion of 
A. WJMSC, B. BMMSC, C. TBMSC to collagen from blood. 
Antibodies were added to blood with MSC and perfused at a wall shear rate of 35s
-1
 for 
4 min.  Data are mean ± SEM from 3 (A) or 2 (B,C)) experiments.  *=p<0.05 for 




















Finally, we tried to test the role of different integrins when WJMSC were 
perfused over collagen.  Figure 6.7 shows drastic, significant inhibition of WJMSC 
adhesion from blood flow compare to control after the MSC were treated with 
antibody against β1-integrin. In addition,  we noticed lesser inhibition of WJMSC 
adhesion from blood flo  after the cells  ere treated  ith antibody against β3-
integrin or αv-integrin.  The reduction was presumably because the MSC did not 
Figure ‎6-6: Microscope images of collagen surfaces after A. perfusion of blood 
containing MSC, B. blood alone. 
A. Phase-contrast microscope images of collagen surface after perfusion of blood in the 
absence or presence of antibodies against GpIIbIIIa or GP1b.B. Fluorescence images of 
WJMSC adherent from blood onto collagen in the presence of antibody against 




adhere to platelets.  We decided to test again the effect of inhibition of platelet 
adhesion to collagen (using anti GpIb and anti-GpIIbIIa), but with or without added 
anti-β1-integrin treatment of the MSC as well.  We considered that if we blocked 
platelet adhesion to collagen, as well as platelet adhesion to MSC, we might see 
'bare' MSC adhere to 'bare' collagen.  Inhibiting platelet adhesion to collagen resulted 
in almost total loss of MSC adhesion (Figure 6.7).  The combination of antiGpIb and 
anti-GpIIbIIIa did leave the collagen surafce with very few platelets on it.  Adding 
anti-β1-integrin to the MSC as well, increased adhesion slightly but not consistently, 
although the MSC that did adhere were single spherical cells. 
 
Non-specific antibodies were also tested in the above models.  In experiments 
on binding of isolated MSC on collagen or fibronectin, adhesion with non-specific 
IgG gave adhesion relative to untreated control = 1.01 ± 0.04 (mean ± SEM for 6 
independent experiments).  In addition, in experiments on fibronectin, adhesion with 
antibody against α4-integrin gave adhesion relative to untreated control = 1.05 ± 
0.22 (mean ± SEM for 4 independent experiments combined).  In experiments on 
binding of isolated MSC to platelets deposited on fibronectin from whole blood, 
adhesion with non-specific IgG gave adhesion relative to untreated control = 0.98 ± 
0.04 (mean ± SEM for 3 independent experiments).  In experiments on binding of 
WJMSC to collagen in whole blood, adhesion with non-specific IgG gave adhesion 
































































































Figure ‎6-7: Effects of antibodies against different receptors on adhesion of WJMSC 
to collagen from whole blood  
MSC were  treated with antibodies against β1-, β3- or αv-integrin and added to blood and 
perfused at a wall shear rate of 35s
-1
 for 4 min.  In experiments with anti-GpIb or 
GpIIbIIIa, antibodies were added to the blood before it was perfused.  Not all antibodies 
were tested in all experiments, but untreated controls were used in every experiment. 
Data are mean ± SEM from 3 to 9 experiments. *=p<0.05, **=p<0.01 for comparison to 
untreated control by paired t test. 





This chapter describes for the first time the adhesion mechanisms when MSC 
are flowed over matrix proteins, and how these change when MSC are added to 
blood and also interact with platelets.  We followed a stepwise investigation to find 
out first how MSC can directly bind to collagen or fibronectin or platelets.  We then 
investigated blood to try to find out what interactions were important for adhesion 
there, and to explain the results that  only WJMSC adhered to collagen and no MSC 
adhered to fibronectin. 
When isolated WJMSC or BMMSC  ere treated  ith antibody against β1-
integrin, we observed marked reduction in number of adherent cells to collagen for 
both cells types, although the effect was stronger and more consistent for the 
BMMSC.  Both cells types also showed reduced adhesion after treatment with 
antibody against β3-integrin.  A combination of antibodies against both integrins had 
little extra effect suggesting that some other adhesive mechanism also existed.  For 
BMMSC, we also used anti-αᴠβᴣ-integrin and there was a reduction in number of 
adherent cells similar to  anti-β3-integrin.  Surprisingly, anti-αᴠ-integrin did not 
show any effect on number of adherent cells. 
On fibronectin, when isolated WJMSC  and BMMSC were treated with anti-
β1-integrin, we observed huge, significant reduction in number of adherent cells 
compared to non-treated cells. When isolated WJMSC and BMMSC were treated 
with anti-βᴣ-integrin, the number of  adherent  isolated cells only decreased slightly. 
However, after treatment  ith antibodies against αᴠβᴣ-integrin or αᴠ-integrin, we did 
detect significant  decrease in the number of adherent MSC on the fibronectin 
surface.  Interestingly, adherent WJMSC and BMSC  after treatment with anti-β3-
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integrin lost the ability to spread on fibronectin surface. It is possible that this 
antibody affected signaling after adhesion which promoted spreading but not 
adhesion itself, while the anti-αᴠβᴣ-integrin did inhibit adhesion. 
Our results are consistent with earlier studies, although none directly tested 
adhesion of flowing MSC to matrix proteins.  Others have reported that β1-integrin 
is expressed on the surface of undifferentiated MSC (Goessler et al., 2008). Gronthos 
et al. reported that α1β1- and α2β1-integrins were involved in MSC binding to 
collagen and that MSC bound to fibronectin through α5β1-integrin (Gronthos et al., 
2001). Another study concluded that the interaction bet een α5β1-integrin and 
fibronectin was crucial for MSC adhesion and control of cell migration (Veevers-
Lowe et al., 2011). MSC  ere also reported to express αvβ3-integrin which 
supported MSC adhesion to platelets (Langer et al., 2009).    
Our results indicate that both β1- and β3-integrins assist adhesion to collagen 
and to fibronectin, for WJMSC as well as BMMSC.  The earlier adhesion studies 
(Chapter 3) showed WJMSC adhered at higher levels then BMMSC for both 
surfaces, but BMMSC spread faster than WJMSC (Chapter 4).  Recent studies in our 
laboratory compared integrin expression for WJMSC and BMMSC by flow 
cytometry.  These studies showed that both cell types expressed both integrins, 
although the level of β1-integrin appeared much higher.  There was a slightly higher 
level of integrins on the WJMSC (Lewis Clarke, unpublished observations).  It is 





Next we tested how MSC adhered to platelets.  We perfused isolated 
WJMSC and BMMSC over platelet monolayers which had been deposited onto 
fibronectin from whole blood.  We detected major, significant reduction in the 
number of adherent cells when MSC were treated with anti-β1-integrin, and lesser 
effect when MSC were treated with anti-β3-integrin.  When the blood used to 
deposit the platelets was treated with anti-GpIIbIIIa, there was little stable adhesion 
of MSC as the platelets did not spread and they were pulled off the surface by MSC 
rolling past.  This is consistent with the finding that platelets adhere to fibronectin 
using GpIIbIIIa (Beumer et al., 1994). It also indicates that the platelets do not use 
this receptor to bind MSC because adhesion still occurred but the platelets came off 
the surface.  When anti-GpIIbIIIa  was combined with treatment of MSC with anti-
β1-integrin, MSC lost all adhesion ability and rolling was not seen.  This shows 
again that β1-integrin supported adhesion of MSC to the platelets.  
Having tested the adhesion mechanism between MSC and collagen and 
between MSC and platelets, we investigated mechanism of adhesion when MSC 
were added to whole blood and perfused over collagen.  First we investigated the 
roles of platelet receptors.  When whole blood was treated with anti-GPIb, we 
observed reduction in WJMSC adhesion to collagen. Large aggregates of platelets 
did not form on the collagen, and the adherent WJMSC after anti-GPIb treatment 
instead adhered as single cells surrounded by platelets.  GpIb reduced platelet 
adhesion to collagen and build up of aggregates, but clearly did not stop platelets 
adhering to MSC.  Secondly, when whole blood was treated with anti-GPIIbIIIa, we  
observed a total reduction of WJMSC adhesion to collagen, although a few platelets 
were adhered on the surface.  Without platelet-platelet adhesion it seems WJMSC 
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could not bind in large numbers or aggregates. However, nor did they bind to the 
nearly bare collagen, presumably because they still had  platelets attached to them 
and obstructing them.  
BMMSC and TBMSC showed very little adhesion on collagen from whole 
blood, as demonstrated in Chapter 5.  After whole blood was treated with anti-Gp1b 
or anti-GPIIbIIIa, adhesion was barely detectable.  Again, it is likely that the MSC 
did have platelets attached in blood,  and could not attach to the exposed collagen 
directly. 
The behaviour of the platelets on collagen is in agreement with the literature 
which shows that platelets treated with anti-GPIb or  anti-GPIIbIIIa have impaired 
adhesion and aggregation on collagen (Varga-Szabo et al., 2008, Savage et al., 
1996).  The results are also consistent with the in vivo study by Teo et al. who 
demonstrated that platelet depletion led to a decrease in MSC homing to the 
inflammed ear skin (Teo et al., 2012).  
 Finally, we investigated the role of integrins on MSC, with or without 
inhibition of platelet adhesion as well.  On the collagen surface, we demonstrated 
that   hen WJMSC  ere treated  ith  antibody against β1-integrin, the number of  
adherent  WJMSC from flo ing blood  as greatly decreased.   Antibody against βᴣ- 
or αv-integrin reduced adhesion but not as much.  This is consistent with the finding 
above that WJMSC bind to platelets via β1-integrin and to a lesser extent β3-
integrin.  Treatment of platelets with anti-GpIIbIIIa alone or with anti GpIb again 
reduced adhesion because of the loss of platelet binding to the collagen, but not 
platelet binding to the MSC in the blood.   Treatment of MSC with anti-β1-integrin 
at the same time as the platelets did not recover adhesion.  This should have inhibited 
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the platelets from binding to the MSC, but they still did not adhere to the collagen 
except in quite small numbers.  It seems that the anti-β1-integrin also stopped that 
adhesion to collagen. 
6.4 CONCLUSIONS 
Adhesion of MSC to matrix proteins and to platelets involves both β1- and 
β3-integrins,  ith the β1-integrins having greater effect.  Previous studies with static 
assays have shown importance of both families of integrins, but were not in flow.  
We found β3-integrins affected spreading after initial adhesion.  In static systems, it 
is not possible to separate initial adhesion from spreading and stabilisation 
afterwards.  As expected, platelets used GpIb and GpIIbIIIa to adhere and spread on 
collagen and GpIIbIIIa on fibronectin.  These receptors did not affect interaction 
between MSC and platelets.  We were not able to devise an experiment where we 
blocked platelet binding to collagen, and platelet binding to MSC, to recover 
adhesion of flowing 'bare' MSC to 'bare' collagen.  This was because the same 
receptors mediated MSC-collagen and MSC-platelet adhesion, and blockade of 







































7.1 Main findings 
 In this thesis we aimed to investigate the ability of MSC from different 
sources to  adhere, spread and migrate on different surfaces using dynamic flow 
assays, and to study the effects of  haematological and rheological factors on 
adhesion when MSC were suspended in blood.  The studies were designed to give 
information on how MSC might behave in vivo if infused for therapy. The main 
findings are listed below. 
7.1.1  Adhesive properties of different  progenitor cells under flow  
 Progenitor cells could adhere from flow onto collagen or fibronectin and the 
adhesion was more effective on the matrix proteins than on selectins.  
 EPC adhered in greater number to P-selectin than MSC, but still in low 
numbers, and were slowed in flow slightly by P-selectin. 
 MSC and EPC adhesion decreased the higher the wall shear rate, with 
adhesion not detectable at wall shear rate above 70s
-1
.  
 The velocity of non-adherent MSC was greater, the bigger the mean diameter 
of the cell sample perfused, and smaller MSC adhered better than larger.  
 WJMSC, BMMSC and TBMSC adhered to collagen significantly more than  
to fibronectin. 
 The different MSC tested adhered in the order WJMSC>BMMSC>TBMSC.  
 
7.1.2 Spreading and migration of MSC from different sources 




 On fibronectin BMMSC also spread faster compared to WJMSC or TBMSC.  
 Spreading was more efficient, more rapid and to a greater area on fibronectin 
than on collagen.  
 WJMSC were more effective in transmigration than BMMSC on  collagen, 
fibronectin  or albumin.  
 Coating the lower surface with collagen or fibronectin promoted MSC 
migration compared to coating the top, for both proteins similarly. 
 Coating of the upper side of filter with fibronectin promoted migration for 
fibronectin more than collagen.  
 Smaller cells of BMMSC and WJMSC showed more efficient migration.   
 Overall, comparing BMMSC and WJMSC for which we have the most 
complete data, WJMSC adhered in greater numbers from flow but  BMMSC spread  
more efficiently and quickly; WJMSC migrated in greater numbers then BMMSC, 
especially when the lower surface was coated. 
7.1.3 Adhesion of MSC to matrix proteins from flowing whole blood and 
interaction with platelets  
 MSC within whole blood adhered to collagen or fibronectin much less than 
isolated MSC.  
 Only WJMSC adhered to collagen effectively in blood, and they are 
associated with platelets, and also bound together by them.  
 WJMSC formed clumps of cells, some large with several MSC, which 
included platelets and occasional leukocytes 




 On collagen, many platelets adhered from blood and formed scattered clumps 
or 'thrombi' ; on fibronectin platelets formed almost confluent layer of spread 
platelets but no thrombi. 
 Isolated MSC adhered to the platelet monolayer on fibronectin in large 
numbers, which increased if the platelets were activated with TRAP; adhesion was in 
the order WJMSC>BMMSC>TBMSC.  
 Although MSC are larger than leukocytes, MSC could be seen marginated by 
the red blood cells in the blood flowing at the low wall shear rate used (35s
-1
).  
 Both WJMSC and BMMSC aggregated slightly with platelets, and larger 
aggregates were formed if collagen was added. 
 All MSC could bind to platelets but only WJMSC appeared to activate the 
bound platelets.  
7.1.4 Mechanisms of adhesion between MSC,  platelets and matrix proteins 
 There was a marked reduction in the number of adherent cells to collagen for 
isolated WJMSC or BMMSC  hen treated  ith antibody against β1-integrin.  
 On collagen, MSC adhesion was also reduced  after treatment with antibody 
against β3-integrin.  
 A combination of β1-integrin and β3-integrin antibodies treatment, had little 
extra effect on MSC adhesion.  
 There even greater reduction of adhesion to fibronectin for isolated WJMSC 
or BMMSC  hen treated  ith antibody against β1-integrin.  
 There  was only slight reduction in number of adherent cells to fibronectin 
for isolated WJMSC or BMMSC  hen treated  ith antibody against βᴣ -integrin 
antibody, but after treatment  ith antibodies against αᴠβᴣ-integrin or αᴠ-integrin, 
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there was significant decrease in the number of adherent MSC on the fibronectin 
surface.   
 Antibody against β3-integrin caused adherent WJMSC and BMSC to lose 
their ability to spread on fibronectin, suggesting that different antibodies against β3-
integrin could affect adhesion or spreading separately. 
 β1- and β3-integrins assist adhesion to collagen and to fibronectin, for 
WJMSC as well as BMMSC.   
 When isolated WJMSC and BMMSC were perfused over platelet ma marked 
reduction in the number of adherent cells when MSC were treated with anti-β1-
integrin, and lesser effect when MSC were treated with anti-β3-integrin.   
 When the blood used to deposit the platelets is treated with anti-GpIIbIIIa, 
there is little stable adhesion of MSC as the platelets do not spread and they will be 
pulled off the surface by MSC rolling past.  
 Anti-GpIb decreased platelet adhesion to collagen from blood, but did not 
stop platelets adhering to WJMSC.   
 There was  almost total loss of WJMSC adhesion to collagen when whole 
blood was treated with anti-GPIIbIIIa. 
 Treating whole blood with anti-Gp1b or anti-GPIIbIIIa, BMMSC and 
TBMSC showed very little adhesion on collagen from whole blood.  
 Overall, even when platelets adhesion was lost from the collagen, MSC were 
not seen adhering from flowing blood, suggesting they were still 'blocked' by 
platelets adhered to them. 
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 Treatment of WJMSC with anti-β1-integrin, greatly reduce the adhesion of 
WJMSC from flo ing blood,  hile antibodies against βᴣ- or αv-integrin reduced 
adhesion but not as much. 
 Combining blockade of β1-integrins on MSC and platelet adhesion in whole 
blood did not recover adhesion of individual MSC to the 'bare' collagen.  β1-
integrins appeared to mediate adhesion of MSC to collagen as well as to platelets in 
the whole blood assay. 
7.2 Relation to previous findings  
 
 Adhesion from flow may be the first and critical step for the recruitment of 
stem cells for vascular protection.  For the first time, this thesis reports the 
comparison in this behaviour  for MSC from different tissues: BMMSC,WJMSC and 
TBMSC.  It also assessed their behaviour after adhesion, that might affect their fate 
once deposited in damaged tissue. 
 The finding that MSC could bind to matrix proteins, collagen and fibronectin, 
but not selectins, at wall shear rates up to about 70s
-1 
agrees with some but not all 
literature.  One study found adhesion of  BMMSC to endothelial cells at shear stress 
0.1Pa (equivalent to140s
-1
) (Segers et al., 2006), but others found that shear needed 
to be reduced to about 0.01Pa (14s
-1
) (Ruester et al., 2006, Luu et al., 2013); Luu et 
al.,( 2013) to detect adhesion, or could not detect adhesion from flow (Chamberlain 
et al., 2011).  Some of these studies showed roles for selectins and VCAM-1 in 
adhesion (Segers et al., 2006, Thankamony and Sackstein, 2011).  We could not 
reproduce adhesion to selectins here, while others in our laboratory previously 
examined adhesion to purified VCAM-1 and did not detect adhesion of BMMSC 
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form flow (Gerard Nash; unpublished observations).  Adhesion from flow directly to 
collagen or fibronectin has not been reported previously.  In one study, BMMSC did 
not adhere to a collagen surface at a wall shear rate of 1000s
-1
 (Jiang et al., 2012).  In 
another study, BMMSC were settled onto surfaces and then flow was increased to 
study the strength of attachment; collagen coating increased the strength (Lan et al., 
2003).  Differences between results in adhesion studies could depend on the source 
and culture conditions for the MSC, and possibly also for the endothelial cells.  P-
selectin used here did support some adhesion of EPC as expected, and could also 
support rolling of leukocytes. 
 
We found that adhesion was in the order WJMSC>BMMSC>TBMSC.  We 
also found that BMMSC spread more rapidly and efficiently than WJMSC or 
TBMSC, while migration rate through filters was in the order 
WJMSC>BMMSC>TBMSC.  Most of the studies of adhesion and migration in the 
literature examine only a single type MSC (BMMSC) using static assays. In this 
thesis we compared the behaviour of three different types of MSC by using flow 
adhesion assays to get a better understanding of MSC behaviour and to study the 
effect of their sources.   We expected differences based on the findings of Aldridge 
et al. (2012)  who suggested that the expression of adhesion molecules on MSC were 
affected by their source and the isolation method (Aldridge et al., 2012).  The high 
WJMSC adhesion compared to BMMSC on collagen and fibronectin may be linked 
to differences in regeneration ability. WJ MSC have been shown to be more 
neurogenic and angiogenic than BMMSC, possibly also linked to differences in their 
secretomes (Hsieh et al., 2013).  Regarding the low adhesion and migration of 
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TBMSC compared to WJMSC and BMMSC, we suggest this difference may be due 
to the fact that TBMSC were obtained from aged patients undergoing knee 
replacement.  Coipeau et al. (2009) suggested that  MSC were modified inherently 
because of the burden of the diseases. 
 
Cell spreading and migration are the initial kinetic processes following 
adhesion, which are likely to affect the outcome after MSC adhere or become 
trapped in vessels.  In this thesis -for the first time - we concluded that MSC spread 
more efficiently, more rapidly and to a greater area on fibronectin than on collagen. 
We found clear differences in behaviour of MSC that are used in current research 
and therapy, from bone marrow and Wharton's jelly.  Trabecular bone is less 
frequently used to obtain MSC, and TBMSC behaved similarly to the WJMSC for 
spreading but not migration.  We are not aware of any previous kinetic or 
comparative similar studies for MSC. 
 
Cell diameter is expected to be one of the main factors which influences 
shear sensitivity of cell adhesion and thus of MSC recruitment. There has been no 
previous study of the role of stem cell diameter in adhesion. We showed that small 
size MSC adhered better than larger cells.  Leukocytes are about 10µm in diameter 
while MSC were about 20µm.   Leukocytes use specialised capture receptors, 
selectins, that act quickly, while the MSC binding we measured was to unspecialised 
matrix receptors via integrins.  This is in agreement  with  studies assessing the effect 
of the cell diameter on adhesion behaviours.  Watts et al. reported that cell size, 
margination, and a cell-free layer influenced the adhesive abilities of platelets and 
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leukocytes (Watts et al., 2013). They showed that platelets were able to adhere at 
high shear rate and they attributed this to their small size which subsequently 
minimized the force experienced and their velocity.  The wall shear rate thus plays 
an important role in the adhesion of cells. In this thesis, the highly significant 
reduction in adherent cells  noticed with increased wall shear rate, suggests that shear 
rate and stress play critical roles in EPC and MSC adhesion.  In fact, infused MSC 
are cleared from the blood and many rapidly become deposited in the lungs (Fischer 
et al., 2009, Kang et al., 2012). These results suggest that trapping may be 
mechanical and not adhesive, so that size in important for that reason.  If that is the 
case, the comparisons of data for capture for different MSC may be less important 
than the comparisons of ability to spread, integrate and migrate.  However, the 
adhesion data for the isolated MSC may be less important than the results for 
behaviour in the blood. 
 
In addition to the comparison of MSC types, this thesis aimed to improve our 
understanding of the behaviour of MSC in blood and the role of blood cells such as 
platelets in MSC adhesion.   We demonstrated that MSC within whole blood adhered 
to collagen or fibronectin much less than isolated MSC.  Indeed, there was no 
detectable adhesion to fibronectin, and on collagen, only occasional adherent 
BMMSC and TBMSC were seen.  Only WJMSC adhered to collagen effectively in 
blood, and they were associated with platelets, and also bound together by them.  
There have been no previous studies of MSC adhesion in blood in vitro, but a few 
studies of flow or of infused MSC in animals that may be relevant.  In vitro, Jiang et 
al. (Jiang et al., 2012) perfused rat BMMSC over collagen with or without platelets 
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added to the MSC, and found that MSC adhesion only occurred with platelets; these 
studies were at high wall shear rate (1000s
-1
).  In the same study, recruitment of 
infused MSC to the lung of rats was also dependent on platelets.   Teo et al.  (GS Teo 
et al) demonstrated that in mice, injection of endotoxin into the ear caused 
preferential recruitment of infused human BMMSC to microvessels in that ear.  
Intravital observations showed that the deposited MSC were associated with platelets 
and neutrophils.  Langer et al. found that platelets attached to endothelial cells in 
vitro increased adhesion of BMMSC, and that injected BMMSC became attached to 
damaged arteries via platelets (Langer et al., 2009).  These results are consistent with 
our finding that all MSC could adhere to platelets deposited on a surface or to 
platelets in suspension, and that WJMSC adhered with platelets to collagen from 
blood.  We revealed that isolated MSC adhered to platelets in the order 
WJMSC>BMMSC>TBMSC and that the different behaviour of WJMSC was 
mediated through ability to activate and aggregate platelets.  This has not been 
observed before. 
 
We used function blocking antibodies to obtain a better understating of  MSC 
interactions with matrix proteins and with platelets, in isolation and in blood.  We 
found that BMMSC and WJMSC both used a combination of β1-integrin and β3-
integrins to adhere to collagen , fibronectin and platelets, with β1-integrins more 
important in binding especially on fibronectin and platelets.   Our results are 
consistent with earlier studies. Others have reported that β1-integrin is expressed on 
the surface of MSC (Goessler et al, 2008).  Gronthos et al. reported that α1β1- and 
α2β1-integrins were involved in MSC binding to collagen and that MSC bound to 
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fibronectin through α5β1-integrin (Gronthos et al, 2001).  Another study showed that 
α5β1-integrin controlled MSC adhesion and migration on fibronectin  (J Veevers-
Lowe et al 2011).  We observed the interesting result that anti-β3-integrin inhibited 
adhesion to fibronectin slightly, but strongly inhibited spreading.  This suggest that 
this integrin affected signalling after cells adhered, and so might affect migration as 
well as α5β1-integrin.  MSC  ere reported to express αvβ3-integrin which supported 
MSC adhesion to platelets (Langer et al, 2009), but a role for β3-integrins in matrix 
interactions has not been described previously to our knowledge. 
 
When platelets in blood were treated with anti-GpIb or anti-GpIIbIIIa, there 
was little stable adhesion of the platelets to fibronectin or to collagen, as expected 
from previous reports on platelet adhesion to similar surfaces (Beumer at al., 
1994)(Varga-Szabo et al, 2008) (B Savage, 1996).  These treatments also inhibited 
any adhesion of MSC in the blood. The results are consistent with the in vivo studies 
noted above (GS Teo et al)(Jiang et al., 2012)(Langer et al., 2009) who found in 
different animal models that platelet depletion or antibodies reducing platelet 
adhesion also reduced the recruitment of MSC.  Those studies all used BMMSC, and 
there is no information to our knowledge on how the increased interaction of 
WJMSC with platelets would affect adhesion from blood or behaviour in vivo. 
 
7.3 Physiological relevance of this study  
 
MSC have features which make them potential therapies for a number of 
diseases but their therapeutic uses via infusion may depend on their ability to migrate 
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into tissue as well as adhere and spread on the surface of vessels. The ability of MSC 
to differentiate into organ specific cells, makes them useful for regenerative therapy 
and there have been many clinical trials e.g., to treat spinal cord injury and 
myocardial infarction (Wei et al., 2013).  MSC are also able to suppress immune 
responses (Teo et al., 2015, Karp and Teol, 2009).   However, there is not a large 
body of data to clearly define the steps by which they would adhere locally (within 
the vessel) or transmigrate across the endothelium.    Our results, and previous 
studies with endothelial cells, suggest that MSC will bind better from flow to 
damaged vessels exposing matrix than inflamed vessels with intact endothelium.  
Thus, whether MSC can specifically home remains unclear, although our results 
suggest they could adhere, with or without platelets, in wounded tissues.  The range 
of low shear rates where we observed adhesion indicate that recruitment would be 
more likely in the venous circulation rather than arterial. Alternatively, because of 
their large size, many could get physically trapped in the microcirculation in vivo. 
  
Shear stress is a critical hemodynamic force because it modulates the 
function of endothelial cells and also influences the ability of circulating cells to 
adhere to the vessel wall (Chien et al., 1998, Topper and Gimbrone, 1999).  The 
highly significant reduction in adherent cells  noticed with increased wall shear rate 
in our experiments with isolated cells, suggests that shear rate and stress play critical 
roles in MSC adhesion.  In blood, margination is necessary for effective adhesion, 
and is dependent on cell size, with larger cells tending to move inward in the flow 
more.  In a low shear rate environment, the velocity of flowing MSC being low will 
maximize adhesion near to the vessel wall, and margination will also be promoted by 
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red cell aggregation. Although MSC are larger than leukocytes, they can still be 
marginated at low shear rates, as we have shown for the first time in this thesis.  We 
observed adhesion for WJMSC on the upper surface of the microslide and so it was 
not promoted by sedimentation.  Even when there was no adhesion, fluorescent MSC 
added to the blood could be seen flowing near the upper surface.  In small vessels in 
vivo, the efficiency of MSC adhesion may be increased per unit volume of blood 
perfused because of their occupation of a larger proportion of the lumen and their 
having a lesser distance to marginate.  The results described may be relevant to the 
behaviour of MSC if infused for therapy for inflamed tissue. During inflammation, 
fibrinogen production increases, accompanied by decline in venous flow rate and 
increase in red cell aggregation, which would be expected to assist adhesion of large 
cells (Watts et al., 2013).   
 
This thesis demonstrated that MSC within whole blood adhered to collagen 
or fibronectin much less than isolated MSC, showing that their behaviour in vivo 
will modified by blood components, especially platelets.   In the case of WJMSC but 
not BMSC or TBMSC, we observed clumps of cells which included platelets, 
indicating that the different cells would behave differently in vivo, in addition to 
differences in their adhesiveness for matrix proteins and ability to spread and 
migrate.  Adhesion to the vessel wall may be unlikely for BMMSC or TBMSC even 
in damaged vessels with exposed matrix but WJMSC might adhere to exposed 
vessels along with platelets. There is also the possibility that WJMSC could cause 
thrombus formation in the blood and that this could block microvessels and be 
dangerous in recipients.  On the other hand, such thrombi might actually help 
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recruitment to target tissues, and platelets seem to assist recruitment to damaged sites 
in vivo (Langer et al., 2009; Jiang et al., 2012; Teo et al., 2015).  MSC appear to be 
rapidly cleared if infused, and it is not certain whether they would be trapped first 
and then collect platelets, or bind platelets in the blood and then become localised.  It 
does seem to be significant that different MSC interact differently with platelets, and 
the platelet activation induced by WJMSC should be considered if these cells are 
used for therapy via infusion. 
 
While MSC will not be' isolated' for long in blood in vivo, the behaviour of 
the isolated cells is still relevant.  The therapeutic uses of MSC may depend on their 
ability to migrate into tissue as well as adhere and spread on the surface.  BMMSC 
spread more quickly than BMMSC or TBMSC and might become stabilised in the 
wall of blood vessels more quickly.  On the other hand, WJMSC were more effective 
in transmigration than BMMSC on all surfaces studied here.  Veevers-Lowe et al. 
found that binding to collagen did not induce the same level of signalling in 
BMMSC as fibronectin (Veevers-Lowe et al., 2011), but in our studies this did not 
cause a difference in migration.  Migration was more efficient when the back of 
filters was coated, but the migration to collagen or fibronectin were similar.  The 
walls of vessels contain collagen as well as fibronectin, and our results thus suggest 
that WJMSC would migrate more effectively than other MSC in the vessel wall. 
 Our results show that the not only is the cell adhesion cascade affected by 
cell diameter, but also migration.  We found that smaller cells in BMMSC and 
WJMSC samples showed more efficient migration as well as adhesion.  Larger cells 
may migrate less easily through gaps than smaller ones, and this applied to both 
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types of MSC, which had similar diameters.  The size distribution for MSC 
measured by the Coulter counter was very wide, and there might be some advantage 
for selecting MSC of smaller size for infusion.  Not only could recruitment onto and 
into the vessel wall be more effective, but their trapping in organs such as the lung 
might be less, so that more arrive at the target tissue. 
7.4 Future work 
 
 The in vitro flow assay used in this thesis represents the first attempt to study 
the rheology of MSC adhesion.  It could be used to conduct further studies to 
investigate the effects of other rheological factors of blood on the margination and 
adhesion of MSC and their interactions with platelets.  Studies could be done with 
platelets removed from the blood, and for varying levels of haematocrit or red cell 
aggregation, to study effects of the blood variables with and without platelets 
present.  Using different sources of MSC would be useful to test whether their 
behaviour differs in the absence of platelets.  In this thesis, we used low shear rates in 
flow adhesion assays; replicating the experiments using high flow shear rate, and 
possibly disturbed flow, could be used to mimic blood environment in arteries.   
These studies would provide a more complete understating of the physical factors that 
have an impact on MSC recruitment. 
 A question that requires further study is how much WJMSC activate platelets 
and why they differ from BMMSC.  Since completion of experiments described in 
this thesis, others in our laboratory made a simpler 'static' assay with MSC deposited 
on tissue culture dishes to which PRP was added.  This verified greater adhesion of 
platelets to WJMSC than to BMMSC. They have also adapted the MSC-platelet 
aggregation assay to use slower stirring and found that WJMSC cause strong platelet 
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aggregation judged by changes in light transmission, while BMMSC do not.  Future 
work needs to show the molecular basis for these differences, as they are likely to be 
important for infused cells. 
 It is difficult to predict which of the properties such as adhesion, spreading 
and migration for the different MSC will be more important for in vivo behaviour 
and therapy.  Different types of MSC (WJMSC VS BMMSC) may spread and 
integrate into the wall faster if e.g., mechanically trapped in small vessels.  Further 
studies in flow models coated with endothelial cells, or by intravital microscopy, 
might be able to answer these questions about the effectiveness of the different MSC.  
IN vutri, MSC bound to the platelets adhered to the collagen; it might be possible in 
vivo to show which cells adhered first.   The results may suggest that adhered 
platelets captured perfused MSC, but it is also possible that platelets adhered toMSC 
assist their trapping in microvessels.    
 Comparison of the circulation of different in MSC infused in animal models will 
provide more insights about the behaviour of different MSC types in the circulation.  
Recent studies in our laboratory compared the outcome when BMMSC and WJMSC 
were injected systemically via the tail vein in mice. They showed that WJMSC caused a 
decrease in blood platelet count but BMMSC did not. Thus MSC show origin-
dependent interaction with platelets in vivo that may influence their adhesion to 
damaged vessels, and potentially cause thrombotic complications. More work needs 
to be done to investigate the mechanism that control MSC recruitment and 
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